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General Introduction
CHAPTER 1
RETROVIRUSES
Retroviruses are RNA viruses, characterized by two essential 
steps in their replication: reverse transcription of the single-
stranded RNA genome into double-stranded DNA and its 
integration into the host chromosomal DNA.
 These membrane-coated viruses carry two identical copies of 
a single-stranded RNA genome. The retroviral RNA molecules 
form a dimer stabilized by the dimer linkage structure (DLS) 
located near the 5’-end of each molecule. All retroviral genomes 
consist of three major genes: gag, pol and env (FIG. 1). The 
genomic RNA is capped at the 5’-end by an m7G5’ppp5’Gmp 
structure, whereas the 3’-end contains a poly (A) tail. At both 
ends, immediately after the cap at the 5’ end and upstream to the 
poly (A) tail, there are short identical repeated sequences (R). 
Downstream to the 5’-R lies a unique non-repeated sequence, 
termed U5, which includes one of the attachment (att) sites 
required for proviral integration. The U5 region is followed by 
the primer binding site (PBS), the site of initiation of reverse 
transcription at which a host tRNA is bound. Encapsidation of 
the viral genomic RNA into the viral particle requires a specific 
sequence, called ψ (psi) which is located downstream to the 
primer binding site. The bulk of sequences that follow are genes 
encoding viral proteins. They are organized in three major 
regions: gag (group-specific antigen), pol (polymerase), and env 
(envelope). The gag gene encodes matrix (MA), capsid (CA) 
and nucleocapsid (NC). The pol gene encodes the enzymes: 
reverse transcriptase (RT), ribonuclease H (RH), and integrase 
(IN). The env gene encodes two envelope proteins, the surface 
glycoprotein (SU) and the transmembrane glycoprotein (TM). 
At the 3’ end of the genomic RNA, downstream of the env gene 
lies a short polypurine tract (PPT), which is the initiation-site 
of the plus-strand DNA. The polypurine tract is followed by 
another unique sequence termed U3. The U3 region contains 
one of the attachment sites and a number of key cis-acting 
elements for viral gene expression. The 3’ copy of the R region, 
which is followed by the poly (A) tail, is located downstream to 
the U3 region.
 The retroviral replication cycle is a multi-step process (FIG. 
2). The major steps are receptor binding and entry, uncoating, 
reverse transcription, transport of viral DNA into the nucleus, 
integration into chromosomal DNA, transcription of proviral 
DNA, splicing of primary transcripts, export of mRNAs to the 
cytoplasm, translation and post-translational modification, 
assembly, release, and maturation. The virus binds to host cell 
receptors via its receptor binding site (RBS), which is located 
in the surface glycoprotein. Binding causes conformational 
changes in both the receptor and viral envelope leading to the 
fusion of virus and cell membranes, internalization of the viral 
core and uncoating. Reverse transcription takes place in the 
cytoplasm in a reverse transcription complex which includes 
the viral RNA, the enzymes (reverse transcriptase, ribonuclease 
H, and integrase), and the nucleocapsid protein. The viral 
dsDNA that results from reverse transcription is transported as 
a pre-integration complex to the nucleus. The integrase cuts the 
DNA of a host chromosome and integrates the viral DNA into 
the gap. The integrated provirus replicates synchronously with 
cellular DNA and each of the daughter cells carries a copy of 
the integrated viral DNA. The cellular RNA polymerase II starts 
transcription at the U3-R junction in the 5’ long terminal repeat 
(LTR) and continues to a point located at the R-U5 junction in 
the 3’LTR. Each full-length transcript is capped and carries a 
poly (A) tail. RNA transcripts are divided into two populations: 
spliced and unspliced. Unspliced transcripts serve as genomic 
 FIG. 1. Retroviral genome organization. The genome organization of a typical retroviral provirus is shown in comparison to the 
genome organizations of EIAV (Equine infectious anemia virus) and FIV (Feline immunodeficiency virus).
RNA, or become translated into Gag, Gag-Pro, and Gag-Pro-
Pol precursor polyproteins. The precursor proteins encoded by 
the env gene are translated from spliced mRNAs. The envelope 
proteins are cleaved by a cellular protease into surface and 
transmembrane molecules, glycosylated and transported from 
the golgi complex to the cell membrane. Some retroviruses 
assemble in the cytoplasm, but most retroviruses form immature 
particles on the inner surface of the plasma membrane. This 
process is driven primarily by the Gag precursor protein. Three 
domains of Gag are essential for assembly: membrane binding 
domain (M), interaction domain (I), and late assembly domain 
(L). The membrane binding domain located at the N-terminus 
of Gag precursor within the MA part is responsible for Gag 
binding to the cellular membrane. The interaction domain 
is mainly located within the nucleocapsid part, binds to the 
viral genomic RNA and mediates the formation of the RNA 
dimer. The late assembly domain binds host cell factors that are 
involved in the budding process. Viral proteins together with 
viral genomic RNA assemble at the cell periphery into immature 
viral particles that are released from the cell by budding of the 
plasma membrane. Budding of retroviruses requires cellular 
ESCRT proteins. Infectious virions are generated outside the cell 
by a maturation process with proteolytic cleavage of Gag and 
Gag-Pol by the viral protease. After Gag cleavage the matrix, 
the capsid and the nucleocapsid proteins are released, while the 
cleavage of Pol forms the viral enzymes. 
LENTIVIRUSES
The genus Lentivirus of the Retroviridae family is characterized 
by its morphology, accessory genes, which are not present 
in other retroviral genomes, and by a biphasic course of viral 
gene expression. Six subgroups of lentiviruses (primate, 
feline, ovine, bovine, equine, and lagomorph lentivirus) were 
identified, reflecting the mammalian hosts with which they are 
associated. In 2007 the last group of lagomorpha lentiviruses 
was discovered in the European rabbit (Oryctolagus cuniculus) 
(45). It was the first characterized endogenous lentivirus, which 
was termed rabbit endogenous lentivirus type K (RELIK). This 
virus is >7 million years old and thus provide evidence for an 
ancient origin of the lentiviruses.
 The lentiviruses are naturally restricted in their host range, 
but natural cross-species infections have been detected for SIV 
(Simian immunodeficiency virus) in different monkey lineages 
(32, 39). In addition, experimental infections of Baboons with 
HIV-2 (Human immunodeficiency virus-2) and chimpanzees 
with HIV-1 were reported (57, 58, 72), but transmissions of SIV 
and HIV to non-primates were unsuccessful. 
 All lentiviruses have the ability to replicate in macrophages. 
HIV and SIV also infect CD4+ lymphocytes. Primate lentiviruses 
use a receptor (CD4) and a chemokine co-receptor (mainly 
CCR5 and CXCR4) for entering these target cells. CXCR4 is also 
used by the non-primate lentivirus FIV (Feline immunodeficiency 
virus) as entry co-receptor (22, 75, 94, 108). 
 In addition to the gag, pol, and env structural genes present 
in all retroviruses, the majority of lentiviruses have additional 
genes like tat (transactivator of transcription) and rev 
(regulatory virus factor). Tat is essential for the replication of 
HIV, SIV and EIAV (Equine infectious anemia virus) as a general 
activator of transcription. All three lentiviruses have long 
terminal repeats with low basal activity that is strongly induced 
by their respective Tat proteins. Rev protein regulates the export 
of unspliced and single spliced viral RNA containing a Rev 
response element (RRE) from the nucleus to the cytoplasm.
Except EIAV and RELIK, all members of the lentiviral family 
possess a vif (virus infectivity factor) gene. A deletion of the vif 
gene results in dramatically reduced viral replication (30, 47, 90, 
98). Four accessory genes are specific for primate lentiviruses: 
nef (negative regulatory factor), vpr (viral protein R), vpx (viral 
protein X), and vpu (viral protein U). Nef down-regulates the 
CD4 and MHC class I and II proteins expression at the host cell 
surface of infected cells. Vpr of HIV-1 facilitates a G2 cell-cycle 
arrest (38, 44, 76) and counteracts not identified cellular proteins. 
Other primate lentiviruses like HIV-2 contain a vpx gene which 
is important for infection of resting monocytes (7, 91). Vpu 
enhances virion production by counteraction of the cellular 
tetherin protein (69, 104) and mediates the degradation of CD4 
by the ubiquitin-conjugating pathway (86, 109). Exclusively 
non-primate lentiviruses include a domain for deoxyuridine 
triphosphatase (dUTPase) in the pol region. dUTPase catalyzes 
the conversion of dUTP to dUMP and inorganic pyrophosphate 
(PPi). The coding region of dUTPase may have been lost during 
FIG. 2.
 FIG. 2. Scheme of retroviral replication cycle. 1, attachment to 
the cell surface receptor; 2, internalization; 3, core disassembly 
and release of viral RNA; 4, reverse transcription into genomic 
DNA; 5, transport into the nucleus; 6, integration of genomic 
DNA in the cellular chromosomal DNA; 7, synthesis of RNA 
transcripts and transport of newly synthesized genomic RNAs to 
the cytoplasm; 8, transcription of mRNA encoding viral proteins 
and transport of these transcripts in the cytoplasm; 9, translation 
of viral proteins; 10, transport of structural viral proteins and 
genomic RNAs to the sites of assembly; 11, assembly and 
budding of virions; 12, mature virions. Figure taken from (106).   .
the evolution of primate lentiviruses. Alternatively, one viral 
lineage may have acquired dUTPase sequences from another 
viral lineage by a recombination event (5). The loss of dUTPase 
in the evolution could have forced a replication of primate 
lentiviruses in activated cells (lymphocytes) whereas non-
primate lentiviruses predominantly replicate in resting cells with 
little potential to divide (macrophages). Primate lentiviruses are 
able to incorporate uracil DNA glycosylase through binding 
to vpr (63). Both dUTPase and uracil DNA glycosylase reduce 
misincorporation of dUTP in reverse transcription products 
(17).
EIAV
The Equine infectious anemia virus is the smallest and simplest 
characterized lentivirus. Beside the three major genes (gag, pol, 
and env), the EIAV genome contains three open reading frames 
encoding Tat, Rev, and S2 proteins (FIG. 2). The S2 gene is 
unrelated to other lentiviral genes and is encoded as a distinct 
reading frame in the pol-env intergenic region. The function of 
the small S2 protein (8 kDa) remains unclear. Mutation studies 
indicate that S2 is dispensable for in vitro replication (53), but 
it is important for in vivo infection (52). S2 is detectable in the 
cytoplasm where it potentially interacts with Gag but is not 
incorporated into EIAV particles (83, 112). 
 EIAV lacks a virus infectivity factor gene, but the pol gene 
of EIAV encodes a dUTPase protein, which is important for 
replication in non-dividing macrophages (55, 97, 101). Cells of 
the monocyte/macrophage lineage are the primary targets for 
EIAV infection. Whereas monocytes are permissive for EIAV 
infections (89), viral expression occurs only in differentiated 
macrophages (66). Interestingly, EIAV can utilize a single cellular 
receptor, designated equine lentivirus receptor-1 (ELR1), to 
infect target cells (99, 114). Equine lentivirus receptor-1 is a 
member of the tumour necrosis factor receptor (TNFR) protein 
family. TNFR-like proteins have also been identified as receptors 
for certain avian oncoviruses and FIV (CD134) (1, 6, 13, 22, 94, 
114).
 EIAV is non-pathogenic in humans (88), suggesting that it is 
an intrinsically safe virus and of interest for therapeutic studies. 
Therefore, EIAV-based vectors have been used for gene therapy 
in experimental models of human diseases (3, 4, 35).
FIV
Infection with Feline immunodeficiency virus induces an 
AIDS-like syndrome in cats. The progression of the disease is 
characterized by typical phases which were initially observed 
for primate lentiviruses (15). FIV has been currently classified 
into five subtypes (A-E), based on their gag and env sequences. 
The subtypes are distributed according to the geographic 
location. Besides the domestic cat, many other felids including 
lions, pumas, and leopards, are infected with species-specific 
FIVs. Further sequence analyses demonstrated also a species-
specific FIV infection in Hyaenidae (102). The phylogenetic data 
indicate that most of these FIV types isolated from different 
felids are monophyletic (73, 102). However, cross-species 
transmission of FIV have been observed in wild cats, indicating 
that repeated and/or multiple historic FIV cross-species felid-
to-felid transmission events can occur in the wild or in captivity 
(16, 31, 71, 73, 102, 105).
 FIV shows a tropism for T cells (74), macrophages (14), and 
cells of the central nervous system (26). In spite of the CD4+ 
cell tropism, CD4 is not used as binding receptor for FIV. 
The primary cellular receptor for FIV is feline CD134 (94). 
Interestingly, FIV can use both feline and human CXCR4 as co-
receptor, but cannot use human CD134 (21, 22).
 The FIV genomic organization is similar to HIV, nevertheless 
it has important differences. Like other retroviruses, the 
integrated provirus is bordered by long terminal repeats and 
possesses gag, pol, and env genes (FIG. 1). Unlike primate 
lentiviruses, FIV lacks nef (negative regulatory factor), vpr (viral 
protein R), and vpu (viral protein U) genes. However, one open 
reading frame of FIV, termed OrfA, was speculated to be an 
transactivator like Tat (transactivator of transcription) (23, 96, 
107). In addition, OrfA acts similar to Vpr and is also involved 
in virus release and influences the cell cycle (34). Recently 
it was shown that OrfA reduces the cell surface expression of 
the FIV primary binding receptor CD134 (41). Overall, the 
findings suggest that OrfA may be a multi-functional protein. 
In contrast to HIV-1 FIV contains a P2 protein (28) instead 
of P6 protein, which is necessary for virus budding (62). FIV 
pol encodes protease, reverse transcriptase, integrase and also 
dUTPase. (28). A lack of dUTPase results in significant increase 
of base changes, primarily G→A transitions, during replication 
in macrophages (51). 
 The FIV genome contains a homologous gene to the HIV-
1 vif gene. Both virus infectivity factors of FIV and HIV-1 act 
to reduce G→A mutations by preventing cytidine deamination 
by cellular APOBEC3 (apolipoprotein B mRNA editing enzyme 
catalytic polypeptide 3) proteins (60, 68, 115). 
APOBEC3
The relevance of apolipoprotein B mRNA editing enzyme 
catalytic polypeptide 3 (APOBEC3) was discovered through 
the study of Vif. Vif HIV-1 virions produced in permissive cells 
were able to infect permissive and non-permissive cells, whereas 
∆Vif virons produced in non-permissive cells were unable to 
productively infect target cells (33, 80). These findings suggested 
the existence of an antiviral factor that Vif was able to neutralize 
(59, 95). This Vif-sensitive cellular factor was described in 2002 
by Sheehy et al. termed CEM15 (later named APOBEC3G) (92). 
APOBEC3G was found to be highly expressed in non-permissive 
cells and poorly expressed or even absent in permissive 
cells. Meanwhile, it could be shown that other lentiviruses, 
gammaretroviruses, deltaretroviruses, spumaviruses, LTR/
Non-LTR retrotransposons, orthohepadnaviruses, and 
avihepadnaviruses are also sensitive to APOBEC3 activity (24, 
25, 27, 29, 56, 60, 77-79, 81, 87, 103). 
 APOBEC3 proteins belong to a family of polynucleotide 
cytidine deaminases that exhibit RNA and DNA editing 
activity. In humans the APOBEC3 gene family includes seven 
members (APOBEC3A, -B, -C, -D, -F, -G, -H) (20, 43), whereas 
the number of APOBEC3 genes varies in other mammals (12, 
49, 68, 116). A multiplicity of evolutionary events, including 
preservation, deletion, gene duplication, subfunctionalisation, 
and neofunctionalisation, have led to different numbers of 
APOBEC3 genes.
 All APOBEC3 proteins have one or two conserved cytidine 
deaminase sites (His-X-Glu-X23-28-Pro-Cys-X2-4-Cys) (43) 
coordinating Zn2+ ions (48). The enzymatic activity results in the 
hydrolytic deamination at the C4 position of the cytosine base of 
either RNA or DNA, thereby converting cytidine to uridine. 
 The best characterized APOBEC3 protein is human 
APOBEC3G. In absence of VifHIV-1, APOBEC3G is incorporated 
into HIV-1 virions through an RNA-dependent interaction 
with the nucleocapsid (2, 46, 82, 100). Both, nucleocapsid 
and APOBEC3G are able to bind RNA (8, 54). Incorporated 
APOBEC3G specifically deaminates cytidine to uridine in newly 
synthesized single-stranded DNA during reverse transcription, 
leading to viral genome degradation or hypermutation (10, 37, 50, 
60, 64, 115). Uridine-containing viral minus-strand DNA can be 
targeted by uracil DNA glycosylase, leading to destruction by the 
apurinic-apyrimidinic endonuclease (85, 111). Non-degraded 
minus-strand DNA serves as template for plus-strand synthesis, 
where the deoxyuridine residues promote G→A mutations in the 
DNA plus-strand. These misincorporations alter open reading 
frames and introduce inappropriate translation termination 
codons, and inhibit tRNALys3-primed reverse transcription, 
FIG. 3.
 FIG. 3. Model for human APOBEC3G antiviral function. The absence of Vif results in the packaging of APOBEC3G 
into HIV virions budding from producer cells. In target cells, encapsidated APOBEC3G acts as an inhibitor of virus 
replication. These inhibitory effects are divided in deaminase-independent and deaminase-dependent activities. Binding of 
APOBEC3G to HIV-1 RNA prevents the progress of reverse transcriptase and results in a deaminase-independent decrease 
of early viral reverse transcripts ❶. Single-stranded viral DNA serves as a target for deaminase-dependent activity of 
APOBEC3G. APOBEC3G causes hypermutation of the minus-strand viral DNA, resulting in the conversion of deoxycytidine 
to deoxyuridine. Uracil-containing minus-strand DNA can be targeted by uracil DNA glycosylase, which could lead to 
endonucleolytic cleavage ❷. APOBEC3G may also cause defects in tRNALys3 primer cleavage leading to the formation of 
viral DNA with aberrant ends that could interfere with subsequent chromosomal integration ❸. Figure taken from (18).
which is essential for chromosomal integration of viral DNA 
(36, 37, 50, 60, 115) (FIG. 3). 
 However, APOBEC3 proteins also have deaminase-
independent antiviral activities (70). Several studies have shown 
that deaminase-deficient APOBEC3 mutants are still able to 
reduce accumulation of reverse transcription products during 
the early stages of viral replication (9, 40) (FIG. 3). Other studies 
found that human APOBEC3G is able to inhibit all stages of 
reverse transcription (42). The ability of APOBEC3 to bind 
viral RNA appears to be involved in deaminase-independent 
inhibition (9, 70).
APOBEC and Vif
The interaction of APOBEC3 and Vif proteins is best 
characterized for human APOBEC3G and VifHIV-1. The virus 
infectivity factor forms an interaction between APOBEC3G 
and an ubiquitin E3 ligase complex consisting of Elongin B 
and C, Cullin5, and Ring Box-1 (113). This interaction results 
in polyubiquination, which leads to proteasomal-mediated 
degradation of the APOBEC3G protein (19, 65, 67, 93, 113) 
(FIG. 4). For human and African Green Monkey (AGM) 
APOBEC3G this interaction was shown to be species-specific. 
Both APOBEC3G proteins differ in one amino acid which 
is sufficient for resistance of AGM APOBEC3G against Vif-
mediated degradation (11, 61, 84, 110). Equally, AGM but 
not human APOBEC3G is inactivated by the Vif protein of 
SIVAGM (11, 84). This species-specific interaction could be an 
explanation for the host range of the certain primate lentiviruses.
SCOPE OF THIS THESIS
This thesis focuses on the detection and characterization of 
APOBEC3 proteins of mammalia outside the well-characterized 
human/primate system. Previous studies have shown an 
important diversity in quantities, expression levels and antiviral 
properties of APOBEC3 proteins of different species. For 
instance, the human genome carries seven APOBEC3 genes, 
whereas the mouse genome contains only a single APOBEC3 
gene. Many details are known about the suppression of 
productive replication of HIV-1 in non-human cells and the 
species-specificity of the APOBEC3-Vif interaction. In order 
to complete these studies Felis catus and Equine caballus were 
examined for APOBEC3 genes. 
 The presence of different feline APOBEC3 proteins leads 
to the question, whether these proteins show an inhibitory 
effect against retroviruses and variability in their antiviral 
activity. Chapter two describes the restriction of HIV-1 in feline 
cells expressing human CD4- and CCR5-receptors by feline 
APOBEC3 proteins. This work also investigated the possibility 
of using Felis catus as an animal model for studying HIV-
infection / AIDS-progression.
FIG. 4.
 FIG. 4. Model of the interaction of VifHIV-1 and human APOBEC3G.  Vif targets the human APOBEC3G protein for proteasomal 
degradation ❶. The Expression of Vif also partially impairs the translation of human APOBEC3G mRNA ❷. These two effects of 
Vif effectively eliminate APOBEC3G from the virus-producing cell and lead to production of infectious virions lacking APOBEC3G 
❸. Figure taken from (18).
 The studies in chapter three extend the analyses of feline 
APOBEC3 and show the inhibitory activity against feline viruses 
and SIV, respectively. The parallels between FIV and HIV-1 
concerning pathology and molecular structure, were of special 
interest. In order to show similarities in resistance between FIV 
and HIV-1, the interaction of feline APOBEC3 and VifFIV was 
characterized. The analyses suggest parallels of feline APOBEC3 
and human APOBEC3 proteins in their individual specificity 
and support a complex evolutionary history of expansion, 
divergence, selection and individual extinction of antiviral 
APOBEC3 genes. 
 Another aim of this thesis was to get more details about host 
cell factor interactions of the more primitive lentivirus EIAV. It 
was interesting to study the question how EIAV can replicate 
without a VIF protein in cells that likely express APOBEC3 
proteins. In chapter four, equine APOBEC3s were investigated 
for their antiviral activities and EIAV for its mechanisms 
of resistance to APOBEC3. Two candidate proteins, S2 and 
dUTPase, were tested whether they are able to adopt the 
function of Vif.
 Previous studies have suggested the Vif-APOBEC3 interaction 
to be species-specific and thereby preventing cross-species virus 
transmission. Chapter five provides a detailed analysis of Vif 
from FIV and APOBEC3 restriction factors of different felids. 
The study describes the ability of Vif to counteract APOBEC3 
proteins from different felid species, implying that APOBEC3 
does not form a block against cross-species transmission 
between these closely related animals. Finally, Vif of FIV was also 
found to be expressed in the heterologous HIV-1, strengthening 
the idea of a cat HIV/AIDS model.
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Multiple Restrictions of Human Immunodeficiency Virus Type 1 in 
Feline Cells
The productive replication of human immuno-
deficiency virus type 1 (HIV-1) occurs exclusively 
in defined cells of human or chimpanzee origin, 
explaining why heterologous animal models for 
HIV replication, pathogenesis, vaccination, and 
therapy are not available. This lack of an animal 
model for HIV-1 studies prompted us to examine the 
susceptibility of feline cells in order to evaluate the cat 
(Felis catus) as an animal model for studying HIV-1. 
Here, we report that feline cell lines harbor multiple 
restrictions with respect to HIV-1 replication. The 
feline CD4 receptor does not permit virus infection. 
Feline T-cell lines MYA-1 and FeT-1C showed 
postentry restrictions resulting in low HIV-1 luciferase 
reporter activity and low expression of viral Gag-
Pol proteins when pseudotyped vectors were used. 
Feline fibroblastic CrFK and KE-R cells, expressing 
human CD4 and CCR5, were very permissive for 
viral entry and HIV-long terminal repeat-driven 
expression but failed to support spreading infection. 
KE-R cells displayed a profound block with respect 
to release of HIV-1 particles. In contrast, CrFK 
cells allowed very efficient particle production; 
however, the CrFK cellderived HIV-1 particles had 
low specific infectivity. We subsequently identified 
feline apolipoprotein B-editing catalytic polypeptide 
3 (feAPOBEC3) proteins as active inhibitors of 
HIV-1 particle infectivity. CrFK cells express at least 
three different APOBEC3s: APOBEC3C, APOBEC3H, 
and APOBEC3CH. While the feAPOBEC3C did not 
significantly inhibit HIV-1, the feAPOBEC3H and 
feAPOBEC3CH induced G to A hypermutations of the 
viral cDNA and reduced the infectivity 10- to 40-fold. 
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Like many retroviruses, human immunodeficiency virus type
1 (HIV-1) has a very limited host range; spreading replication
is seen only in Homo sapiens and by artificial inoculation in the
close relative the chimpanzee (Pan troglodytes) (2, 16), preventing
the setup of an efficient small animal model for HIV-1
research. Many reasons argue against the widespread use of
chimpanzees in research, including the ethical problems involved
in the use of an endangered species, budgetary problems,
and the very low induction of simian AIDS either from
HIV-1 or its ancestor simian immunodeficiency virus cpz
(SIVcpz) in infected chimpanzees (25, 26, 30, 57, 58, 60, 63).
    In general, the tropism of HIV-1 in human tissue is determined
by the expression of its receptor protein CD4 together
with CCR5 or CXCR4 chemokine receptors. Simian CD4 but
not murine CD4 supports entry of HIV-1 (15, 33). HIV-1 entry
through receptor-mediated membrane fusion is required for
reverse transcription of the viral genomic RNA into a double- 
stranded DNA molecule. Murine T cells show early postentry
restriction of HIV-1 at reverse transcription (3). In simian
cells, a related restriction of HIV-1, but not of SIVs (5, 10, 53),
involves the simian TRIM5a protein, which leads to increased
viral uncoating and thereby suppresses reverse transcription
(73). Since HIV-1 does not show spreading replication in non-
humancells, cell type- and tissue-specific tropism was studied
mostly using human cells. Soon after identifying the relevance
of the chemokine coreceptors for HIV infection, it was realized
that certain receptor- and coreceptor-positive human cells,
mostly nondividing, were still resistant to full HIV-1 replication.
HIV-1 can infect human cells arrested in the cell cycle
at the G0/1a or G2 stage (13, 21, 37). Remarkably, in a few
quiescent and nonactivated human cells, such as monocytes
and resting peripheral T lymphocytes, HIV-1 is restricted
soon after membrane fusion. It has been discussed that a
limiting nucleotide pool (31, 83) and/or a unique and un- 
chracterized activity of low-molecular-weight complexes of
a protein called apolipoprotein B-editing catalytic polypeptide
3G (APOBEC3G) (see below) exclusively found in resting
cells perturbs reverse transcription in these cells (9). In
some experimental systems using nondividing human cells, the
nuclear import and/or the integration of viral DNA into chro- 
mosomal DNA is also very inefficient (55, 69, 74). This is,
however, not a general feature of resting cells in vivo, since
human resting T cells residing within lymphoid tissues are
permissive for HIV-1 infection (13), indicating that subtle dif- 
ferences in cell physiology play a crucial role in whether a given
cell is permissive to HIV-1 replication or not.
  Beside these so-called early replication blocks, nondividing
human cells also show late blocks (for a review, see reference
81). In dividing murine cells, low levels of transcription by
nonfunctional p-TEFb complexes (consisting of cyclin T1 and
CDK9) have been observed (7, 17, 32, 79). Murine cells show
several additional late blocks of HIV replication, such as disturbed
RNA export (47, 75, 85) and processing and assembly
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blocks of the viral proteins (6, 45). One of the best-characterized
cellular proteins  efficily restricting HIV-1 is the cytidine- 
deminase APOBEC3G (70). Encapsidation of APOBEC3G and
other members of the APOBEC3 family in HIV-1 virus particles
leads to deamination of cytosine residues to uracil in growing
single-stranded DNA during reverse transcription (8, 24, 34, 42,
43, 84). HIV uses the viral infectivity protein (Vif) to prevent or
at least reduce incorporation of APOBEC3G into progeny virions
(43, 46, 71). Despite vif expression, low levels of APOBEC3-
mediated cytidine deamination are detectable, indicating that
even wild-type (wt) HIV-1 is weakly restricted by the presence of
APOBEC3 proteins (61). Because the HIV-1 Vif protein exclusively
binds and inactivates human APOBEC3 proteins in a species-
specific way, HIV-1 is strongly inhibited by the simian and
murine orthologues of APOBEC3G (43) that evade HIV-1 Vif
counteraction.
  Given that there is neither a small animal model nor a
primate model available for HIV-1 investigations, rodent systems
were developed to model specific steps of HIV-1 infection.
Transgenic mice containing full-length or individual
genes under the control of non-HIV promoters were used to
study the postintegration phase of the viral life cycle. These
models provide a means for assessing effects of HIV-encoded
proteins in vivo and mammalian responses to different viral
gene products (23, 35, 65, 76). In addition, severe combined
immunodeficient (SCID) mice, engrafted with human peripheral
blood mononuclear cells or fetal thymus and fetal liver
cells, have been used as a model for HIV-1 (50, 54). With both
SCID models uncontrolled HIV-1 infections, limited to the
engrafted cells, peak at 3 to 4 weeks postinoculation and are
characterized by variable depletions of the engrafted CD4 T
cells and a lack of humoral or cellular responses to the virus (1,
51). To increase the longevity of the engraftment with multilineage
hematopoiesis and properties of a more functional hu-
man immune system, Rag2-/-gc-/- or NOD/SCID/IL2Rg-/-
mice engrafted with human hematopoietic stem cells were recently
used for HIV-1 infection studies (4, 20, 78).
  The potential usefulness of an animal with an intact immune
system as a model of HIV-1 infection and disease warrants
further efforts directed at an assessment of the limitations and
blocks in the viral life cycle in animals that may serve for
animal experimentation. The cat (Felis catus) is an established
animal model for studies of the brain, genetics, pharmacology,
nutrition, and virology (59). Unlike rodents, cats are permissive
for infection by a lentivirus, the feline immunodeficiency
virus (FIV). But FIV is only distantly related to HIV-1; thus,
studies of FIV are suitable only to a limited extent for understanding
HIV-1 pathogenesis. Initial observations of the host
range of HIV-1 in feline cells showed a lack of reverse transcriptase
(RT) production after virus inoculation (36), but subsequent
experiments using vesicular stomatitis virus G protein
(VSV-G)-pseudotyped HIV vectors containing cytomegalovirus
(CMV) promoters demonstrated robust gene transfer into
feline cell lines (28, 64, 66). Cellular factors restricting HIV-1
in the cat are currently unknown. However, in a recent study
of feline foamy viruses (FFV), we characterized a feline
APOBEC3 protein (39), demonstrating that in addition to
primates and rodents, felines also express cytosine-deaminases
restricting retroviral replication. Because feline cells are
known to be highly permissive for reporter gene expression by
HIV vectors, we were curious to extend this finding and to
explore the use of the cat as a potential small-laboratory animal
model for HIV-1 infection.
  We show here that cell lines derived from Felis catus show
several restrictions to HIV-1 replication regarding entry, particle
release, and particle infectivity. The feline APOBEC proteins
3H and 3CH were identified as potent inhibitors of
HIV-1 in feline cells.
MATERIALS AND METHODS
   Cells and transfections. The adherent human cell lines HOS (American Type
Culture Collection [ATCC] CRL-1543), HOS.CXCR4 (National Institute for
Biological Standards and Control [NIBSC] ARP5000), HOS.CCR5 (NIBSC
ARP5001), HOS.CD4.CCR5 (NIBSC ARP078), HT1080 (ATCC CCL121), and
293T and feline cell lines CrFK (ATCC CCL-94; feline kidney cells) and KE-R
(feline embryonic fibroblast cells; a gift of Roland Riebe, Friedrich-Loeffler
Institut, Riems, Germany) were maintained in Dulbecco’s high-glucose modified
Eagle’s medium (Dulbecco’s modified Eagle’s medium complete; Invitrogen)
supplemented with 10% heat-inactivated fetal bovine serum (FBS), 0.29 mg/ml
L-glutamine, and 100 units/ml penicillin/streptomycin. Cells of the human T-cell
line A3.01 (NIBSC ARP098) were cultured in complete RPMI 1640 medium–
10% heat-inactivated FBS–0.29 mg/ml L-glutamine–100 units/ml penicillin/strep-
tomycin. Cells of the feline T-cell lines MYA-1 (ATCC CRL-2417) and FeT-1C
(ATCC CRL-11968) were cultured in complete RPMI 1640–0.29 mg/ml L-glu-
tamine–10 mM HEPES–1.0 mM sodium pyruvate supplemented with 0.05 mM
2-mercaptoethanol, 100 units/ml human recombinant interleukin-2 and 10%
heat-inactivated FBS, and 100 units/ml penicillin/streptomycin. Plasmid trans-
fection into 293T and CrFK cells was done with Lipofectamine 2000 according to
the instructions of the manufacturer (Invitrogen). Feline CD4 was amplified
from cDNA of feline peripheral blood mononuclear cells after activation with
phytohemagglutinin (3 µg/ml), the forward primer 5‘fCD4-EcoRI(5‘-GAATT
CATGAATCAAGGAGCCGTTTTTAGG-3‘), the reverse primer 3‘fCD4-BglII
(5‘-AGATCTTCAAATGGGATTACATGTCTTCTG-3‘), and Pwo polymerase
(Roche Diagnostics). Thirty cycles were run at 94°C for 30 s, 58°C for 1 min, and
72°C for 2 min. PCR products were cloned into pMSCVneo (Clontech) by use of
EcoRI and BglII restriction sites. The identity of the resulting pMSCVneo-fCD4
was confirmed by sequencing. pMSCVneo-hCD4 was generated by transferring
hCD4 cDNA from T4-pMV7 (41) into pMSCVneo by use of EcoRI restriction
sites. Retroviral vector stocks of pBABE-CCR5 (puro) (12), pMSCVneo-hCD4,
and pMSCVneo-fCD4 were used to infect cells. After selection with puro-
mycin for CCR5 and G418 for CD4 vectors, receptor expression was confirmed
by flow cytometry. The cells were stained for human CD4 with SK3-
PerCP (BD PharMingen), for feline CD4 with 3-4F4-PE (SouthernBiotech),
for human CCR5 with 2D7-PE (BD PharMingen), and for human CXCR4
with 12G5-PE (BD PharMingen).
  Viruses and infections. Replication-competent HIV-1NL4.3 and HIV-1NL-BaL
(NL4.3 with the env BaL) (44) virus stocks were prepared by harvesting the
supernatant of transfected 293T cells. To generate VSV-G-pseudotyped HIV-1,
293T cells were cotransfected with HIV-1 DNA (pNL4.3; pNL-BaL) and pMD.G
VSV-G expression plasmid (14). HIV-1 single-cycle luciferase reporter viruses
(HIV-Luc) were produced by cotransfecting 293T cells with pNL-LucRE (a
gift from Nathaniel R. Landau; 45), JR.FL (pcJR.FL; 12), L102, a variant of the
C-terminally truncated (at amino acid 712) HIV-1 Env strain BH10 (pcL102),
HXB2 (pSV7d; 62), BaL.01 (HIV-1 clone BaL.01; 38), BaL.26 (HIV-1 clone
BaL.26; 38), or VSV-G expression vector. Dvif HIV-Luc was produced by co-
transfecting 293T cells with pNL-LucR-E-Dvif (43) and VSV-G expression
plasmid. Single-cycle HIV-1-green fluorescent protein (GFP) (VSV-G) expressing
enhanced GFP (EGFP) by an internal CMV promoter were generated by
transfection of 293T with pHIV.NL4-3DE-EGFP (52) together with pMD.G.
EGFP vectors were titrated by serial dilutions using HT1080 cells as described
previously (52), 4 x 105 cells were transduced using a multiplicity of infection
(MOI) of 5, and GFP expression was determined by flow cytometry 3 days
posttransduction. FIV single-cycle luciferase (FIV-Luc) vectors were produced
by cotransfecting 293T cells with pFP93 (a gift of Eric M. Poeschla; 40),
pvLucFIVDenv, and pMD.G. pvLucFIVDenv vector was derived from p34TF10,
a replication-competent molecular clone of FIV, contains a 2 kb internal deletion
in env, and has most of gag-pol region replaced by the firefly luciferase gene
under the control of an internal CMV promoter. RT of viruses was determined
by use of a Cavidi HS Lenti RT kit (Cavidi Tech). Alternatively, viruses were
quantified using an HIV-1 p24 antigen enzyme-linked immunosorbent assay
(ELISA) based on a previously published method (48, 49). Briefly, p24 antigen
is captured from a detergent lysate of virions (1% Empigen; Calbiochem) by use
of a polyclonal antibody (D7320 sheep anti-HIV-1-p24 gag; Aalto Bio Reagents,
Dublin, Ireland) adsorbed to a solid phase. Bound p24 is detected using an
alkaline phosphatase-conjugated anti-p24 monoclonal antibody (BC 1071-AP
alkaline phosphatase conjugate of anti-HIV-1-p24 mouse monoclonal antibody;
Aalto Bio Reagents, Dublin, Ireland) and a luminescence detection system
(Tropix ELISA-Light immunoassay system; Applied Biosystems) and analyzed
using a Berthold MicroLumat Plus luminometer. For reporter virus infections,
the adherent cells were seeded at 2.0 x 103 cells/well per day before transduction
and suspension cells were seeded at 5.0 x 104 cells/well on the day of transduc-
tion in 96-well plates and then infected with reporter virus stocks normalized for
RT. Firefly luciferase activity was measured according to the manufacturer’s
directions 3 days later with a Steadylite HTS reporter gene assay system
(PerkinElmer) on a Berthold MicroLumat Plus luminometer.
  APOBEC3 expression and plasmids. Feline APOBEC3C (previously termed
feAPOBEC3 [fe3]; GenBank accession no. AY971954) was described previously
(39). Feline APOBEC3H and feline APOBEC3CH cDNAs were identified by
using 5‘ and 3‘ rapid amplification of cDNA ends (RACE) reactions (5‘/3‘-
RACE kit; Roche Diagnostics) employing total RNA from CrFK cells. For
full-length expression cloning of C-terminal hemagglutinin (HA)-tagged feline
APOBEC3H, forward primer fAPO-29 (5‘-TGCATCGGTACCTGGAG
GCAGCCTGGGAGGTG-3‘) and reverse primer fAPO-28 (5‘-AGCTCGA
GTCAAGCGTAATCTGGAACATCGTATGGATATTCAAGTTTCAAAT
TTCTGAAG-3‘) and Pwo polymerase (Roche Diagnostics) were used; for
feline APOBEC3CH, forward primer fAPO-30 (5‘-TGCATCGGTACCACC
AAGGCTGGAGAGAGGAATGG-3‘) and reverse primer fAPO-28 and Pwo
polymerase were used. Each of 30 cycles was run at 94°C for 30 s, 58°C for 1
min, and 72°C for 2 min, PCR products were cloned into the KpnI and XhoI
sites of pcDNA3.1(+), and correct clones were identified by sequencing.
Expression studies of feline APOBEC3 RNA of CrFK cells were done by
RT-PCR using total RNA, Taq polymerase (QIAGEN), and forward primer
fAPO3F-18 (5‘-TAGAAGCTTACCAAGGCTGGCGAGAGGAATGG-3‘)
and reverse primer fAPO3F-19 (5‘-AGCTCGAGTCAAGCGTAATCTGGA
ACATCGTATGGATACCTAAGGATTTCTTGAAGCTCTGC-3‘) for feline
APOBEC3C, forward primer fAPO3F-9 and reverse primer fAPO-26
(5‘-CTGCCCGAAGGCACCCTAATTC-3‘) for feline APOBEC3H, and forward
primer fAPO3F-11 (5‘-ACCAAGGCTGGCGAGAGGAATGG-3‘) and
reverse primer fAPO-27 (5‘-TCGTACTCGAGGCAGTTTATGAAGCATT
GAGATGC-3‘) for feline APOBEC3CH. PCRs were run for 30 cycles of
94°C for 30 s, annealing for 1 min for feA3C at 62°C, for feA3H at 61°C, and
for feA3CH at 60°C, and 72°C for 2 min.
 Immunoblot analysis. Cells were infted with HIV-1NL.BaL(VSV-G) or co-
transfected with plasmids for HIV-Luc or DvifHIV-Luc, and APOBEC3-HA
expression plasmids and lysates and virions were prepared 3 days later. Virions
were pelleted by centrifugation of filtered culture supernatant through a 20%
sucrose cushion at 35,000 rpm in an SW40Ti rotor for 1.5 h and lysed in lysis
buffer (100 mM NaCl, 10 mM EDTA, 20 mM Tris [pH 7.5], 1% Triton X-100,
1% sodium deoxycholate). Cell lysates were prepared by removing infected cells
from the medium, washing the cells with phosphate-buffered saline, and lysing
the cells in lysis buffer. Protein in the lysates was quantitated using Coomassie
blue reagent (Bio-Rad). Lysates containing 20  g of protein were separated by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to
polyvinylidene difluoride filters. Filters were probed with mouse anti-capsid p24
hybridoma supernatant (a-p24 183-H12-5C; provided by Egbert Flory) (1:50
dilution) or HIV-1 Vif antiserum (HIV-1HXB2 Vif antiserum; 19) (1:2,000 dilution)
or anti-HA antibody (MMS-101P; Covance) (1:6,000 dilution) or mouse
anti-a-tubulin (clone B5-1-2; Sigma-Aldrich) (1:4,000 dilution) followed by horse-
radish peroxide-conjugated rabbit anti-mouse antibody (/-mouse-IgG-HRP; Amer-
sham Biosciences) and developed with ECL chemiluminescence reagents (Amer-
sham Biosciences). 
  Sequencing of viral reverse transcripts. HOS cells (1 x 106) were infected
with DNase I (Roche)-treated HIV-Luc(VSV-G) (1,000 pg RT). At 10 h postinfection,
cells were washed with phosphate-buffered saline and DNA was isolated
using a DNeasy DNA isolation kit (QIAGEN). A 600 bp fragment covering
long terminal repeat gag (LTR-gag) was amplified using Taq DNA polymerase
(QIAGEN) and the primers MH 531 (5‘-TGTGTGCCCGTCTGTTGTGT-3‘)
and CM100 (5‘-TGGAGGTTCTGCACTATAGGG-3‘). Each of thirty cycles
was run at 94°C for 30 s, 58°C for 1 min, and 72°C for 2 min, and PCR products
were cloned into TOPO TA-cloning pCR4 vector (Invitrogen) and sequenced.
The nucleotide sequences of at least 10 independent clones were analyzed.
   Nucleotide sequence accession numbers. The sequences reported in this paper
have been deposited in the GenBank database as follows: feline APOBEC3H
(accession no. EF173020) and feline APOBEC3CH (accession no. EF173021).
RESULTS
   HIV-1(VSV-G) infects feline adherent cells but is restricted
in feline T cells. To evaluate the cat (Felis catus) as an animal
model for HIV-1, established feline cell lines were used to
characterize HIV-1 replication. Because Tat transactivation of
the HIV-LTR in murine cells is inefficient (7, 17, 32, 79), we
were interested in discovering whether HIV-LTR-driven reporter
viruses in cat cells would generate high expression of the
reporter protein. Feline adherent cell lines (KE-R and CrFK)
and feline T-cell lines (MYA-1 and FeT-1C) were transduced
with VSV-G-pseudotyped HIV-1 luciferase reporter viruses.
To draw a comparison to results obtained in investigations of
the feline cells, the permissive human cell lines HOS and A3.01
were coinoculated with the luciferase virus. Pseudotyping of
the particles with VSV-G allowed infection of cells that were
negative with respect to HIV receptor expression. The virus
particles were produced by transient transfection in human
293T cells, and 2, 20, and 200 pg RT were used for transduction.
At 3 days postinfection (dpi) luciferase activity in feline
and human cells was analyzed. The results presented in Fig. 1A
(left panel) show that CrFK cells had equal luciferase activity
levels and that KE-R cells had two- to fourfold-lower luciferase
counts than HOS cells. In contrast, the feline T-cell lines
MYA-1 and FeT-1C showed 5- to 12-fold-lower luciferase activity
levels than the human T-cell line A3.01. The results of
these experiments indicate that the degree to which feline
fibroblasts were permissive for HIV-1 transduction was similar
to that seen with the human HOS cells, suggesting efficient
LTR-driven transcription.
  To confirm that the feline T-cell lines used are susceptible to
retrovirus transduction and luciferase reporter gene expression,
a different lentiviral system, VSV-G-pseudotyped FIVLuc
was analyzed. The single-round replicating vector uses an
internal CMV promoter for luciferase expression. At 3 days
posttransduction we detected equal levels of luciferase activity
in the human A3.01 and feline CrFK cells (Fig. 1A, center
panel). FIV-Luc expression was only slightly (1.3- to 1.7-fold)
higher in the human A3.01 cells than in the feline Fet-1C and
MYA-1 cells. To rule out reduced HIV-LTR-driven expression
in the feline T cells, we transduced the cells with a single-round
HIV-1 vector which uses an internal CMV promoter to express
the GFP gene (HIV-GFP). The HIV-GFP vector particles
were also VSV-G pseudotyped. We inoculated the cells with at
an MOI of 5 and analyzed the GFP expression by flow cytometry
at 3 days posttransduction. The results obtained with the
HIV-GFP vector resembled the previous results seen using the
HIV-Luc transductions (Fig. 1B): 99% of A3.01 cells were
positive for GFP expression, with a mean fluorescence intensity
of 2,080, while in the culture of feline MYA-1 cells only
11% green cells were present, with a fivefold-lower mean flu-
orescence intensity of 414. We detected also a low mean GFP
fluorescence intensity of 113, with 26% green cells, in the
analyzed feline FeT-1C cells. Analogous results were obtained
using a CMV promoter with HIV-2–GFP or SIVPBj-GFP vec-
tor (data not shown). Taken together, the data indicate that 
CMV promoter-driven expression of a reporter gene works in a
FIV vector with similar levels of efficiency in human and feline
T-cell lines. Apparently, HIV-1 vectors expressing GFP by use
of an internal CMV promoter do not overcome the low level of
expression of HIV in feline T-cell lines. The data also suggest
that the HIV restriction in the feline T-cell lines is not related
to cytoplasmic entry of the viral particles by VSV-G. 
  Feline cells expressing human CD4/CCR5 are permissive
for HIV-1 reporter virus transduction. Because the feline
CrFK and KE-R cells were more permissive for HIV-1 infection
than the feline T-cell lines, we stably transduced CrFK and
KE-R cells with retroviral vectors expressing human CD4
(huCD4) and huCCR5. Flow cytometry was used to confirm
cell surface expression of huCD4 and huCCR5 in the CrFK.
CD4.CCR5 and KE-R.CD4.CCR5 cells. The results demonstrated
levels of expression of CD4 and CCR5 similar (CD4
with lower and CCR5 with higher expression) to those seen
with the cell line HOS.CD4.CCR5 used as a reference (Fig.
2A). In order to find out whether the human receptors provide
entry for HIV-1 into feline cells, we generated HIV-Luc re-
porter viruses pseudotyped with HIV-1 Env surface proteins.
We used expression plasmids for CCR5-tropic JR.FL env and
for env genes of HIV-1 strains L102 and HXB2 using CXCR4
as coreceptor. After transduction with JR.FL-pseudotyped re- 
porter virus, feline CrFK.CD4.CCR5 and KE-R.CD4.CCR5
cells exhibited reporter activity as high as that found in human
HOS.CD4.CCR5 cells (Fig. 2B and C). Because we planned to
use replication-competent CCR5-tropic HIV-1 (NL-BaL; 44)
for spreading-replication studies, we also pseudotyped HIV-Luc
with BaL Env (Fig. 2C). Since there was no BaL env expression
plasmid encoding the BaL gene of pNL-BaL available, we used
BaL.01 and BaL.26; in addition, we cotransfected HIV-Luc
with NL-BaL. The BaL gene in HIV-1NL-BaL differs from
BaL.01 by 29 and from BaL.26 by 37 amino acid positions in
gp160 (38). All BaL-pseudotyped HIV-Luc particles trans-
duced the HOS.CD4.CCR5, CrFK.CD4.CCR5, and KE-R.
CD4.CCR5 cells with similar levels of efficiency (Fig. 2C). Cells
inoculated with the mixture of HIV-Luc/NL-Bal showed 10-
   FIG. 1. HIV-1 infects feline adherent cells but is restricted in feline T cells. (A) Left panel: adherent cell lines (human [HOS] and 
feline [CrFK, KE-R]) and T-cell lines (human [A3.01] and feline [MYA-1, FeT-1C]) were infected with increasing amounts of HIV-
Luc(VSV-G). Luciferase activity (in counts per second) was determined at 3 dpi. Center panel: CrFK, A3.01, MYA-1, and FeT-1C 
cells were inoculated with increasing amounts of FIV-Luc(VSV-G). Luciferase activity was determined at 3 dpi. (B) CrFK, A3.01, 
MYA-1, and FeT-1C cells were transduced using HIV-GFP(VSV-G) at an MOI of 5. GFP fluorescence was determined 3 dpi by flow 
cytometry. The data are presented as side scatter versus the intensity of green. The quantity (percent) of GFP-positive cells over the 
threshold is indicated above of the horizontal line in each panel; mean fluorescence intensity is specified below the horizontal line.

fold-lower luciferase activity, most likely because the replication-
competent virus induced massive syncytium formation at 2
to 3 dpi. The X4-tropic envelopes (L102, HXB2) did not allow
infection of the huCD4-positive feline cell lines, while reporter
viruses carrying either of these glycoproteins infected the CD4-
expressing HOS.CD4.CCR5 cells. These results could imply
that endogenously expressed CXCR4 protein in HOS cells, but
not in feline cells, efficiently supports HIV-1 infection. The cell
lines expressing no CD4 (HOS.CXCR4 and K-ER) showed
luciferase activity only after inoculation with VSV-G-
pseudotyped HIV-Luc particles. In experiments using human
HOS cells expressing the feline CD4 protein together with
huCCR5 or huCXCR4 (HOS.feCD4.CXCR4, HOS.feCD4.
CCR5) (Fig. 2A), luciferase activity of HIV-Luc (JR.FL or
L102 or HXB2) was not detectable (Fig. 2D). These results
argue against the use of feline CD4 as a potential HIV-1 entry
factor.
  Lack of spreading replication of HIV-1 in feline cells ex-
pressing human entry receptors. In order to further evaluate
the capacity of the feline CrFK.CD4.CCR5 and KE-
R.CD4.CCR5 cells to support HIV-1 replication, they were
infected at a low MOI (0.05) with replication-competent HIV-
1NL-BaL (44). Quantification of released CA.p24 in the super-
natant of infected cells by ELISA showed a peak of viral
replication in the human HOS.CD4.CCR5 cells at 7 dpi (Fig.
3A). Supernatants of infected feline cells yielded only back-
ground levels of p24, indicating the absence of spreading rep-
lication in the feline fibroblasts. Interestingly, the HIV-inocu-
lated feline cells showed syncytium formation at 3 to 4 dpi (Fig.
3B), suggesting successful initial infection of some cells with
HIV-1NL-BaL.
  Processing and release of HIV-1 proteins in feline cells.
Since the feline CrFK.CD4.CC5 and KE-R.CD4.CCR5 cells
were permissive with respect to transduction by HIV-Luc re-
portervirus whereas cultres infected with the replication-
competent HIV-1NL-Bal did not show viral spreading, we
wanted to investigate the molecular basis of this restriction. In
a first step we characterized the expression patterns of viral
proteins in feline and human cell lines. To ensure a single
round of infection, receptor-negative feline cell lines (KE-R,
    FIG. 2. Feline cells expressing human CD4/CCR5 are permissive for HIV-1 reporter virus transduction. (A) Receptor expression 
of human CD4, feline CD4 (feCD4), human CCR5, and human CXCR4 on HOS, KE-R, and CrFK cells stably transduced by retrovi-
ral expression vectors (black) and mock transduced (grey). The cells were stained for human CD4 with SK3-PerCP, feline CD4 with 
3-4F4-PE, human CCR5 with 2D7-PE, and human CXCR4 with 12G5-PE. Fluorescence intensity was analyzed by flow cytometry. 
(B and C) Human and feline cell lines coexpressing human CCR5 and human CD4 were infected with HIV-Luc pseudotyped with 
VSV-G- or HIV-1-derived envelopes (JR.FL, BaL.01, BaL.26, L102, HXB2). NL-BaL, virus generated by cotransfection of HIV-Luc 
and HIV-1NL-BaL. Luciferase activity (in counts per second) was determined 3 dpi. Cells expressing no CD4 (HOS.CXCR4 and K-ER) 
were used as controls. (D) Human HOS cells expressing feline CD4 (feCD4) or human CD4 (CD4) together with human CCR5 or 
human CXCR4 were infected with HIV-Luc pseudotyped with VSV-G- or HIV-1-derived envelopes (JR.FL, L102, HXB2). Luciferase 
activity (in counts per second) was determined 3 dpi. Cells expressing no CD4 (HOS.CXCR4 and HOS.CCR5) were used as controls.
  FIG. 3. Feline cells expressing HIV receptors do not support spreading replication of HIV-1. (A) HOS.CD4.CCR5, KE-R.CD4.
CCR5, and CrFK.CD4.CCR5 cells were infected with R5-tropic HIV-1NL-Bal at an MOI of 0.05. Supernatant virions were quantified 
by p24 ELISA at the indicated days. (B) HIV-1NL-Bal-infected feline cells, KE-R.CD4.CCR5 cells, and CrFK.CD4.CCR5 cells showed 
syncytium formation (arrows) at 3 to 4 dpi (magnification, x10).
CrFK, MYA-1, FeT-1C) and human cell lines (293T, A3.01)
were used for infection with VSV-G-pseudotyped HIV-1 [NL-
BaL(VSV-G)] and analyzed. We used 0.3, 3.0, and 30.0 ng RT
for infection, carefully washed the cells to remove the input
viral particles at 5 h postinfection, and studied the expression
of the HIV-1 Gag/Gag-Pol proteins by anticapsid immunoblot-
ting at 3 dpi. Cell lysates of the infected 293T, KE-R, and CrFK
cells showed comparable high levels of expression of the HIV-1
proteins that were dose dependent (Fig. 4A). A significant but
lower level of expression was detectable in the A3.01 cell line.
Cell lysates of the feline T-cell lines MYA-1 and FeT-1C
showed only weak signals with even the highest amount of
input virus. The processing patterns in human and feline cells
showed no obvious differences. In addition, viral particles re-
leased from cultures initially inoculated with 30 ng RT were
collected and purified by centrifugation through a sucrose
cushion and regular aliquots were analyzed by immunoblotting
(Fig. 4B). While the two human cell lines (293T and A3.01)
released similar amounts of HIV-1 particles, the feline CrFK
cells showed two- to threefold more particles in the cell culture
supernatant. In stark contrast, in repeated experiments the
feline KE-R, MYA-1, and FeT-1C cells showed no or almost
no particles released into the supernatants. This finding cor-
relates with the modest amounts of intracellular HIV Gag in
MYA-1 and FeT-1C cells, whereas KE-R cells clearly showed
a substantial block in particle release.
   HIV-1 virions produced in CrFK cells show low infectivity.
The lack of virus particle release in KE-R cells is probably a
major reason for the replication block of HIV-1 in KE-
R.CD4.CCR5 cells (Fig. 3A). Additional restrictions in feline
cells must exist, since CrFK.CD4.CCR5 cells also did not allow
spreading HIV-1 replication, although efficient release of par-
ticles occurred in infected CrFK cells. In order to study the
infectivity of virus particles, we generated HIV-Luc(VSV-G)
reporter virions in feline CrFK and human 293T cells by plas-
mid transfection. The collected viral vectors were normalized
by RT activity and used to infect human HOS and feline CrFK
cells. HIV-Luc(VSV-G) produced from 293T cells showed
high luciferase activity. In contrast, particles from CrFK cells
showed only background luciferase activity in human and in
feline cells (Fig. 5A), suggesting that these particles had very
low infectivity. Several attempts to produce HIV-Luc(VSV-G)
in K-ER cells by plasmid transfection were unsuccessful (data
not shown).
  To identify the cause of the reduced infectivity of CrFK-
derived HIV-1 particles, we treated the virus-containing su-
pernatant with DNase I to remove potentially contaminating
plasmid DNA and infected human HOS cells. Reverse tran-
scription products were amplified using PCR primers specific
for late-RT products (a 600 bp fragment covering LTR-gag) at
10 h postinfection, cloned, and analyzed by sequencing (Fig.
5B). HIV genomes derived from human 293T cells showed no
   FIG. 4. Reduced HIV-1 Gag expression in feline T cells and restricted HIV-1 release from feline KE-R cells. The results of im-
munoblot analysis of HIV-1 Gag protein expression and processing by feline and human cells are shown. 293T, KE-R, CrFK, 
A3.01, MYA-1, and FeT-1C cells were infected with the indicated amounts of HIV-1NL-Bal(VSV-G). At 3 dpi, lysates of the cells 
were prepared (A) and virions pelleted from the supernatants were analyzed on immunoblots using p24-specific monoclo-
nal antibody (B). For cell lysates of T cells, immunoblots were coprobed using anti-tubulin antibody to show equal samp-
le concentrations. For virions, equal volumes corresponding to 0.5 ml supernatant of cells infected with 30 ng RT were loaded 
per lane. Gag precursor proteins (Pr 160 Gag-Pol, Pr 55 Gag, Pr 41) and p24 capsid protein (p24 CA) are indicated by arrows.
G→A exchanges, but G→A substitutions were highly enriched
(0.72%) in reverse transcripts of HIV particles made in feline
CrFK cells (Table 1). The number of G→A exchanges ranged
between four and seven per sequence (Fig. 5B). When we
analyzed the positive strand for the sequence context which
contained the G3A hypermutations, 25.5% were GG to AG
changes, 68% were GA to AA exchanges, and only 6.5% were
GC to AC or GT to AT mutations (Fig. 6D). Mutations of a
guanosine-purine sequence to an adenosine-purine sequence
on the DNA positive strand are typically found in APOBEC3-
edited retroviral genomes (8, 24, 34, 39, 42, 43). In summary,
the mutation rates showed a strong correlation with the infec-
tivity levels of the HIV particles made in 293T and CrFK cells,
explaining the lack of virus spread in CrFK.CD4.CCR5 cells.
  Feline CrFK cells express several APOBEC3 RNAs. It has
been shown that wt HIV-1 can replicate in the presence of
human APOBEC3G; however, its infectivity is dramatically re-
duced by the presence of heterologous, nonhuman APOBEC3
proteins (43). Based on this observation and the presence of
typical G→A mutations in cDNAs from CrFK-derived parti-
cles, we assumed that feline APOBEC3 deaminases are a major
reason for the low infectivity of HIV-1 produced in CrFK
cells. Recently, we described feAPOBEC3C (feA3C; previously
termed feAPOBEC3 [fe3]) (39) as being expressed in
CrFK cells. For the present study we cloned two additional novel
feline cDNAs, termed feAPOBEC3H and feAPOBEC3CH
(feA3H and feA3CH), from CrFK-derived RNA by a combina-
tion of RT-PCR and 5‘- and 3‘-RACE techniques. The feA3CH
cDNA is composed of the fused open reading frames of feA3C
and feA3H.We propose a nomenclature classification based on
the overall consensus and positions identical between feline
and human APOBEC3s: feline APOBEC3C has 43.8% amino
acid identity to human APOBEC3C, and feline APOBEC3H
shares 44.4% identical amino acids with human APOBEC3H.
Using diagnostic PCR primers we confirmed expression of the
feA3s in CrFK cells (Fig. 6A). The sizes of the detected am-
plification products are in line with the structure of the cDNAs.
In several experiments using different primer and PCR proto-
cols for amplification of the three feA3 cDNAs, we always
observed significantly more PCR product for feA3C than for
feA3H and feA3CH (Fig. 6A and data not shown). We used
the cloned feA3H and feA3CH cDNAs to generate HA-tagged
expression plasmids.
  Feline APOBEC3 proteins inhibit the infectivity of HIV-1.
To assess the antiviral activity of feA3 proteins, HIV-Luc re-
porter viruses were generated in human 293T cells in the
  FIG. 5. HIV-1 particles produced in feline CrFK cells show low infectivity. (A) HIV-Luc(VSV-G) was produced in human 293T 
and feline CrFK cells (producer cells [p.c.]) by plasmid transfection. Normalized viruses containing supernatants were used to 
infect human HOS and feline CrFK cells (target cells [t.c.]). Luciferase activity (in counts per second) was determined 3 dpi. no 
virus, uninfected cells. (B) Genome editing of HIV-Luc(VSV-G) produced in 293T or CrFK cells. A fragment in LTR-gag was 
amplified from reverse transcripts 10 h postinfection. At least 5 to 10 independent nucleotide sequences were determined. The 
mutations in the clones of each group are shown. Each mutation is indicated and coded with respect to the nucleotide substitution.
TABLE 1. Sequence characteristics of HIV-Luc DNA genomes of virions derived from CrFK cells and 293T-expressing feline 
APOBEC3 proteins (feA3C, feA3H, feA3CH) or empty expression plasmid
presence of cotransfected feA3 expression plasmids and equal
amounts of particles were used for infection experiments. The
results depicted in Fig. 6B show that two of the three feline
APOBEC3 proteins are inhibitors of HIV-1-mediated gene
transfer: feA3H and feA3CH reduced the infectivity of HIV-1
by 7- and 37-fold, respectively. Only marginally reduced titers
were observed in experiments using feA3C. The suppression of
reporter gene transfer clearly correlated with a significantly
increased G→A mutation rate in viral reverse transcription
products (Fig. 6C, Table 1): cotransfection of feA3H or
feA3CH resulted in 1.08% and 1.52% G→A substitutions,
respectively. Viral genomes derived from transfections omit-
ting an feA3 expression plasmid showed no G→A editing;
using the feA3C expression plasmid only 0.03% G→A ex-
changes were detectable (Fig. 6C, Table 1). The sequence
context of the majority of the G→A exchanges in viral genomes
derived from 293T cells coexpressing feA3H was similar
to that seen with CrFK cell-derived particles (Fig. 6D): feA3H
induced 28% GG→AG and 65.7% GA→AA exchanges in the
positive strand of the DNA; similarly, viral genomes of CrFK
cell-released virions showed 25.5% GG→AG and 68%
GA→AA mutations. The editing context of the more antiviral
feA3CH showed a different distribution of dinucleotides con-
taining G→A exchanges: 40.4% were GG→AG changes, 34%
were GA→AG mutations, and GC or GT to AC or AT
changes were found in 15% or 10%, respectively. These find-
ings support the idea that the HIV-1 genome editing of CrFK-
derived particles may be attributable to feA3H or to a closely
related feline cytidine deaminase.
  All three feline APOBEC3C proteins were detectable in
purified particles of wt and Dvif HIV1-Luc reporter viruses by
immunoblotting (Fig. 7B), suggesting that the Vif protein of
HIV-1 cannot induce their exclusion from virions as it does
with huAPOBEC3G (data not shown). Particles generated in
the presence of feA3CH showed in addition to the 53 kDa
protein a second smaller protein of ~23 kDa, which was de-
  FIG. 6. Defined feline APOBEC3 proteins inhibit HIV-1 infectivity to different degrees. (A) Analysis of feline APOBEC3C 
(feA3C; lane 1), APOBEC3H (feA3H; lane 3), and APOBEC3CH (feA3CH; lane 5) expression by RT-PCR of total RNA from 
feline CrFK cells. In lanes 2, 4, and 6, PCRs using the primers specific for feA3C (lane 2), feA3H (lane 4), and feA3CH (lane 
6) were performed without template cDNA added. (B) HIV-Luc(VSV-G) was produced in 293T cells in the presence or ab-
sence of the indicated feline APOBEC3. Infectivity of the viruses was determined by quantification of luciferase activity in 
HOS cells infected with equal amounts of viruses 3 dpi. (C) A fragment in LTR-gag was amplified from reverse transcripts of 
HIV-Luc generated in the presence of the indicated feline APOBEC3 10 h postinfection. A total of 5 to 10 independent nuc-
leotide sequences were determined. The mutations in the clones of each group are shown. Each mutation is indicated and 
coded with respect to nucleotide mutation. (D) Comparison of the dinucleotide sequence context of G (underlined)→A 
mutations in the positive-strand DNA of HIV-Luc derived from CrFK cells and from feAPOBEC3-expressing 293T cells.
tectable in protein lysates of the producer cells only as a very
faint band (compare the results shown for anti-HA in lane
fe3ACH of Fig. 7A with those shown for anti-HA in lane
feA3CH of Fig. 7B). We do not know whether this 23 kDa
protein is generated in the 293T cells and preferentially en-
capsidated or produced in virus particles by cleavage of the
feA3CH with the viral- or a particle-associated protease. In
conclusion, it is likely that feline APOBEC3 proteins identical
or related to feA3H and eventually to feA3CH significantly
contribute to the block of spreading replication of HIV-1 in the
CrFK.CD4.CCR5 cells.
DISCUSSION
  In this study, we characterized the ability of different feline
cell lines to support HIV-1 replication with the long-term aim
to use cats (Felis catus) or genetically modified cats as an
animal model for HIV-1 studies. We found that the expression
of functional CD4 and coreceptor molecules in feline cell lines
was insufficient to constitute a permissive environment for
HIV-1 replication. In fact, additional blocks to HIV-1 are
present in feline cells. We identified the feline cytidine deami-
nases of the APOBEC3 family as one of the factors which exert
a strong inhibitory effect on HIV-1 replication in feline cells.
To study the transduction of and entry into defined feline
cells by HIV-1, single-round, replication-deficient HIV-Luc
was used. In these assays with VSV-G-pseudotyped HIV-Luc,
two adherent feline cell lines, CrFK and KE-R, were shown to
be very permissive towards transduction by HIV vectors: HIV-
LTR-driven expression generated a level of luciferase activity
as high as in the human reference cell line HOS. In contrast,
two feline T-cell lines used showed a restriction, with ~10-fold-
lower luciferase counts compared to the human T-cell line
A3.01. Infection with HIV-1NL-BaL(VSV-G) followed by im-
munoblotting revealed a strong correlation of the expression of
the luciferase reporter and viral Gag proteins: the feline ad-
herent cells showed high expression of Gag-Pol, whereas, in
contrast, the feline T-cell lines expressed low levels of Gag-Pol.
Using FIV-based reporter vectors, we could show that the
VSV-G-mediated entry pathway for lentiviruses works equally
in human and feline T-cell lines, ruling out a trap of the
HIV(VSV-G) particles in endosomal vesicles. Because HIV
vectors expressing an EGFP gene driven by an internal CMV
promoter were, like HIV-Luc, also clearly restricted in the
feline T cells, our data suggest that the restriction to HIV-
1(VSV-G) virions is not because of VSV-G pseudotyping and
LTR-driven transcription but is a cytoplasmic postentry block
due to the presence of HIV proteins. This observation is reminiscent
of studies of HIV-1 restriction in rodent cells. In trans-
genic rat lymphocytes, HIV-1-luciferase levels were three- to
sevenfold lower than those seen in parallel infections of primary
human T lymphocytes (29). Baumann et al. (3) reported
that murine T-cell lines had a nonsaturable block at an early,
postentry replication stage which was not present in murine
fibroblastic cell lines. While murine and feline T cells are more
restrictive towards HIV-1 replication than fibroblastic cell
lines, studies of simian cells also revealed a postentry restric-
tion in fibroblastic cells, which was identified as an early satu-
  FIG. 7. Feline APOBEC3 proteins are encapsidated into HIV-1 virions. Virions were generated by cotransfection of 293T cells 
with wt HIV-Luc or Dvif HIV-Luc and HA-tagged feline APOBEC3C (feA3C), APOBEC3H (feA3H), APOBEC3CH (feA3CH), 
and murine APOBEC3 (muA3) expression plasmids or pcDNA3.1 (vector). (A) APOBEC3 expression in the transfected cells was 
detected by immunoblotting using anti-HA monoclonal antibody, Vif expression was detected using Vif antiserum, and expression 
of HIV-1 gag proteins (Pr 55 Gag, Pr 41, p24 CA) was detected using p24CA-specific monoclonal antibody. control, lysate of 293T 
cells not transfected. (B) Encapsidated APOBEC3 in virions normalized by RT activity was detected by probing with anti-HA anti-
body on a parallel immunoblot. Immunoblots of virions were also probed with Vif antiserum and anti-p24CA monoclonal antibody.
rable block at reverse transcription (5, 10, 53). The discovery of
the cytoplasmic-body protein TRIM5a was a milestone in
characterizing this cellular inhibitory activity in simian cells
(72). It is currently unknown whether members of the Felidae
carry a TRIM5 gene. Interestingly, however, Mus musculus
seems to be devoid of it. Since the adherent feline cells did not 
show a TRIM5a-like restriction to HIV-1, the HIV-1 restriction
in the feline T-cell lines could be TRIM5a dependent only
if TRIM5a or a different inhibitor was expressed in a cell
type-specific way. Although feline and rodent T cells have a
postentry restriction for HIV-1 in common, we do not know
whether the underlying mechanisms for this reduced suscepti-
bility are related to each other. The involvement of a TRIM5a-
like protein in the restriction of HIV-1 in feline T-cell lines is
possible, but the involvement of a missing factor cannot be
ruled out.
  HIV-1 can enter cells expressing CD4 and CCR5 molecules
of human and simian origin (15). We generated feline CrFK
and KE-R cells expressing huCD4 and huCCR5. HIV-Luc
viruses pseudotyped with HIV-Env efficiently transduced these
cells, indicating that the human proteins are functional as HIV
receptors or coreceptors in feline cells. In addition, we used
HIV-1 to test the ability of feline CD4 in human cells to
support entry of CXCR4 or CCR5. Our results suggest that
feline CD4, in similarity to mouse and rabbit CD4 molecules
(22, 33), cannot support the entry of HIV-1. Willett et al. (80)
reported that feline CXCR4 functions as a coreceptor for
Env-mediated cell fusion for the HIV-1 strain LAI. In our
study we did not address the role of feline CCR5 or CXCR4,
mostly because an antibody against feCCR5 was not available
and attempts to detect feCXCR4 at the cell surface were un-
successful.
  Expression of huCD4 or huCCR5 did not render the feline
CrFK or KE-R cells susceptible to spreading replication of
CCR5-tropic HIV-1. In contrast to results seen with CrFK
cells, KE-R cells in repeated experiments showed a profound
block in HIV-1 particle release, suggesting differential expres-
sion of required and/or inhibitory cellular factors. But in con-
trast to the results previously obtained regarding the assembly
and release block of HIV-1 in murine cells (6, 45), KE-R cells
efficiently processed the Gag precursor. In primate cells, a
similar cell type- and species-specific block in the release of
progeny virions was described as dependent on the presence or
absence of the viral vpu gene. Vpu facilitates the release of
particles. Some cells are “permissive” and others are “nonper-
missive” of viral replication in the absence of Vpu (18, 67, 68).
In nonpermissive cells, Vpu is considered to counteract a dom-
inant-negative factor whose identity remains to be determined
(56, 77). It is possible that levels and/or species-specific vari-
ants of the ion channel TASK-1 are responsible for the block
in release of virions in primate and feline cells (27). Clearly,
more studies of the HIV-1 release block in KE-R cells are
required to support or rule out the relevance of Vpu for HIV-1
replication in feline cells.
  While the feline CrFK cells efficiently released HIV-1 par-
ticles, these virions showed a strongly suppressed level of in-
fectivity. The viral cDNAs of these virions were mutated and
preferentially showed G→A mutations, which are typically
found when APOBEC3 proteins are encapsidated into retro-
viral particles, transferred into the newly infected cell, and
deaminate single-stranded reverse transcription intermediates
(8, 24, 34, 39, 42, 43, 82, 84). HIV-1 Vif can only counteract
APOBEC3 cytidine deaminases after species-specific molecu-
lar interactions (43). In consequence, HIV-1 is able to replicate
in the presence of the human APOBEC3G but is strongly
suppressed by the orthologous proteins of African green mon-
keys or mice (43). Therefore, we analyzed the effect of the
activity of three CrFK cell-derived feline APOBEC3s on the
infectivity of HIV-1. We found that feA3C, a potent inhibitor
of FFV (39), showed only a mild inhibitory effect on HIV-1. In
contrast, feA3H and feA3CH were strong inhibitors of HIV-1.
Only feA3H and feA3CH induced significant number of G→A
mutations in the viral cDNA during the infection of target
cells. The feA3H and feA3CH proteins were encapsidated in
HIV particles, suggesting that the HIV-Vif protein does not
bind and exclude them from released virions or that it targets
them for proteasome-mediated destruction (compare the re-
sults shown for anti-HA in the wt lanes in Fig. 7B with the
results shown in the Dvif lanes). Interestingly, feA3C is also
packaged into HIV particles but fails to mutate the HIV ge-
nome. A very similar observation was described for the
huAPOBEC3C, which is also encapsidated by HIV-1 but does
not reduce its infectivity (82). Currently we are characterizing
the retrovirus restriction activity of the feline APOBEC3s by
use of FIV-, FFV-, and feline leukemia virus-based reporter
systems.
  The development of a transgenic animal model permissive
for HIV-1 infection would aid studies of HIV transmission and
pathogenesis and would allow testing of therapeutic strategies
that include vaccines. A major obstacle to this end has been the
inability of cells from present transgenic rabbit or rodent mod-
els to support a robust productive HIV-1 infection (6, 11, 45).
Our study extents the list of multiple restriction mechanisms in
nonhuman cells by describing the presence of antiretroviral
factors in feline cells. In particular, components of the ge-
nome-deaminating machinery have been identified and char-
acterized in this study. A detailed analysis of how FIV can
overcome the cellular barriers active against HIV will likely
generate knowledge showing how to genetically adjust HIV-1
to feline cells. 
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BACKGROUND: Over the past years a variety of 
host restriction genes have been identified in hu-
man and mammals that modulate retrovirus infec-
tivity, replication, assembly, and/or cross-species 
transmission. Among these host-encoded restriction 
factors, the APOBEC3 (A3; apolipoprotein B mR-
NA-editing catalytic polypeptide 3) proteins are po-
tent inhibitors of retroviruses and retrotranspo-
sons. While primates encode seven of these genes 
(A3A to A3H), rodents carry only a single A3 gene.
RESULTS: Here we identified and characterized several 
A3 genes in the genome of domestic cat (Felis catus) by 
analyzing the genomic A3 locus. The cat genome pre-
sents one A3H gene and three very similar A3C genes 
(a-c), probably generated after two consecutive gene 
duplications. In addition to these four one-domain 
A3 proteins, a fifth A3, designated A3CH, is expressed 
by readthrough alternative splicing. Specific feline A3 
proteins selectively inactivated only defined genera of 
feline retroviruses: Bet-deficient feline foamy virus was 
mainly inactivated by feA3Ca, feA3Cb, and feA3Cc, 
while feA3H and feA3CH were only weakly active. 
The infectivity of Vif-deficient feline immunodefici-
ency virus and feline leukemia virus was reduced only 
by feA3H and feA3CH, but not by any of the feA3Cs. 
Within Felidae, A3C sequences show significant ad-
aptive selection, but unexpectedly, the A3H sequences 
present more sites that are under purifying selection.
CONCLUSION: Our data support a complex evo-
lutionary history of expansion, divergence, se-
lection and individual extinction of antiviral A3 
genes that parallels the early evolution of Placen-
talia, becoming more intricate in taxa in which the 
arms race between host and retroviruses is harsher.
The domestic cat (Felis catus) is an established animal model
for studies of the brain, genetics, pharmacology, and nutrition
[1]. In addition, the cat serves as a model for viral infectious
diseases. For instance, since feline immunodeficiency virus
(FIV) shares many features in common with human immun-
odeficiency virus (HIV), FIV-infected cats serve as an important
model for HIV/AIDS, for example, with respect to
therapy, vaccination and pathogenesis [2]. In addition, two
other exogenous retroviruses are prevalent in cats, with very
different outcomes of infection. Feline leukemia virus (FeLV)
is a serious oncogenic pathogen of cats [3] whereas feline
foamy virus (FFV) has not been firmly linked to any disease
[4] and shows potential as a gene transfer vehicle for cats [5].
FIV is endemic to at least 21 free ranging Felidae species,
including lion, cheetah, and puma as well as domestic cat [6],
while the prevalence of other feline viruses is less character-
ized. Although molecular and genetic features of these feline
retroviruses have been unraveled over the past years, studies
on the contribution of host genes in permissiveness towards
virus replication and especially in actively restricting virus
multiplication, determining disease, and influencing spread
and transmission are only now becoming possible due to new
achievements in genomics. Recently, the lightly covered
whole genome shotgun (WGS) sequences of the domestic cat
(1.9× genome coverage) were assembled and annotated based
on the comparison with conserved sequence blocks of the
genome sequences of human and dog [7]. The detailed
upcoming 7× WGS sequence and analysis of the feline
genome will provide an important mammalian comparative
genome sequence relative to primates (human and chimpanzee),
rodents (mouse and rat), and carnivores (cat and dog)
and will likely provide new insights into disease inheritance
and the relationship between genetic background of the host
and infectious diseases.
  The APOBEC3 (A3; for apolipoprotein B mRNA-editing cata-
lyticpolypeptide 3) genes are of particular interest because
they form part of the intrinsic immunity against retroviruses
(for a review see [8]), are under a high adaptive selection [9],
and might have undergone a relatively recent unique evolutionary
expansion in primates [10]. In humans, A3F and A3G
specifically are capable of terminally editing HIV-1 by deami-
nation of cytidine to uracil during reverse transcription in
addition to other, still ill-defined antiviral activities [11].
However, the virion infectivity factor (Vif) of HIV actively
counteracts this host-mediated restriction [12-16]. The inter-
action between Vif and A3 proteins is species-specific and
may thus limit cross-species virus transmission [17]. Similar
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editing has been implicated in the replication of a number of
viruses, including simian immunodeficiency virus (SIV),
FFV, FIV and hepatitis B virus [18-21]. While foamy retrovi-
ruses also utilize an accessory viral protein (Bet) to counteract
A3 inactivation, other viruses like human T-cell leukemia
virus have evolved vif-independent mechanisms to evade A3-
mediated restriction, underpinning the importance of this
host restriction [21-23].
  Our objective was to identify and characterize A3 genes in the
feline genome and compare them to those in the human and
dog genomes. Fosmid clones used for the 1.9× WGS cat
genome project and the accompanying data were organized
into a database that could be used for targeted sequencing of
regions underrepresented in the 1.9× genome sequence of the
cat. We have used this resource to characterize the feline A3
region and to infer its evolutionary history. Our results reveal
that, within Felinae, the A3 locus underwent a unique tripli-
cation of the A3C gene, whereas the A3H gene exists as a single
copy. In addition, we found a gene read-through generating 
a double-domain A3CH protein. APOBEC3 pro-
teins of the cat are active inhibitors of various feline retrovi-
ruses and show differential target specificity.
RESULTS
Recently we described an antiviral cytidine deaminase of the
A3 family in cells of the domestic cat [21]. Feline A3 (feA3)
was found to be an active inhibitor of bet-deficient FFV [21]
and SIV (data not shown and see below), but failed to show
antiviral activity against wild-type or Δvif FIV (data not
shown and see below). However, the presence of a vif gene in
the FIV genome, assumed to counteract the anti-viral activity
of A3 proteins, strongly argues for additional feline
APOBEC3s in the cat. This prompted us to search the genome
of F. catus more thoroughly for A3 genes. Initial attempts to
clone cat A3 cDNAs by a combination of PCR and 5’ and 3’
rapid amplification of cDNA ends (RACE) detected, in addition
to feA3, at least two more A3-related RNAs in the feline
cell line CrFK [24].
  Genomic organization of the feline APOBEC3 locus
Comparative genomic analysis has shown that the genome of
the domestic cat contains gene sequences orthologous to
AICDA (activation-induced cytidine deaminase; also known
as AID) and APOBEC1, 2, 3 and 4 in that they map to syntenic
chromosomal regions of human and dog. The chromosomal
localizations of APOBEC1, 2, 3 and 4, were determined on cat
chromosomes B4, B2, B4, and F1, respectively. To further
identify and characterize A3 genes in the annotated Abyssinian
cat genome sequence, we studied fosmids that had been
end-sequenced as part of the 1.9× domestic cat genome
project from Agencourt Bioscience Corporation. To establish
a web-based fosmid cloning system, the 1,806 fosmid 384-
well plates were stored in assigned locations. A fosmid data-
base of 1,288,606 fosmid clones, sequence-trace IDs, plate
and well IDs, and freezer location IDs was generated and
linked to the GARFIELD browser and the National Center for
Biotechnology Information (NCBI) trace IDs. In this system,
fosmid cloning is achieved by using potential orthologues
(that is, human, mouse, dog or yeast) of genes of interest and
searching for fosmid trace IDs by gene ID/symbol in the 
GARFIELD browser or by discontinuous MEGABLAST of
orthologous sequences to F. catus WGS at the NCBI BLAST
site. With the trace ID, the fosmid freezer location ID can be
retrieved from the fosmid database. We have tested 704 fos-
mids and could identify with a 99% accuracy 616 of them
(87.5%), as confirmed by fosmid end-sequencing. Using this
system, we selected a total of seven fosmids that were pre-
dicted to encompass A3 genes and three clones were subse-
quently analyzed by nucleotide sequencing (Figure 1) 
  Figure 1a shows a percent identity alignment of the 50 kb A3
region sequenced aligned to itself. Gene modeling studies
using the predicted nucleotide and amino acid sequences of
cat A3 and A3H cDNAs and the programs Spidey [25] and
Genewise [26] demonstrated the presence of three feline A3C
genes designated A3Ca (identical to A3C cDNA [21]), A3Cb
and A3Cc and a single A3H gene arrayed in a head-to-tail formation
spanning 32 kb of the 50 kb region sequenced (Figure
1a,b). The A3C genes each consist of four exons with coding
sequences that span 3,693, 6,457 and 6,498 bp for A3Cc,
A3Ca, and A3Cb, respectively, whereas A3H contains one 5’
untranslated exon followed by four coding exons that span
2,237 bp (Figures 1 and 2). Consensus splice acceptor sites
were observed for exons 2 to 4 in the three A3C genes and
exons 2 to 5 in the A3H gene. Consensus splice donor sites
were observed for exons 1 to 4 in A3H and in all four coding
exons of the three A3C genes. Interestingly, splicing at the
splice donor sites of exon 4 (bold) in all A3C genes eliminates
the overlapping termination codon (underlined) of the feA3
cDNA (CTT AGG TGA), allowing the generation of chimeric
read-through transcripts. Consensus polyadenylation signals
(AATAAA) were observed at positions downstream of exon 4
for all three A3C genes - A3Ca (positions 32,505, 33,376 and
33,444), A3Cb (positions 42,083, 42,954 and 43,022), and
A3Cc (positions 22,960 and 23,831) - and A3H (position
50,319).
  The initially identified cDNA of feA3 (A3Ca) and the coding
sequences of the genes A3Cb and A3Cc show 97.6% and
98.9% identical nucleotides, respectively, and 96.3-96.5%
identical amino acids to each other. The predicted proteins of
A3Cb and A3Cc differ in six or seven amino acids from feA3
(A3Ca; Figure 3; Figure S2 in Additional data file 3). The
feline A3C genes show high overall similarity to human A3C
with 43.3-43.8% identical amino acids (Figure S2 in Additional
data file 3). In addition to the high degree of sequence
identity between the coding sequences of the three cat A3C
genes, the pattern of repetitive elements, especially in intron
1 of A3Ca and A3Cb (Figure 1A), and self dotplot analyses
(Figure 1c) suggested significant sequence identity in noncod-
ing regions of these highly related genes. Supplementary
Table 1 in Additional data file 2 shows the size of each intron
and the pairwise percent identities between the introns of the
three genes: the introns of A3Ca and A3Cb have a high degree
of nucleotide sequence identity (98-99%) across all three
introns whereas A3Cc shows a lower degree of sequence iden-
tity to either A3Ca or A3Cb (67-96%), depending on the size
of the intron. Based on the very high similarity of the A3C
genes, two gene duplications in rather recent evolutionary
times seem to be highly likely. The first duplication yielded
A3Cc and an A3Ca/b progenitor gene. A3Ca/b subsequently
duplicated again, resulting in A3Ca and A3Cb. As expected,
the cat A3C genes have a more distant relationship to the
human A3C group, the feline A3H clusters with the dog A3H
gene, but the dog A3A is only distantly related to human A3A
(Figure 4a). Double-domain APOBEC3 genes structurally
analogous to human A3F or A3G have not been found in the
genomes of either cat or dog..
    FIG. 1. Gene organization of the feline APOBEC3 region. (a) Shown is a Pipmaker analysis of the 50 kb nucleotide sequence 
of the APOBEC3 region showing the intron/exon organization of the four identified feline A3 genes (A3Cc, A3Ca, A3Cb and 
A3H) and annotation of repetitive elements (see inset for key: Simple, simple repeat sequence poly(dT-dG).poly(dC-dA); LTR, 
long terminal repeat retrotransposons; SINE, short interspersed elements; SINE/MIR, MIRs are tRNA-derived SINEs that amplified 
before the mammalian radiation; SINE/lys, tRNA-lys-derived SINE; LINE1, long interspersed element 1; LINE 2, long interspersed 
element-2; CpG/GpC ratios are indicated). (b) Organization and gene content of the fosmids used for nucleotide sequencing. (c) 
Selfdotplot of the percent identities of the A3C region showing the high degree of sequence identity between A3Cc, A3Ca, and A3Cb.
    FIG. 2. Representation of the feline APOBEC3 genomic region, portraying the detected A3 transcripts. Transcripts with translated 
exon (rectangles) and splicedout introns (dotted lines) are indicated. Please note that the transcript for A3H comes in two versions: 
with complete exon 2 and further spliced exon 2, resulting in 5' truncation (Ex. H2 5'Δ). The mRNA for A3CH includes exon 4 of 
A3Cb in an additionally spliced version, 3' truncating the sequence one nucleotide before the stop codon (Ex. Cb4 3'Δ).
 Expression of feline APOBEC3 genes. Initially, we 
applied 3' RACE assays using the A3Ca sequence in order to 
clone additional feline A3 cDNAs. We detected the single-
domain A3H and a cDNA composed of the fused open 
reading frames of A3C and A3H, designated A3CH [24]. A 
closer inspection of the sequence of A3CH revealed that the 
transcript is encoded by exons 1-3 of A3Ca, the complete coding
sequence of exon 4 of A3Cb and exons 2-5 of A3H (Figure
2). Importantly, the consensus splice donor of exon 4 of A3Cb, 
located only one nucleotide 5’ of the stop codon TGA, is
used for in-frame splicing to A3H exons 2-5. The doubledomain
A3CH RNA was found in three tested cell lines (CrFK,
MYA-1, KE-R) and also in feline peripheral blood mononu-
clear cells (PBMCs; Figure 5a). In 20 cloned PCR products
from independent reverse-transcriptase (RT)-PCR reactions
using RNA from CrFK, MYA-1 and PBMCs, the A3CH cDNAs
were always exactly as described above (exons 1-3 of A3Ca,
the 3’ truncated exon 4 of A3Cb and exons 2-5 of A3H). In no
case did we observe sequence variation in the A3CH mRNA,
for example, by contribution of other A3C exons. We used
diagnostic PCR primers to analyze the expression of A3Ca, 
A3Cb, A3Cc, and A3H in total RNA of feline PBMCs (of two
cats of unknown pedigree) and cell lines (CrFK, KE-R, MYA-
1). About half of the mRNAs from the activated feline PBMCs
corresponded to A3Ca (22 of 40 clones) and approximately
17% were identical with A3Cb (7 of 40 clones) as determined
by RT-PCR allowing detection of all three A3Cs. The remain-
ing PCR products of A3C cDNAs represented additional variants,
designated A3Cx and A3Cy, each containing six amino
acid differences relative to A3Ca (Figure S1 in Additional data
file 3), indicating further genetic allelic variation in cats.
Sequence-based genotyping by direct PCR of genomic DNA
using locus specific primers for exons 2-4 from eight domestic
cat breeds resulted in finding zero, thirteen, and four non-
synonymous substitutions and zero, one, and two synony-
mous substitutions in A3Ca, A3Cb and A3Cc genes, respectively
(Figure 3b; details in supplementary Table 4 in
Additional data file 2). MYA-1 cells expressed A3Ca, A3Cb
and A3Cc genes (15, 5 and 1 clone out of 21, respectively), but
CrFK and KE-R cells expressed only A3Ca (10 of 10 clones for
each). Feline A3H was detected in all analyzed cell lines and
PBMCs (Figure 5a). Interestingly, the transcript for A3H
seems to be subject to alternative splicing, since we consist-
ently detected an additional variant containing a 5’ truncated
exon 2, generating a cDNA with a 149 nucleotide shorter 5’
untranslated region (Figure 2).
  In order to determine whether the different A3 proteins are
present in feline CrFK and MYA-1 cells, immunoblot analyses
using antisera directed against cat A3C and A3H as well as a
serum directed against the A3CH-specific sequence flanked
by the C- and H-domains in A3CH (linker) were employed. In
extracts from CrFK and MYA-1 cells the anti-linker serum
detected a protein band that clearly co-migrated with A3CH
expressed from plasmid pcfeA3CH in transfected 293T cells
(Figure 5c). The C- and H-domain-specific antisera detected
the corresponding A3C and A3H proteins in CrFK cells while
only after over-exposition of the immunoblot was the A3CH
protein detectable with these sera (data not shown). This
detection pattern may reflect low-level expression of A3CH or
may indicate that the corresponding epitopes are masked in
the two-domain A3CH protein.
  To search for transcription factor binding sites that might
regulate A3 expression in the domestic cat A3 gene cluster, we
first aligned the upstream 1.1 kb, including 100 bp of the pre-
dicted exon 1 for each gene A3Ca, A3Cb, A3Cc, and A3H using
ClustalW. This analysis showed considerable sequence simi-
larity in the proximal 5’ flanking sequences of all four A3
genes, with A3Cc the most divergent (Figure S3 in Additional
data file 3). Using MEME to search for conserved sequence
elements in a set of DNA sequences using an expectation-
maximization algorithm, we detected two highly conserved
50 bp sequence motifs between all four promoter regions, one
located flanking the putative transcription start site and the
other approximately 200 bp upstream [27,28]. Individual 5’
flanking sequences were analyzed using the Match program,
which uses a library of nucleotide weight matrices from the
TRANSFAC6.0 database for transcription factor binding sites
[29]. The first 50 bp motif contains putative transcription fac-
tor binding sites for HNF-4 and Elk-1 as well as a site report-
edly present in all phenobarbital-inducible promoters 30 bp
upstream of the transcriptional start site. No obvious TATA or
CAAT boxes were identified, similar to the human A3 region
[30]. The second site (200 bp upstream of the start site)
includes Octamer and Evi-1 transcription factor binding sites,
which are associated with transcription in hematopoietic cell
lineages. Further 5’, the sequences and predicted transcrip-
tion factor binding sites of A3Ca, A3Cb and A3H are relatively
well conserved whereas A3Cc is divergent, suggesting that
   FIG. 3. Comparison of the nucleotide coding and amino acid sequences of the feline A3C genes. (a) Pairwise comparison of the 
domestic cat A3 cDNA to the predicted A3Ca, A3Cb and A3Cc genomic coding sequences and the predicted amino acid sequences. 
(b) Amino acid sequence alignment of A3C cDNA and the predicted proteins for A3C genes. Highlighted in yellow are amino acid 
residues different between the A3Cs based on the genomic sequence, whereas amino acid sites displaying non-synonymous amino acid 
substitutions are boxed in blue and red for A3Cb and A3Cc, respectively, as identified by SNP genotyping of eight domestic cat breeds 
for exons 2-4 of A3Ca, A3Cb and A3Cc (for more details see Table 4 in Additional data file 2). Arrows indicate exonic junctions. Below 
the alignments, variant amino acids are boxed in red for A3Cc (for example, W65R) and blue for A3Cb with respect to the breed from 
which they were identified: Turkish van (VAN), Egyptian mau (MAU), Sphynx (SPH), Birman (BIR) and Japanese bobtail (BOB). A 
dash indicates the amino acid is identical to genomic sequence. Numbers adjacent to breed identifiers refer to alleles 1 and 2 identified 
by clonal sequence analysis of the PCR products that are in phase for exons 3 and 4, but not for exon 2 (1/2). The residue corresponding 
to functionally significant amino acid replacement identified in human A3G (D128K) is highlighted by an asterisk (see text).
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   FIG. 4. (see legend on next page)
A3Cc has a unique transcription profile as indicated in our
RT-PCR expression studies. Another approach to identify
transcription factor binding sites, ModelInspector uses a
library of experimentally verified promoter modules or mod-
els that consist of paired transcription factor binding sites,
orientation, order and distance. Using this method, we iden-
tified four paired transcription factor binding sites shared
between one or more of the feline A3 promoters and that of
human A3G [31], including two ETS-SP1 (A3Ca, A3Cb, A3Cc
and A3H), IKRS-AP2 (A3H), and NFκB paired with either
CEBP (A3Ca and A3Cb), RBPF (A3Ca, A3Cb and A3Cc) or
STAT (A3Ca, A3Cb and A3H). Future studies are required to
demonstrate the potency of these elements. 
  Diversity of APOBEC3 in the family Felidae. It was 
demonstrated that primate A3 genes are under a strongpositive 
selection predating modern lentiviruses [9,32,33]. Currently, 
it is not known whether the rapid adaptive selection of A3 
genes is unique to primates or represents rather a general 
feature of Placentalia. To gain further insight into this 
question, we analyzed A3 sequences of additional Felidae spe-
cies. We cloned the orthologous cDNAs of A3C and A3H from
activated PBMCs of lion (Panthera leo bleyenberghi), two
tiger subspecies (Panthera tigris sumatrae and Panthera
tigris corbetti), leopard (Panthera pardus japonensis), lynx
(Lynx lynx) and puma (Puma concolor). Together with F.
catus, this collection comprises four of the eight extant lineages
within Felidae [34]. We characterized two to six transcripts
for A3C and A3H of each species, one animal per
species. The phylogenetic relationships and identities to the
domestic cat A3 genes are shown in Figure 4b,c, and supple-
mentary Tables 5 and 6 in Additional data file 2. In lynx, lion
and tiger, the cDNAs for A3C depicted some degree of intra-
species genetic variability and all variants were included in
our analysis. In three of six A3C isolates of Sumatra-tiger and
both Indochina-tiger cDNAs, the sequence encoded a lysine
at position 185, while in the three other clones of Sumatra-
tiger a glutamate was encoded. No further diversity in A3Cc-
DNAs of Sumatra-tiger and Indochina-tiger was found. We
detected only a single type of A3H transcript in each of the
above-mentioned felid species. In Indochina-tiger A3H, we
found a polymorphism encoding either an arginine or a lysine
at amino acid position 65, whereas in A3H cDNAs of
Sumatra-tiger, only K65 was seen. The A3CH transcript was
also detected in cDNA preparations of lion, puma, Sumatra-
tigerand lynx (leopard was not analyzed) (Figure 5b).
   Comparing non-synonymous substitution rates (Ka) and syn-
  FIG. 4. (see previous page) Phylogenetic analyses of the feline A3C and A3H genes. (a) Maximum clade credibility tree 
obtained after Bayesian phylogenetic inference with BEAST for the three large clusters of APOBEC3 sequences: A3A, A3C and 
A3H. Domains in two-domain proteins were split and analyzed separately, their position in the original sequence indicated as 
CT or NT, for carboxy-terminal or amino-terminal, respectively. Values in the nodes indicate corresponding support, as follows: 
Bayesian posterior probability/maximum likelihood (percentage after 500 cycles bootstrap)/distance analysis (percentage 
after 1,000 cycle bootstrap) parsimony analysis (percentage after 1,000 cycles bootstrap). The scale bar is given in substitutions 
per site. The domains within the A3 proteins can be divided into three groups of related proteins: A3H (Z2), A3A (Z1B) and 
A3C (Z1A). (b,c) Zoom-in on the maximum clade credibility tree obtained after Bayesian phylogenetic inference with BEAST, 
focusing on the Felinae APOBEC3C sequences (b) and APOBEC3H (c) sequences. Values in the nodes indicate corresponding 
support, as in the main tree in (a). The scale bar is given in substitutions per site. Figures above the branches indicate Ka/Ks 
ratios, calculated using Diverge. In some instances, zero synonymous substitutions lead to an apparent Ka/Ks ratio of infinity.
onymous substitution rates (Ks) within the alignment of the 
A3C and A3H cDNA sequences, several Ka/Ks ratios were
above 1, indicating positive selection among the A3C
sequences (Table 2 in Additional data file 2) and the A3H
sequences (Table 3 in Additional data file 2) of the different
felids. Because extreme Ka/Ks ratios below or above 1 may
appear when only few residues are under positive or purifying
selection, we used the sliding window approach to determine
whether defined regions of the A3 proteins are under any type
of selection. The results in Figure S4 in Additional data file 3
show that comparison of feline A3s to the corresponding
human A3s do not show clear positive or negative selection as
expected due to the evolutionary divergence. In contrast, positive
selection of cat, tiger, lion and leopard A3Cs peaks
around 200 bp (at the start of the Zn2+-coordinating domain)
while comparison with lynx and puma A3Cs reveal different
sites under positive selection. In the case of A3H the sliding
window comparison was not meaningful because the small
number of substitutions led to many infinity values due to Ks
= 0. Therefore, the trees of the A3C and A3H genes (Figure
4b,c) were further tested for the presence of selection among
amino acid sites using the Phylogenetic Analysis by Maxi-
mum Likelihood (PAML) program version 3.15 [35,36]. Eval-
uating the difference of the maximum likelihood values for
the trees calculated with different evolutionary models, a
probability estimate for positive selection can be deduced. In
the case of A3H the difference is not statistically significant (P
= 0.4; Additional data files 1 and 2), but in model 2, which
allows for three different ω values (ω = 1 means neutral evo-
lution, ω < 1 purifying selection, ω > 1 positive selection), 71%
of A3H are summarized with ω = 0, supporting purifying
selection as the simplest evolutionary model. In contrast, pos-
itive selection can be found for several residues for A3C
sequences (P < 0.0001; 15% of A3C are summarized with ω =
7.2 under model 2). Comparable results were obtained when
using the webserver Selecton version 2.2 [37,38] for cat A3Ca
and cat A3Cc with the alignment of A3C with all felid species
and for cat A3H using the alignment of A3H sequences (data
not shown).
  The diverse feline APOBEC3s differentially inhibit feline 
retroviruses. In a recent study we showed that cat A3Ca is a 
potent inhibitor of bet-deficient FFV (FFVΔbet) [21]. We were 
interested to extend this finding and tested A3Ca, A3Cb, A3Cc, 
A3H and A3CH as well as dog A3A and A3H with viral reporter 
systems for FFV, FIV and FeLV. To monitor the activity of the A3s,
plasmids expressing hemagglutinin (HA)-tagged versions of
        FIG. 5. Expression analysis of feline A3C, A3H and A3CH. (a,b) Analysis of expression of feline A3C, A3H and A3CH by RT-PCR of 
total RNA from feline cell lines (CrFK, MYA-1, KE-R) and feline PBMCs (a) and expression of A3CH in PBMCs of lion, puma, Sumatra-
tiger (tiger), and lynx (b). H2O indicates PCRs using primers specific for the A3s without template cDNA added. (c) Analysis of expression 
of cat A3CH by immunoblot using rabbit serum against the sequence flanked by the C- and H-domains in cat A3C (linker) using 293T 
cells transfected with A3 expression plasmid or empty vector as indicated and CrFK and MyA-1 cells (two independent cultures each).
A3 were used. All A3 proteins could be detected in immuno-
blots; cat A3Ca, A3Cb, A3Cc and A3CH were comparably
expressed, and the expression of cat and human A3H was
reduced three- to five-fold (Figure 6a).
   The effect of A3 co-expression on wild-type and Bet-deficient
FFV was studied after transfection of 293T cells. For this purpose,
the infectivity of FFV titers was determined two days
after transfection by using FeFAB reporter cells [39].
Cotransfection of A3Ca did not reduce the wild-type FFV
titer, whereas a 700-fold reduction in titer was detected with
the Bet-deficient FFV (Figure 6b), as described previously
[21]. Quite similarly, A3Cb and A3Cc did not inhibit wild-type
FFV but reduced the titer of Δbet FFV by 200- and 70-fold,
respectively. Feline A3H and A3CH showed a comparable low
antiviral activity and reduced Bet-deficient but not wild-type
FFV to a much lower degree. Dog A3A and A3H did not
inhibit the infectivity of Δbet FFV or wild-type FFV. To assess
the antiviral activity of the cat A3s on FIV, vesicular stomatitis
virus-G protein (VSV-G) pseudotyped wild-type FIV-luci-
ferase (FIV-Luc), Δvif FIV-Luc and Δvif FIV-Luc cotrans-
fected with Vif expression plasmid (pcFIV.Vif-V5) reporter
vectors were generated in 293T cells in the presence of A3
expression plasmids. Equal amounts of particles were used
for transduction experiments. The results depicted in Figure
6c show that only two of the five cat A3 proteins are inhibitors
of FIVΔvif-mediated gene transfer: feline A3H and A3CH
reduced the infectivity by five- and ten-fold, respectively, sim-
ilar to the human A3H. Feline A3Ca, A3Cb or A3Cc and dog
A3A expression plasmids did not reduce infectivity of wild-
type or Δvif FIV. In contrast, dog A3H showed antiviral activ-
ity against wild-type and Δvif FIV, causing a three-fold reduc-
tion. We recently showed that the inactivation of Δbet FFV
and HIV-1 by feline A3s was attributable to cytidine deamina
tion of viral reverse transcripts [21]. The suppression of Δvif
FIV by feline A3H and A3CH also correlates with a significant
increased G→A mutation rate in the viral genomes (Figure
S5a,b in Additional data file 3): cotransfection of feA3H or
feA3CH resulted in 1.61% and 1.31% G→A substitutions,
respectively. Viral genomes of Δvif FIV derived from transfec-
tions omitting an A3 expression plasmid showed no G→A
editing; using feA3Ca, feA3Cb or feA3Cc expression plasmids,
only 0.1% G→A exchanges were detectable at most. These
data highly correlate with the inhibitory activity detected in
the infectivity studies. The presence of Vif protein inhibited
the genome editing nearly completely (Figure S5 in Addi-
tional data file 3). The sequence context of the majority of the
G→A exchanges in the viral genomes derived from co-
expressing feA3H and feA3CH showed no clear preference for
a dinucleotide: feA3H induced 17% GG→AG, 35% GA→AA
and 42% GC→AC exchanges in the positive strand of the
DNA. The editing context of the A3CH showed 28% GG→AG
changes, 39% GA→AG mutations, and 28% GC→AC changes.
Both A3s edited in 5-6% GT→AT dinucleotides (Figure S5c in
Additional data file 3). Interestingly, in the FIV system, the
more antiviral A3CH generated slightly lower numbers of
mutations than the less antiviral A3H (Figure S5a,b,d in
Additional data file 3). This result could point either to addi-
tional and unknown activities of A3 proteins or to differences
between the degradation kinetics of uracil-containing DNAs.
   To analyze the impact of cat A3 proteins on the infectivity of
FeLV, we used a molecular clone of FeLV subgroup A (p61E-
FeLV). Reporter particles were generated by co-transfection
of the p61E-FeLV packaging construct, a murine leukemia 
virus (MLV)-based green fluorescent protein (GFP)-reporter
genome, a VSV-G pseudotyping plasmid and the different A3
expression plasmids. The FeLV/GFP virions were normalized
for RT activity and used for infection of 293T cells. The GFP
expression pattern of the inoculated cells demonstrated that
cat A3Cs and dog A3H did not reduce the infectivity of FeLV/
GFP (Figure 6d). Cat A3H and dog A3A had a marginal effect
and A3CH showed a significant effect on FeLV, inhibiting the
virus by a factor of 5. We also tested the simian lentivirus
SIVagm-LucΔvif and found that all cat A3s, except A3Cc, and
dog A3H showed strong antiviral activity. Dog A3A did not
reduce the infectivity of SIV (Figure 6e).
   In summary, the feline A3Ca, A3Cb, and A3Cc proteins dis-
played very high activity only against FFVΔbet while A3H and
A3CH reduced FFVΔbet infectivity much less. In contrast,
only feline A3H and A3CH had a moderate inhibitory effect
on Δvif FIV, and A3CH weakly but significantly inhibited
FeLV. The Vif protein of FIV counteracted feline A3H and
A3CH, but failed to neutralize the antiviral activity of human
and canine A3H. The FFV Bet protein mainly counteracted
feline A3Ca, as recently shown [21], and A3Cb and A3Cc. We
conclude that the various feline A3 proteins differentially tar- 
get feline retroviruses with a remarkable virus-specific
profile.
DISCUSSION
   Phylogenetic analysis of the domestic cat APOBEC genes rel-
ative to human and dog demonstrated that cat and dog con-
tain genes orthologous to human AICDA (AID), APOBEC1
(A1), A2, A3 and A4. The human A3 gene cluster on chromo-
some 22 spans 130 kb and contains seven genes that can be
classified according to the presence/absence of the Z1a, Z1b
and Z2 zinc-coordinating motifs [32,40]. Z1a, the A3C family,
consists of human A3C, the carboxy- and amino-terminal
domains of human A3DE and A3DF, and the amino-terminal
domains of human A3B and A3G (Figure 4a). The Z1b group,
the A3A family, contains human A3A and the carboxy-termi-
nal domains of human A3B and A3G. The human A3H repre-
sents the Z2 zinc-finger domain. Accordingly, human A3B,
A3G, A3DE, and A3F have two domains, while A3A, A3C, and
A3H have one domain. Our analysis shows that the genome of
the domestic cat contains three A3C genes (A3Ca to A3Cc) in
addition to one A3H. The feline A3C genes have a single
domain and are related to the human Z1a group but form
their own cat specific lineage (Figure 4a). None of the domes-
tic cat genes identified fall into the Z1b group. Cross-species
BLAST analyses of the cat 1.9× genome sequence employing
dog predicted genes for A3A and A3H using NCBIs cat WGS
contig, trace and end-sequence databases failed to identify
any cat gene other than A3C and A3H. Presumably, either the
cat does not contain Z1b family genes or these genes are not
represented in the 1.9× sequence. The fosmid DNA library
and database described here provide an additional genomic
DNA resource for isolation and characterization of feline
genes involved in infectious and inherited disease. Since the
fosmids in the library have been mapped to the 1.9× cat
genomic sequence by end sequencing, it is not necessary to
screen genomic libraries by hybridization or PCR to isolate
genes of interest as with previous genomic libraries.
   Human A3G and A3F have been shown to be active against
HIV-1, which lacks the virion infectivity factor (vif) [13-
16,41]. The Vif protein of HIV-1 exclusively binds and inacti-
vates human A3 proteins in a species-specific way [17]. The
D128K mutation in the human A3G gene altered the Vif inter-
action [42-44] and H186R correlated with slow AIDS pro-
gression in African American populations [45]. In felids three
types of exogenous retroviruses are known: within Orthoret-
roviridae, FIV, a lentivirus related to HIV-1, and the gamma-
retrovirus FeLV; and, within Spumavirinae, FFV. FIV infects
both wild and domestic felid species [6]. Similar to the diver-
sification of SIV in African monkeys and apes, species-spe-
cific strains of FIV have been described [46]. But unlike SIV,
which is detectable only in African species, FIV is endemic in
African, South American and Asian Felidae [6]. For FeLV the
prevalence in wild species is not known and limited studies on
FFV supported the presence of FFV-related isolates in two
species of the leopard cat lineage [47].
   The ability of Vif proteins to counteract the antiviral activity
of A3 proteins is specific for a virus-host system. Thus, while
the HIV-Vif protein counteracts the human A3F and A3G pro-
teins, it is not effective against cat A3H and A3CH, as we
recently reported [24]. In contrast, FIV-Vif neutralizes the cat
A3H and A3CH induced cytidine deamination. Since we could
not detect homologous genes to A3F or A3G in the domestic
cat genome, the essential role of controlling retrovirus repli-
cation seems to be covered by different A3 proteins in permis-
sive mammals (humans and cats). Interestingly, neither
human A3C nor A3H proteins are inhibitors of wild-type or
Genome Biology 2008, 9:R48
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Δvif HIV-1 [18,32], supporting a host-specific genetic adapta-
tion of A3 genes.
   The vif gene of FIV is a relevant modulator of spreading virus
infection, since FIV in which the vif gene was deleted showed
a replication block in feline CrFK cells that express A3, as we 
showed [21,24,48]. Furthermore, in domestic cats experi-
mentally infected with FIVpco isolated from P. concolor, the
virus was controlled and the cats did not develop clinical signs
associated with FIV infection. The restriction of FIVpco was
attributed to feline A3 proteins, because the viral genomes of
FIVpco grown in cats accumulated extensive G-to-A muta-
tions [20]. It is likely that insufficient molecular recognition
and inactivation of heterologous feline A3 by the Vif protein
of FIVpco caused this attenuated virus infection. It is interest-
ing to emphasize here that the Puma genus is the closest relative
of the Felis genus, having diverged approximately 6.7
million years ago [34]. The ability of the cat A3 proteins to
limit FIVpco infection while not being able to limit FIV infec-
tion may thus reflect the fact that the FIV infecting F. catus
has evolved the potential to escape A3-mediated restriction of
its host since the divergence of both felide lineages. Cat A3H
and A3CH also showed some inhibitory activity against FeLV.
In contrast to Δvif FIV, these active antiviral proteins showed
only weak antiviral activity against Δbet FFV. Based on these
findings, we conclude that specific feline A3 proteins selec-
tively recognize and inactivate only defined subgroups of
feline retroviruses, while ‘non-adapted’, heterologous retrovi-
ruses (for example, Δvif SIVagm) can be inactivated by all
three types of feA3s with the remarkable exception of feA3Cc. 
These data also reflect the fact that even without expression of
Vif or Bet proteins, retroviruses differ, for unknown reasons,
in their vulnerability to cognate A3 proteins.
   The analysis of the genomic sequences and cDNAs of the cat
A3 loci allowed us to identify three key-features not present in
the primate A3 system: first, one ancestral A3C gene under-
went two successive duplication events in recent times - the
first event generated the ancestor of the present A3Cc gene
and a second gene, which later on underwent a second dupli-
cation giving rise to the ancestors of the present A3Ca and
A3Cb genes; second, the A3H gene in domestic cats is under
purifying selection; and third, the double-domain A3CH is
generated by a read-through transcription and alternative
splicing of three genes. In addition, we detected at least 15
single nucleotide polymorphisms (SNPs) yielding non-synon-
ymous substitutions in A3C genes of 8 different cat breeds. In
primates, the seven A3 genes (A3A to A3H) are present as sin-
gle copies on chromosome 22. In the genome of the domestic
cat, we found three copies of the A3C gene (A3Ca, A3Cb and
A3Cc) in a head-to-tail orientation on chromosome B4. The
feline A3C genes encode proteins that are different to each
other at six to seven amino acid sites. Phylogenetic analyses
indicate that this gene triplication likely occurred by two con-
secutive duplication steps: one ancestral A3C gene duplicated
to the ancestor of A3Cc and a second gene, which later dupli-
cated, giving rise to A3Ca and A3Cb genes. The presence of a
homologous A3Cc gene in P. concolor closely related to the
cat A3Cc gene suggests that at least the first duplication event
occurred before the divergence of the Puma and Felis line-
ages, approximately 6.7 million years ago. The phylogenetic
position of P. tigris A3C basal to the three cat A3C genes
suggests also that the first duplication event occurred after
the divergence of the Panthera and the Felis lineages, approx-
imately 10.8 million years ago. It is generally believed that the
evolution of new protein functions after gene duplication
plays an important role in the evolution of the diversity of
organisms and typically allows for an increased specialization
or function gain of the daughter genes [49,50]. In light of the
seven A3 genes in primates, it is tempting to speculate that
cats, like primates, were under a specific evolutionary pres-
sure to increase the diversity of the co-expressed A3 proteins
that provided additional fitness. Other mammals, such as
rodents and eventually dogs, were either not faced by these
infectious agents or managed to counteract retroviruses and
related retroid elements in a way not involving A3 proteins.
   While primate A3 genes are under an adaptive (positive)
selection [9,32,33], we detected significant positive selection
only for the feline A3C genes. Feline A3H was found to have
more residues under purifying selection than feline A3C. It
thus appears that restriction against an apparently innocuous
virus (FFV), mediated in cat by the A3C genes, is under high
selective pressure whereas A3H, which is active against two
serious cat pathogens, FIV and FeLV, does not evolve adap-
tively. While we consider it unlikely that FFV has a strong but
currently unidentified pathogenic potential, it is possible that
restriction against additional pathogens has shaped this evo-
lutionary pattern. For instance, the cat A3H may protect
against highly conserved, endogenous retroelements or may
act by targeting highly conserved, invariant viral structures of
FIV and FeLV, both features that would result in purifying
selection. It could also be that cat A3H took over additional
important functions distinct from pathogen defense, induc-
ing purifying selection. Finally, the combination of a con-
served A3H domain carrying specifically optimized effecter
functions with a highly adaptive module allowing recognition
of changing targets may explain that the two-domain feA3CH
is much more active against FIV and FeLV than the corre-
sponding single-domain molecules that are either inactive
(cat A3C) or have intermediate activity (cat A3H). We postu-
late that the generation of the fused A3CH transcript is an
evolutionary way to gain a greater variety of proteins from a
limited number of functional exons.
   In order to express the potent anti-retroviral restriction factor
A3CH, the cat has modularly combined sequences from A3Ca
and A3Cb genes and the constant A3H domain. This was
likely achieved by read-through transcription. Read-through
transcription, also called transcription-induced chimerism, a
mechanism where adjacent genes produce a single, fused
RNA transcript, is found in at least 2-5% of human genes
   FIG. 6. (see previous page) Cat A3 proteins selectively inhibit the infectivity of different retroviruses. (a) A3 expression in the 
transfected 293T cells was detected by immunoblottingwith anti-HA monoclonal antibody. (b-e) Wild-type (wt) or Δbet FFV wild 
type (b), wild-type FIV-Luc, Δvif FIV-Luc + Vif expression plasmid (vif.V5) and Δvif FIV luciferase reporter vector particles (c), FeLV/
GFP (d), and Δvif SIVagm luciferase viruses (e) were produced in 293T cells in the presence or absence of the indicated APOBEC3s.
[51,52]. A general feature of human transcriptional read-
through is that intergenic sequences in these RNAs are proc-
essed via the standard eukaryotic splicing machinery that
removes introns from RNA transcripts. Intergenic splicing is
favored in closely located gene pairs [51,52], as true for the
triplicated feline A3C genes. Currently, the regulation of read-
through transcription is uncharacterized and both cis-acting
sequences and trans-acting suppressors/regulators of the
termination machinery could regulate it. Since the cat A3CH
protein displayed a significantly stronger antiviral activity
against FIV and FeLV compared to the single-domain cat A3C
and A3H proteins, the read-through transcription for cat A3
appears to be functionally relevant.
  In this study we did not investigate whether the upstream
genes (A3Ca and A3Cb) have legitimate transcription termination
sites, and whether the downstream gene (A3H) has a
legitimate promoter region. But consensus sequences for
both regulatory elements are detectable using standard anal-
ysis tools (Figure S3 in Additional data file 3). This analysis
showed considerable sequence similarity in the proximal 5’
flanking sequences of all A3 genes except A3Cc, which has a
unique upstream sequence, supporting the experimental data
that A3Cc may have a unique transcription profile. In
humans, A3 genes are differentially expressed in tissues asso-
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showed [21,24,48]. Furthermore, in domestic cats experi-
mentally infected with FIVpco isolated from P. concolor, the
virus was controlled and the cats did not develop clinical signs
associated with FIV infection. T e restriction of FIVpco was
att ibuted to feline A3 proteins, because the viral genomes of
FIVpco grown in cats acc mulated extensive G-to-A muta-
tions [20]. It is likely that insufficient molecular recognition
and inactivati n of heterologous feline A3 by the Vif protein
of FIVpco caused this attenuated virus infection. It is interest-
ing to emphasize here that the Puma genus is the closest rel-
ative of the Felis genus, having diverged approximately 6.7
million years ago [34]. The ability of the cat A3 proteins to
limit FIVpco infection while not being able to limit FIV infec-
tion may thus reflect the fact that the FIV infecting F. catus
has evolved the potential to escape A3-mediated restriction of
its ho t since the divergenc  of both felide lineages. Cat A3H
and A3CH also showed s me inhibitory activity against FeLV.
In contrast to Δvif FIV, these active antiviral proteins showed
only weak antiviral activity against Δbet FFV. Based on these
findings, we conclude that specifi  feline A3 prot ins selec-
tively recognize and inactivate only defi ed subgroups of
feline retroviruses, while 'non-adapted', heterologous retrovi-
ruses (for example, Δvif SIVag ) can be inactivated by all
three types of feA3s with the remarkable exception of feA3Cc.
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Model of mammalian A3 gene evolution. The model proposes the presence of several A3 genes in Placentalia before the separation of the super-orders 
Afrotheria, Xenarthra, Euarchontoglires and Laurasiatheria. According to the phylogenetic relationships among the extant A3 proteins, a host-specific 
evolution of the A3 genes during the early evolution of the Placentalia orders by means of preservation, deletion and/or gene duplication and concomitant 
subfunctionalization or neofunctionalization is inferred. Successive duplication events from a single ancestral A3 gene might have generated multiple A3 
genes before basal radiation within Placentalia. The divergence times of taxons is in millions of years (Myr) ago. Basal radiation within Monotremata and 
Marsupialia is not shown. A3, APOBEC3; A3Δ5, A3 lacking exon 5 derived amino acids. Relationship of taxa and timing of mammalian evolution is based on 
[85], but please note that the timing is controversial [86]. The study of Wible et al. [87] supports a later diversification of the placentalia superorders 
following the Cretaceous-Tertiary (K/T) boundary 65 million years ago.
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ciated with either endogenous or exogenous retroviral repli-
cation, including testes, the ovary and un-stimulated and
stimulated peripheral blood lymphocytes (for a review, see
[53]). Analysis of cDNA clones from domestic cat PBMCs, and
MYA-1, CrFK and KE-R cells suggest that the cat A3 genes are 
also differentially expressed. An alternative possibility, however,
is that the fused transcript of A3CH results from trans-
splicing between separate pre-mRNAs of A3Ca, A3Cb and
A3H genes. The amount of trans-splicing in mammals is
unknown and only few examples have been described so far
[54,55].
   In the human A3 locus there is evidence of gene expansion. It
was speculated that duplications of single-domain genes
formed the two-domain A3B or A3G, and, subsequently,
duplication of A3B or A3G formed A3F [30]. Primates and
rodents are both part of the placentalia super-order of Euar-
chontoglires (synonymous with Supraprimates). While pri-
mates have seven A3 genes (A3A to A3H), mice and rats carry
only a single A3 gene. In mice, in addition, a splice variant
lacking exon 5 (A3Δ5) is expressed [17,56]. Based on these
data, it was proposed that primates show a relatively recent
and possibly unprecedented gene expansion [10] or that the
gene expansion happened at the beginning of primate evolu-
tion [40]. The lack of data from other mammals was partially
filled by Jónsson et al. [57], who characterized A3 proteins,
designated A3Fs, from certain cetartiodactyla (cow, pig,
sheep). Rodent and cetartiodactyla A3 proteins consist of two
cytosine deaminase domains, where the amino-terminal
domain is similar to human A3C and the carboxy-terminal
domain shows the highest identity to human A3H [32]. This
CH domain configuration is also found in feline A3CH
described here. In our study we detected A3C and A3H genes
in Felidae, while in the dog genome only genes corresponding
to A3A and A3H are present. Cetartiodactyla and Carnivora
are both grouped into the placentalia super-order of Laurasiatheria.
Based on the presence of at least three different A3
types in Laurasiatheria, we propose that a certain set of A3
genes (A3A, A3C, A3H, or more) was already established
before the separation of the placentalia order. During follow-
ing evolution, this set of A3 genes was either preserved, fused,
deleted or re-expanded depending on the specific require-
ments of the host-virus interactions (Figure 7). Following this
idea, an initial expansion of a single A3 gene happened early
in mammalian evolution, eventually before the appearance of
the placentalia. Further studies on the absence or presence of
A3 genes in the other placentalia super-orders (Xenathra and
Afrotheria) and genomics in monotremata and marsupialia
are necessary to critically evaluate our model of a two-stage
evolution of A3 genes.
CONCLUSION
  Recent studies on the evolution of the primate APOBEC3
genes revealed a primate-specific gene amplification. We ana-
lyzed the genomic APOBEC3 region of the domestic cat (F.
catus) and found a chromosomal APOBEC3 locus different to
that of primates, rodents and dogs. Besides our detection of
three very similar APOBEC3C genes and one APOBEC3H
gene, the cat uses the mechanism of transcriptional read-
through alternative splicing to generate a fifth antiviral
APOBEC3 protein. The evolution of antiviral cytidine deami-
nases shows a strong placentalia family specific pattern. Our
results indicate that three APOBEC3 genes (A, C and H) were
present in the evolution of mammals before the placentalia
super-orders separated.
MATERIALS AND METHODS
 Fosmid database construction and utilization. A 
fosmid (pCC1) DNA library consisting of 693,504 clones 
containing an average insert size of approximately 40 kb of 
domestic cat (breed Abyssinian) genomic DNA arrayed in
1,806 384-well plates frozen at -80°C that was end-
sequenced as part of the Feline Genome Project was obtained
from Agencourt Bioscience, Inc. (Beverly, MA, USA) The bar-
coded plates were recorded into a relational database using
Filemaker Pro (Filemaker Inc., Santa Clara, CA, USA) accord-
ing to their rack number and rack position in a -80°C freezer
along with individual trace identification number, trace
name, and clone identification number (which includes the
location of each individual fosmid within the plate).
   Fosmid DNA isolation, PCR, and nucleotide sequencing. 
The appropriate well of a 384-well plate was picked using a 
culture loop and streaked across LB agar plates containing
12.5 μg/ml chloramphenicol and incubated at 37°C overnight.
Fosmid DNA was isolated using a standard alkaline lysis pro-
cedure. DNA was diluted 1/1,000 in H2O and assayed by PCR
containing 1.0 μM of primer pairs for feline sequence tagged
sites, 200 μM deoxynucleoside 5’-triphosphates (dATP,
dTTP, dCTP, dGTP), 10 mM Tris-HCl (pH 8.3), 50 mM KCl,
1.5 mM MgCl2, and 1 unit TAQ-Gold polymerase in a 20 μl
reaction at 95°C for 4 minutes followed by 30 cycles of 95°C
for 30 s, 60°C for 30 s and 72°C for 30 s and 72°C for 7 min-
utes at the end of cycles. PCR products were analyzed on 2%
agarose gels containing 0.5× Tris-Borate-EDTA buffer (TBE)
and positive PCR products were treated with exonuclease/
shrimp alkaline phosphatase and sequenced using BigDye
Terminator chemistry with the appropriate forward and
reverse primer and analyzed using an ABI 3730XL as
described previously [58]. Fosmids were further analyzed by
end sequencing and/or transposon insertions. Sequences
were assembled using Phred, Phrap, and Consed programs
[59-61]. Genomic nucleotide sequences were analyzed using
RepeatMasker [62] to identify repetitive elements. Genscan
[63], Genewise [26] and Spidey [64] were used to identify
coding sequences and Pipmaker [65] to visualize sequence
features. Potential regulatory sites, including transcription
factor binding sites, splice donor/acceptor sites and polyade-
nylation sites, were identified using Match™ [66], WebLogo
[67,68] and MEME [27,28].
 SNP analysis of A3C genes in cat breeds.The 
following locus specific PCR primers were used for PCR
reactions: A3Ca_exon2_F (GCTGTTCTTTGGGGATAGA- 
GAG); A3Cb_exon2_F (GGTTGGGGGTAGGGCGGGCT);
A3Cc_exon2_F (CACCCACCAGGGACAACTCG);
A3Ca_exon2_R (TGGTTCTCTCCTGGAAACAGA);
A3Cb_exon2_R (AGGCTGTGGCTGGGAGCAGA);
A3Cc_exon2_R (TCTGAGAGATCAGAGGGCCG);
A3Ca_exon3_4_F (CTCAAAAAAAAAGACAGGGCAGA);
A3Cb_exon3_4_F (TCAAAAAAAAAGACAGGGCAGG);
A3Cc_exon3_4_F (GATGGATGGATGGATAGATGGAT);
A3Ca_exon3_4_R (GCTGGGGAGGGAGGTGCGGA);
A3Cb_exon3_4_R (GCTGGGGAGGGAGGTGCGGT); and
A3Cc_exon3_4_R (GCTGGGGAGGGAGGTGCGGC). DNA
samples for eight domestic cat breeds (Abysinnian, Birman,
British Shorthair, Egyptian Mau, Japanese Bobtail, Norwe-
gian Forest, Sphynx, and Turkish van) were amplified by PCR
as described above except that we used 25 ng of DNA sample
and the annealing temperature was increased to 64-70°C
depending on primer pair and DNA sample. PCR products
were analyzed as described above and assembled using
Sequencher 4.7 (Genecodes, Ann Arbor, MI, USA).
     Phylogenetic analysis. Reference sequences for human APO-
BEC genes and predicted dog APOBEC genes were identified 
from Ensembl, Refseq and the NCBI annotation of the dog 
7× genome sequence, respectively. Domestic cat APOBEC 
genes were identified using human APOBEC reference gene 
sequences and were used to screen for traces containing related
sequences. Genscan predicted genes were edited and aligned
using Seqed and Clustalx (ABCC, NCI-Frederick, Frederick,
MD, USA). The sequences used in the phylogenetic trees were
aligned using Clustalw [69]. Manual correction of gaps and
trimming of the homologous cDNA regions were
accomplished with Jalview [70]. For consensus tree construc-
tion with bootstrap values, Seqboot (1,000 samples boot-
strapping), Dnadist (maximum likelihood distance),
Neighbor (UPGMA, jumble 10, different seed values), and
Consense from the PHYLIP package [71] were run. The
lengths of the branches were calculated with PAML3.15 (59;
Model 0, Nssites 2, molecular clock, RateAncestor 1). The
ancestral sequences for the different nodes were taken from
the PAML result. Alternatively, cDNA sequences were trans-
lated and aligned at the amino acid level using MUSCLE [72],
manually edited, filtered with GBLOCS [73], and then back-
translated conserving the codon structure. Since some
APOBEC proteins present two concatenated domains
whereas others consist of a single domain, two-domain pro-
teins were split and the individual domains analyzed sepa-
rately. Parsimony analysis was performed with PROTPARS
and with DNAPARS, from the PHYLIP package, after 1,000
cycles bootstrap. Distance analysis was performed using
PROTDIST and Dnadist using both neighbor-joining and
UPGMA (unweighted pair group method with arithmetic
mean), and combining the results. Bayesian phylogenetic
inference was performed with BEAST v1.4.6 [74], partition-
ing the nucleotide sequence following the three codon posi-
tions, under the Hasegawa-Kishino-Yano model of evolution,
using a strict clock and a Jeffreys prior distribution for the
coalescent population size parameter, with no phylogenetic
constraints, in two independent chains of 10,000,000 gener-
ations, sampling every 1,000 generations. Maximum likeli-
hood analysis were performed with RAxML [75,76] under the
Wheland and Goldman model of evolution, executing 500
non-parametric bootstaps.
  Ka/Ks analysis of sequence pairs. Ka/Ks values between 
sequence pairs out of the alignments were calculated 
using the Diverge program (Wisconsin Package, Accelrys 
Inc (San Diego, CA, USA). For the sliding window 
approach (window 300 bp, slide 50 bp) the program was
run with the appropriate part of the sequences. Test for posi-
tive selection: the cat A3C and A3H trees were further tested
for the presence of positive selection among amino acid sites
using PAML. The likelihood ratio test was used to compare
the evolutionary models M1 (neutral) and M2 (selection), M7
(beta) and M8 (beta&omega variations) [77,78]. The likeli-
hood ratio test statistic was calculated by 2 × logΔ, where Δ =
L0 (null modeldata)/L1 (alternative modeldata), L0 is the
likelihood estimate for the simple model, and L1 is the likeli- 
hood estimate for the model with more free parameters. The
degrees of freedom were determined by the difference in the
number of free parameters between the null and alternative
models, and the test statistic was approximated to a χ2 distri-
bution to determine statistical significance. In models M2
and M8, an empirical Bayesian approach is used to calculate
the posterior probability that an amino acid site fits in each
site class and sites with a high posterior probability of falling
into the class of ω of >1 are considered to be under positive
selection. Additionally, we identified the residues under pos-
itive and purifying selection using the webserver Selecton ver-
sion 2.2 [37], submitting the alignments of the cat A3C and
A3H sequences.
    Cells and transfections. Human cell line 293T, and feline cell 
lines CrFK (ATCC CCL-94, feline kidney cells) and KE-R (feline 
embryonic fibroblast cells, a gift of Roland Riebe, Friedrich-
Loeffler Institut, Riems) were maintained in Dulbecco’s high 
glucose modified Eagle’s medium (Biochrom, Berlin, Germany; 
Dulbecco’s modified Eagle’s medium complete) supplemented 
with 10% heat-inactivated fetal bovine serum (FBS), 0.29 mg/ml 
L-glutamine, and 100 units/ml penicillin/streptomycin. Feline
T-cell lines MYA-1 (ATCC CRL-2417) and FeT-1C (ATCC
CRL-11968) were cultured in complete RPMI 1640, 0.29 mg/
ml L-glutamine, 10 mM HEPES, and 1.0 mM sodium pyruvate
and supplemented with 0.05 mM 2-mercaptoethanol,
100 units/ml human recombinant interleukin-2 and 10%
heat-inactivated FBS, and 100 units/ml penicillin/strepto-
mycin. Plasmid transfection into 293T cells was done with
Lipofectamine 2000 according to the manufacturer’s
instructions (Invitrogen, Karlsruhe, Germany). PBMCs of
Felidae and a dog were isolated from EDTA- or heparin-
treated whole blood by Histopaque-1077 (Sigma, 
Taufkirchen, Germany) gradient centrifugation and cultured
after activation with phytohemagglutinin (PHA; 3 μg/ml) for
3 days in RPMI medium 1640 containing 15% FBS, 5 × 10-5 M
2-mercaptoethanol, 2 mM L-glutamine, and 100 units of
human recombinant interleukin-2 per ml at 37°C and 5%
CO2. Blood of one dog (Canis familiaris) of the breed Australian
shepherd was obtained from Karin Kliemann. Blood of F.
catus was obtained from two cats of unknown breed from the
Max Planck Institute for Brain Research, Frankfurt, Ger-
many. Blood from one each of lion (P. leo bleyenberghi),
tigers (P. tigris sumatrae and P. tigris corbetti), leopard (P.
pardus japonensis), lynx (L. lynx) and puma (P. concolor)
were obtained from the Halle Zoo, Germany.
  Viruses and infections. FIV single-cycle luciferase vectors 
(FIV-Luc) were produced by cotransfecting 293T cells with: 
pFP93 (derived from clone FIV-34TF10, a gift of Eric M Poeschla 
[79]), which does not express vif; or pCPRΔEnv (derived from 
clone FIV-PPR, a gift of Garry P Nolan [80]), which does express 
vif; pLinSin; a VSV-G expression plasmid pMD.G [81]; and 
indicated APOBEC3-HA expression plasmids or empty vector
(pcDNA3.1(+) (Invitrogen) or pcDNA3.1(+)zeo (Invitrogen).
Vector pLiNSin was derived from pGiNSin, a self-inactivating
(Sin) vector variant of pGiNWF [79], which is a minimal bi-
cistronic FIV transfer vector plasmid coding for enhanced-
green- fluorescent-protein (EGFP) and neomycin phospho-
transferase containing Woodchuck hepatitis virus posttran-
scriptional regulatory element (WPRE) and FIV central DNA
flap. The EGFP gene in pGiNSin was replaced by the firefly
luciferase gene (luc3) using the restriction sites AgeI and
ApaI. The luciferase gene was amplified by overlapping PCR
using pSIVagmLuc [17] as template and primers (feLuc3_1.f
5’-TCCACCGGTCGCCACCATGGAAGACGCCAA-3’ (AgeI-
restriction site underlined); feLuc3_1.r 5’-CGTTGGCCGCTT-
TACACGGCGATC-3’; feLuc3_2.f 5’-GATCGCCGTG-
TAAAGCGGCCAACG-3’; feLuc3_2.r 5’-
TTCCGGGCCCTCACATTGCCAAA-3’ (ApaI-restriction site
underlined)), subcloned in pCR4Blunt-TOPO (Invitrogen),
and sequence verified. FeLV reporter virions were produced
by transfection of 293T cells with FeLV-A clone p61E-FeLV
[82], MLV-EGFP transfer vector pMgEGFP-ΔLNGFR [83],
VSV-G expression plasmid and the indicated expression plas-
mid for APOBEC3-HA or pcDNA3.1(+). Reverse-transcrip-
tion of viruses was determined by Cavidi HS kit Lenti RT or
C-type RT (Cavidi Tech, Uppsala, Sweden). For reporter virus
infections, HOS cells were seeded at 2.0 × 103 cells/well a day
before transduction in 96-well plates and then infected with
reporter virus stocks normalized for RT. Firefly luciferase
activity was measured three days later with a Steadylite HTS
reporter gene assay system (PerkinElmer, Cologne, Ger-
many) according to the manufacturer’s directions on a
Berthold MicroLumat Plus luminometer. Expression of EGFP
was analyzed by flow cytometry. Propagation of wild-type and
Bet-deficient FFV (pCF-7 and pCF-Bet-BBtr [21]), contrans-
fection with defined APOBEC3-HA expression plasmids,
titration of FFV infectivity, and detection of FFV proteins was
done as described previously [21].
    Sequencing of viral reverse transcripts. 293T cells (1 × 106) 
were infected with DNase I (Roche, Mannheim, Germany) 
treated wild-type or Δvif FIV(VSV-G) (1,000 pg RT) using 
vector pGiNSin produced in 293T cells together with 
feline APOBEC3s or pcDNA3.1(+). At 10 h postinfection, 
cells were washed with phosphate-buffered saline and 
DNA was isolated using DNeasy DNA isolation kit (Qia-
gen, Hilden, Germany). A 300 bp fragment of the egfp gene
was amplified using Taq DNA polymerase and the primers
eGFP.fw (5’-cgtccaggagcgcaccatcttctt-3’) and eGFP.rv (5’-
atcgcgcttctcgttggggtcttt-3’). Each of 30 cycles was run at 94°
for 30 s, 58° for 1 minute, and 72° for 2 minutes, and PCR
products were cloned into TOPO TA-cloning pCR4 vector
(Invitrogen) and sequenced. The nucleotide sequences of at
least eight independent clones were analyzed. 
   Plasmids. All APOBEC3s are expressed as carboxy-terminal 
HA-tagged proteins (APOBEC3-HA). Feline APOBEC3Ca 
(previously termed feAPOBEC3, feA3, GenBank accession no. 
AY971954) was described in [21]. Feline APOBEC3Cb and 
APOBEC3Cc were similarly constructed. Feline APOBEC3H 
and feline APOBEC3CH cDNAs were identified by using 5’ and 3’ 
RACE reactions (5’/3’-RACE kit, Roche Diagnostics) employing
total RNA from CrFK cells [24]. APOBEC3 cDNAs of big cats
were amplified from cDNA of PBMCs after activation with
PHA (3 μg/ml) and Pwo polymerase (Roche Diagnostics) was
applied. The primers were: for A3C forward primer fApo3F-
18 (5’-TAGAAGCTTACCAAGGCTGGCGAGAGGAATGG-3’,
HindIII site underlined) and reverse primer fAPO3F-19 (5’-
AGCTCGAGTCAAGCGTAATCTGGAACATCGTATGGAT-
ACCTAAGGATTTCTTGAAGCTCTGC-3’ (XhoI site under-
lined)); for A3H, forward primer fAPO-29 (5’-
TGCATCGGTACCTGGAGGCAGCCTGGGAGGTG-3’ (KpnI
site underlined)) and reverse primer fAPO-28 (5’-
AGCTCGAGTCAAGCGTAATCTGGAACATCGTATGGA-
TATTCAAGTTTCAAATTTCTGAAG-3’ (XhoI site 
underlined)). Thirty cycles were run at 94°C for 30 s, 58°C 
for 1 minute, and 72°C for 2 minutes. PCR products were 
cloned into pcDNA3.1(+) using restriction sites HindIII and 
XhoI (for A3C) or KpnI and XhoI (for A3H) and sequenced. 
Expression plasmids of 3’-HA-tagged dog (C. familiaris) 
APOBEC3A (GenBank accession number. XM_847690.1) 
and APOBEC3H (GenBank accession number XM_538369.2) 
were generated by PCR. For dog A3A the template was 
expressed sequence tag clone nas31ho7 5’ (GenBank accession 
number DN874273), obtained through Graeme Wistow 
from the National Eye Institute, Bethesda, USA, and Pwo 
polymerase was used. The forward primer was dog-APO-11
(5’-TGCAGGTACCCCGCGGACATGGAGGCTGGCC-3’ 
(KpnI site underlined)), and the reverse primer was Dog-
APO-10 (5’-AGTGCGGCCGCTCAAGCGTAATCTGGAACA-
TCGTATGGATATAGGCAGACTGAGGTCCATCC-3’ (NotI 
site under-lined)). Dog A3H cDNA was amplified from cDNA 
of PBMCs after activation with PHA (3 μg/ml), using forward 
primer Dog-APO-7 (5’-TGCAGGTACCCCACGATGAAT
CCACTACAAGAAGA-3’ (KpnI site underlined)), and reverse 
primer Dog-APO-8 (5’-AGTGCGGCCGCTCAAGCGTAATC
TGGAACATCGTATGGATAAAGTCTCAAATTTCTG-
AAGTC-3’ (NotI site underlined)), and Pwo polymerase 
(Roche). Thirty cycles were run at 94°C for 30 s, 58°C for 
1 minute, and 72°C for 2 minutes. PCR products were 
digested by KpnI and NotI, introduced into pcDNA3.1(+)-
Zeo (Invitrogen) and correct clones identified by sequencing. 
For generation of the pGex-feAPOBEC3CHlinker the feline 
A3CH linker region containing the sequence from amino 
acids 190-244 of the feline A3CH was cloned into a pGEX-
4T3 Vector (Amersham Bioscience, Freiburg, Germany) by 
PCR (forward primer, 5’-CGAGTCGAATTCCCT-TAGTCC
CGGCCAACAAAGAAAAAGAGAC-3’; reverse primer, 5’-
GCATGAGTCGACTGTGGGTCTGGGCAAGAGGAAGG-3’; 
the introduced restriction sites for EcoRI and SalI are 
underlined). Purified DNA fragments were fused in frame 
between the 5’ GST domain and the 3’ SV40 tag (KPPTPP-
PEPET) of correspondingly digested pGEX4T3tag derivatives[84]. 
Clones were identified by restriction enzyme digestion and 
DNA sequencing. pcFIV.Vif-V5 is an expression plasmid for 
the codon-optimized vif of FIV-34TF10 (GenBank acces-
sion number M25381). It was generated by cloning the codon-
optimized vif gene, 3’ fused to the V5-tag, made by Geneart 
(Regensburg, Germany) into pcDNA3.1(+) using the KpnI
and NotI restriction sites; a 3’-WPRE element was included in
the NotI and ApaI sites. 
  Expression studies. Expression studies of feline APOBEC3C 
RNAs in CrFK, KE-R, MYA-1, and Fet1C cells and PHA-
activated PMBCs of cat and other Felidae were done by RT-
PCR using 2 μg of total RNA (RNeasy mini kit, Qiagen) 
and cDNA made by SuperScript III RT (Invitrogen). 
For feline APOBEC3Cs the primers were forward 
fAPO3F-9 (5’-TGGAGGCAGCCTGGGAGGTG-3’), and
reverse fAPO3F-15 (5’-GCGAGACGCAAGGAACAGCAG-3’).
For feline APOBEC3H the primers were forward fAPO3F-9
and reverse fAPO-26 (5’-CTGCCCGAAGGCACCCTAATTC-
3’), or, alternatively, forward feA3H.fw (5’-ATGAATCCACTA-
CAGGAAGTCATAT-3’) and reverse feA3H.rv (5-TCAT-
TCAAGTTTCAAATTTCTGAAG-3’). For feline APOBEC3CH
the primers were forward feAPO3CH.fw (5’-ATGGAGCCCT-
GGCGCCCCAGCCCAA-3’) and reverse fAPO-27 (5’-
TCGTACTCGAGGCAGTTTATGAAGCATTGAGATGC-3’).
Pwo polymerase (Roche) was used for cloning and Taq
polymerase (Fermentas, St. Leon-Rot, Germany) for diagnostic
PCR. PCRs were run for 30 cycles at 94°C for 30 s, annealing
for 1 minute at 60°C for feA3C, 58°C for feA3H, and 59°C
for feA3CH, and 72°C for 2 minutes. PCR products were
cloned in TOPO-vectors (Invitrogen) and sequenced.
   Immunoblot analysis. Cells were cotransfected with plasmids 
for FFV, FIV, FeLV and APOBEC3-HA expression plasmids and 
lysates were prepared two days later. Cell lysates were prepared by 
removing the medium from transfected cells, washing them with 
phosphate-buffered saline, and lysing them in lysis buffer. Protein
in the lysates was quantified using Coomassie blue reagent
(Bio-Rad, Munich, Germany). Lysates containing 20 μg of
protein were separated by SDS-PAGE and transferred to 
polyvinylidene difluoride filters or nitrocellulose membranes.
Filters were probed with anti-HA antibody (1:6,000 dilution,
MMS-101P; Covance, Münster, Germany), or mouse anti-α-
tubulin (1:4,000 dilution, clone B5-1-2, Sigma-Aldrich) or
polyclonal rabbit antibody against the linker region of feline
A3CH (1:250 dilution) followed by horseradish per-
oxidaseconjugated rabbit anti-mouse antibody (α-mouse-
IgG-HRP, Amersham Biosciences) or Protein A-peroxidase 
(Sigma) and developed with ECL chemiluminescence reagents 
(Amersham Biosciences). A polyclonal mono-specific rabbit 
antiserum against the feline A3CH linker sequence (A3CH amino 
acid residues 190-244) was generated using a GST-fusion protein 
made with a pGex-feAPOBEC3CH-linker. The GST-fusion
protein was purified as described and used for vaccination
of rabbits [21].
  Data deposition. The sequences reported here have been 
deposited in the Gen-Bank database: feline A3 genomic locus, 
including feA3Ca, feA3Cb, feA3Cc, and feA3H (EU109281); 
feA3Ca (AY971954); feA3C isolate X (EU057980); feA3C isolate Y
(EU057981); feA3H (EU011792); feA3H (Ex2 5’Δ)
(EF173020); feA3CH (EF173021); feA1, feA2, feA4, and
AICDA (sequences derived from cat genomic project
AANG00000000.1); leopard A3C (DQ205650); tiger A3C#1
(DQ093375); tiger A3C#2 (EU016361); tiger A3C#3
(EU016362); lion A3C#1 (EU007543); lion A3C#2
(EU007544); lynx A3C#1 (EU007546); lynx A3C#2
(EU016363); lynx A3C#5 (EU007547); lynx A3C#6
(EU007548); puma A3C (EU007545); leopard A3H
(EU007551); tiger A3H (EU007550); lion A3H (EU007549);
lynx A3H (EU007553); puma A3H (EU007552); codon opti-
mized vif of FIV (EF989123).
ABBREVIATIONS
A3, APOBEC3; AICDA, activation-induced cytidine deami-
nase (also known as AID; APOBEC3, apolipoprotein B
mRNA-editing catalytic polypeptide 3; FBS, fetal bovine
serum; FeLV, feline leukemia virus; FFV, feline foamy virus;
FIV, feline immunodeficiency virus; HA, hemagglutinin;
HIV, human immunodeficiency virus; Luc, luciferase; NCBI,
National Center for Biotechnology Information; PAML, Phy-
logenetic Analysis by Maximum Likelihood; PBMCs, periph-
eral blood mononuclear cells; PHA, phytohemagglutinin;
RACE, rapid amplification of cDNA ends; RT-PCR, reverse-
transcriptase PCR; SIV, simian immunodeficiency virus; 
SNP, single nucleotide polymorphism; Vif, viral infectivity
factor; VSV-G, vesicular stomatitis virus-G protein; WGS,
whole genome shotgun.
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The following additional data are available with the online
version of this paper. Additional data file 1 provides supplemental
information about the calculation of Ka/Ks. Additional
file 2 provides tables showing percent identity of cat
A3C introns (supplementary Table 1), Ka/Ks ratios of cat A3s
(supplementary Tables 2 and 3), A3C SNPs of cat breeds (sup-
plementary Table 4), percent identities of all described A3C
and A3H cDNAs and proteins (supplementary Tables 5 and 6)
and results of different evolutionary models (supplementary
Table 7). Additional file 3 provides supplementary figures.
Supplementary Figure 1 shows amino acid alignments of
feline APOBEC3 proteins. Supplementary Figure 2 shows
amino acid alignments of feline, canine and human
APOBEC3 proteins. Supplementary Figure 3 contains
sequences and positions of predicted transcription factor
binding sites. Supplementary Figure 4 shows analysis of evo-
lutionary selection by the sliding window approach.
Supplementary Figure 5 presents analysis of cytidine deamination
of FIV by feline A3s. 
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CHAPTER 4
Restriction of Equine Infectious Anemia Virus by Equine APOBEC3 
Cytidine Deaminases
Cover photograph (Copyright © 2009, Ame-
rican Society for Microbiology. All Rights Re-
served.): The horse Equus caballus is the host 
of the lentivirus Equine infectious anemia virus. 
The antiviral genes of the APOBEC3 family 
evolved in horses by at least three gene dupli-
cations, as indicated by the phylogenetic tree. 
The genetic variability of these horse genes 
might modulate the permissivity of individu-
al horses to this pathogenic virus. (See related 
article in August 2009, vol. 83, no. 15, p. 7547.)
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The mammalian APOBEC3 (A3) proteins comprise a 
multigene family of cytidine deaminases that act as potent 
inhibitors of retroviruses and retrotransposons. The A3 locus 
on the chromosome 28 of the horse genome contains multiple 
A3 genes: two copies of A3Z1, five copies of A3Z2, and a single 
copy of A3Z3, indicating a complex evolution of multiple gene 
duplications. We have cloned and analyzed for expression the 
different equine A3 genes and examined as well the subcellular 
distribution of the corresponding proteins.Additionally, we 
have tested the functional antiretroviral activity of the equine 
and of several of the human and nonprimate A3 proteins 
against the Equine infectious anemia virus (EIAV), the Simian 
immunodeficiency virus (SIV), and the Adeno-associated 
virus type 2 (AAV-2). Hematopoietic cells of horses express 
at least five different A3s: A3Z1b, A3Z2a-Z2b, A3Z2c-Z2d, 
A3Z2e, and A3Z3, whereas circulating macrophages, the 
natural target of EIAV, express only part of the A3 repertoire. 
The five A3Z2 tandem copies arose after three consecutive, 
recent duplication events in the horse lineage, after the 
split between Equidae and Carnivora. The duplicated genes 
show different antiviral activities against different viruses: 
equine A3Z3 and A3Z2c-Z2d are potent inhibitors of EIAV 
while equine A3Z1b, A3Z2a-Z2b, A3Z2e showed only weak 
anti-EIAV activity. Equine A3Z1b and A3Z3 restricted 
AAV and all equine A3s, except A3Z1b, inhibited SIV. 
We hypothesize that the horse A3 genes are undergoing 
a process of subfunctionalization in their respective 
viral specificities, which might provide the evolutionary 
advantage for keeping five copies of the original gene.
The Equine infectious anemia virus (EIAV) (family Retroviridae,
genus Lentivirus) infects equids almost worldwide, causing
a persistent infection characterized by recurring viremia, fever,
thrombocytopenia, and wasting symptoms (40). EIAV infections
are used as a model for natural immunologic control of
lentivirus replication and virus persistence and as a test system
to improve vaccines against lentiviruses (10, 40, 41, 82). In vivo
EIAV replicates predominantly in macrophages (77). Interac-
tion with the equine lentiviral receptor 1 (ELR1) has been
demonstrated to be responsible for EIAV internalization (96).
There have been no reported cases of EIAV infections in
humans, suggesting that it is an intrinsically safe virus and of
interest for use in a clinical setting. Therefore, EIAV-based
lentiviral vectors for human gene therapy were recently developed
(1, 67, 68).
  In the last few years, two cellular proteins that inhibit many
different retroviruses have been characterized: tripartite motif
protein 5 alpha (TRIM5a) and apolipoprotein B mRNA-
editing enzyme-catalytic polypeptide 3 (APOBEC3 [A3]) (for
a review, see reference 92). With respect to TRIM5a proteins,
both human and nonhuman primate TRIM5a orthologues can
restrict infection by EIAV (26, 72). The activity of equine 
TRIM5a on EIAV infection, however, has not been described
so far. With respect to A3 proteins, human APOBEC3G
(A3G) is the best-characterized member of the A3 gene family.
The ability of A3G to restrict EIAV was identified by Mangeat
et al. during research focusing on the activity of the Human
immunodeficiency virus type 1 (HIV-1) viral infectivity factor
(Vif) protein (48). The mechanism whereby A3G inhibits
EIAV was not investigated. HIV-1 mutants lacking Vif pack-
age A3G into viral particles. Incorporated A3G specifically
deaminates cytosine residues to uracil in growing single-
stranded DNA during reverse transcription, leading to HIV
genome degradation or hypermutation (5, 25, 39, 48, 49, 98).
More recent studies indicate that deaminase-independent
mechanisms might also be involved in antiviral activity of A3
(4, 27, 28, 30, 54, 61). The amount of encapsidated A3G in
wild-type (wt) HIV-1 virions is dramatically reduced by a Vif-
dependent degradation via the ubiquitination-proteasome
pathway (50, 79, 94, 95). EIAV is the only extant lentivirus
lacking a vif gene, a characteristic shared with Rabbit endoge-
nous lentivirus type K (34). In contrast to the well-characterized
A3-Vif interaction, still little is known about A3-neutralizing
strategies used by retroviruses that do not encode a Vif pro-
tein. It has been reported that foamy retroviruses use the
accessory protein Bet, and Human T-cell leukemia virus type I
has evolved a unique nucleocapsid protein to counteract the
packaging of cognate A3 proteins (12, 44, 58, 71). The debate
over the mechanism of resistance to murine A3 (muA3) of the
rodent gammaretrovirus Moloney murine leukemia virus (Mo-
MLV) has not come up with a generally convincing model,
despite many studies (5, 9, 13, 32, 35, 49). However, recent 
data clearly show that muA3 is an important in vivo restriction
factor of Mo-MLV and the Friend virus complex (45, 73, 89).
  The evolution of the A3 genes appears as a complex, taxon-
specific history of expansion, divergence, selection, and indi-
vidual extinction of antiviral A3 that parallels in some points
the early evolution of placental mammals (38, 58). Humans
carry seven A3 genes, rodents carry one, pigs carry two, horses
carry six, and cats carry four A3 genes (6, 31, 38, 58, 63). For
the sake of clarity, the nomenclature for nonprimate A3s has
been recently changed, based on the characteristics of the zinc
(Z)-coordinating domain, to Z1, Z2, and Z3 (37). In light of
the absence of a vif gene in EIAV and of a recent study of
Bogerd et al. (6) on two equine A3s (eqA3s) (eqA3Z2a-Z2b
and eqA3Z2c-Z2d, previously designated A3F1 and A3F2, re-
spectively) that suggested that EIAV is resistant to eqA3s, we
were interested in eqA3 genes and in the differential ability of
the eqA3 proteins to restrict EIAV and other viruses.
  Here, we identified and characterized five eqA3 proteins in
regard to their activity against EIAV, Simian immunodeficiency
virus (SIV), and Adeno-associated virus type 2 (AAV-2). In
contrast with a previous report (6), we identified eqA3s that
strongly inhibited EIAV. The five eqA3s showed differential
antiviral specificities against EIAV, SIV, and AAV, which we
interpret as evidence for an ongoing subfunctionalization pro-
cess. These results underpin the possibility that specific A3
paralogues protect against distinct viruses. The process of A3
gene duplication and subfunctionalization might result in an
evolutionary advantage, enlarging the antiretroviral armory,
and provide an explanation for the expansion of the A3 family
in many mammalian species.
MATERIALS AND METHODS
  Cells and transfections. The human cell lines 293T, 293, HeLa, and HOS
(ATCC CRL-1543); the feline cell line CrFK (ATCC CCL-94); and equine
macrophage-like cells EML-3C (20) were maintained in Dulbecco’s high-glucose
modified Eagle’s medium (Biochrom, Berlin, Germany) supplemented with 10%
fetal bovine serum, 2 mM L-glutamine, penicillin (100 units/ml), and streptomycin
(100 /g/ml). Equine (Equus caballus) peripheral blood mononuclear cells
(PBMCs) were isolated from heparin-treated whole blood by Histopaque-1077
(Sigma-Aldrich, Taufkirchen, Germany) gradient centrifugation and cultured
after activation with phytohemagglutinin (3 µg/ml) for three days in RPMI 1640
medium (Biochrom, Berlin, Germany) containing 10% fetal bovine serum, 5 
105 M 2-mercaptoethanol, 2 mM L-glutamine, and 100 units of human recombinant
interleukin-2 per ml at 37°C and 5% CO2. Monocyte-derived macrophages
were purified from peripheral equine blood following a standard procedure
(52). Briefly, monocyte-derived macrophages were purified from peripheral
equine blood by gradient centrifugation through Histopaque. Cells were seeded
in six-well plates in high-glucose Dulbecco’s modified Eagle’s medium with 15%
horse serum (Biochrom, Berlin, Germany), 2 mM L-glutamine, penicillin (100
units/ml), and streptomycin (100 µg/ml). Nonadherent cells were removed after
an overnight incubation, and any remaining adherent cells were incubated for 10
days. Plasmid transfections into 293T cells were performed with Lipofectamine
LTX (Invitrogen, Karlsruhe, Germany) according the manufacturer’s instruc-
tions.
  Viruses and infections. EIAV single-cycle luciferase vectors (EIAV-luc) were
produced by cotransfecting 293T cells with the following: pONY3.1 (55),
pONY8.1luc, the vesicular stomatitis virus G protein (VSV-G) expression plasmid
pMD.G (18), and an A3 expression plasmid or empty vector pcDNA3.1(+) (In-
vitrogen, Karlsruhe, Germany). Vector pONY8.1luc was derived from pONY8.1G
(69), a self-inactivating vector variant of pONY8.0 (53) coding for enhanced green
fluorescent protein and a deleted env region. The egfp gene in pONY8.1G was
replaced by the firefly luciferase gene (luc3) using restriction sites SacII and NotI.
The luciferase gene was amplified by PCR using pSIVagmLuc (where agm indicates
the African green monkey SIV host) (49) as a template and the primers Eluc.fw
(5’-CCTCCGCGGCCCCAAGCTATGGAAGACGCCAAA-3’; SacII restriction
site is underlined; where present, fw indicates forward and rv indicates reverse) and
Eluc.rv (5’-AGGCGGCCGCTTTACACGGCGATCTTT-3’; NotI restriction site is
underlined), subcloned in pJET1.2/blunt (Fermentas, St. Leon-Rot, Germany), se-
quence verified, and recloned into pONY8.1 using SacII and NotI restriction sites.
The procedure used to generate pONY3.1 DU results in an in-frame deletion of
270 bp in the predicted dUTPase (DU) coding region (modified after Threadgill et
al. [90]). By using pONY3.1 template DNA and the primer pair EIAV1.fw (5’-GC
GCGCGGCGCCTGGCACCACCACAAGGGCCT-3’) and EIAV-dDU.rv (5’-T
GAGTGCCCTGCATCTTCATCTCT-3’) and the pair EIAV2.rv (5’-GCGCGCG
AATTCCCATTCCAGTCGTTCCTGG-3’) and EIAV-dDU.fw (5’-GCTGGGCA
CTCAAATTCCAGACAG-3’), the 5’ and 3’ fragments were amplified separately.
The fragments were fused through overlapping extension PCR and cloned into
pONY3.1 using restriction sites KasI and EcoRI. pONY3.1 S2 was made as de-
scribed in Mitrophanous et al. (55): the deletion from nucleotide 5345 to 5397 was
made by PCR using overlapping primers EIAV-dS2.fw (5’-GTTATAAGGTTTGA
TATCAGCAT-3’) and EIAV-dS2.rv (5’-CATAGAATGCGATGCTGATATC-
3’). SIV reporter virions were produced via transfection of 293T cells with
pSIVagmLucDvif, a VSV-G expression plasmid, and an expression plasmid for A3 or
pcDNA3.1(). Reverse transcriptase activity of viruses was quantified by using a
Cavidi HS Lenti RT kit (Cavidi Tech, Uppsala, Sweden). For reporter virus infec-
tions, CrFK, EML-3C, or HOS cells were seeded at 2.0  103 cells/well 1 day before
transduction in 96-well plates and then infected with reporter virus stocks normal-
ized for reverse transcriptase. Firefly luciferase activity was measured 3 days post-
transduction with a Steadylite HTS reporter gene assay system (PerkinElmer, Co-
logne, Germany), according to the manufacturer’s directions, on a Berthold
MicroLumat Plus luminometer. To generate recombinant AAV-2, 293 cells were
transfected with the lacZ reporter plasmid pAAV-lacZ (51, 93), the rep-cap encoding
plasmid pAAV-RC (51, 93), the adenovirus helper plasmid pHelper (51, 93), and an
expression plasmid for A3 or pcDNA3.1(+). Cells were harvested for analysis after
72 h. Lysate containing virions was generated by freeze/thaw cycles, and supernatants
were used to transduce fresh 293 cells. Transduction was quantified 3 days later by
measuring b-galactosidase activity using a GalactoStar kit (Applied Biosystems,
Darmstadt, Germany) according to the manufacturer’s instructions.
  A3 expression and plasmids. All A3s are expressed as carboxy-terminal (CT)
hemagglutinin (HA)-tagged proteins, except human A3DE (also known as human
A3Z2c-Z2d), a gift from Y.-H. Zheng, that carries a CT V5 tag (11). The human
A3G and muA3 expression constructs (human A3Z2g-Z1c and muA3Z2-Z3) were
provided by N. R. Landau (49). Human A3B, -C, -F, and -H (A3Z2A-Z1b, A3Z2b,
A3Z2e-Z2f, and A3Z3); feline A3; and canine A3 expression plasmids were previously
described (33, 44, 57, 58). Porcine A3 (A3Z2-Z3) was a gift of Eva Dörrschuck
and Ralf To¨njes (GenBank accession no.EU871587; E. Dörrschuck et al., unpublished
data). eqA3 cDNAs were identified by using 5’ and 3’ rapid amplification of
cDNA ends reactions (5’/3’-RACE kit; Roche Diagnostics, Mannheim, Germany)
employing total RNA from equine PBMCs. For expression plasmids of
eqAPOBEC3Z1b (eqA3Z1b), the primers were E-APO-37 (5’-TTCGTGAATTC
GGGACTGAGACATGGAGGCC-3’; forward) and E-APO-38 (5’-AGAGCTCG 
AGTCAAGCGTAATCTGGAACATCGTATGGATACCCAGAGGAGCCTCT
GAGTG-3’; reverse); for eqA3Z2e, the primers were E-APO-27 (5’-ACGTGGTA
CCTACGTCCAGGCTCCCAGGAAC-3’; forward) and E-APO-28 (5’-TTCTCT
CGAGTCAAGCGTAATCTGGAACATCGTATGGATACTTGAGAATGTCC
TCAAGCTTTG-3’; reverse); for eqA3Z2a-Z2b and eqA3Z2c-Z2d, the primers
were primer E-APO3Ca/c-KpnI.fw (5’-ACGTGGTACCACCCAATGGAGAAGT 
TGGAT-3’; where present, fw indicates forward and rv indicates reverse) and
E-APO3Cb-XhoI.rv (5’-GCGCCTCGAGTCAAGCGTAATCTGGAACATCGT
ATGGATACTTGAGAAGGTCCT-3’) or E-APO3Cd-XhoI.rv (5’-GCGCCTCG
AGTCAAGCGTAATCTGGAACATCGTATGGATACT TGAGAATCT
CCT-3’); for eqA3Z3, the primers were E-APO-35 (5’-TTCGTGAATTCGAGGT
CACTCTCAGATAAGCGGC-3’; forward) and E-APO-36 (5’-AGAGCTCGAG
TCAAGCGTAATCTGGAACATCGTATGGATACCCGAGGTCAACCGACC
CAAG-3’; reverse); Pwo polymerase (Roche Applied Science, Mannheim, Ger-
many) was used. Each of 30 cycles was run at 94°C for 30 s, 58°C for 1 min, and 72°C
for 2 min. PCR products were cloned into pcDNA3.1(+) using restriction sites KpnI
or EcoRI and XhoI, and sequences were verified. EA3F2 (6) was made by exchang-
ing amino acids (V40G, P48V, S339I, and K354N) of the eqA3Z2c-Z2d template
through overlapping extension PCR, and the resulting cloned PCR product was
sequence verified. eqA3Z3 point mutants were generated by exchanging zinc-coor-
dinating amino acids (H84R, C115S, and C118S) or the catalytic glutamic acid
residue (E86Q) through overlapping extension PCR. The 5’ and 3’ fragments were
amplified separately by using primer E-APO-35 containing an EcoRI site or the 3’
primer E-APO-36 containing an XhoI site. The 5’ and 3’ fragments were then mixed
and amplified with the two external primers. The resulting full-length mutant was
cleaved with restriction enzymes and cloned into pcDNA3.1(+) and sequence verified.
The human A3F and A3G point mutants have been described previously (7, 
23). A3F mutants h3FAS1 (E67A), h3FAS2 (E251A), and h3FAS1/AS2 (E67A/
E251A) were a gift of N. R. Landau; the mutant A3G-E259Q was a gift of Barbara
Schnierle. Expression studies of eqA3 RNA of PBMCs, macrophages, and spleen
cells were done by reverse transcription-PCR (RT-PCR) using total RNA, Taq
polymerase (Fermentas, St. Leon-Rot, Germany), and the primers E-APO-3 (5’-A
GACACCTTCACTGAGAACTTC-3’; forward) and E-APO-2 (5’-ATGGACCAG
TAGCGACTCTCA-3’; reverse) for eqA3Z1a and eqA3Z1b; the primers rtE-
A3Ce.fw (5’-TTGCATCCCAAGACCTCC-3’; where present, fw indicates forward
and rv indicates reverse) and rtE-A3Ce.rv (5’-GGTACTGCTTCATGAAGTCA-
3’) for eqA3Z2e; the primers rtE-A3Ca.fw (5’-GTGATGTTGCGCAAGGA-3’)
and rtE-A3Cb.rv (5’-CCCTTGGCAAATTTCAG-3’) for eqA3Z2a-Z2b; the prim-
ers rtE-A3Cc.fw (5’-TGACACTGGCGGCCA-3’) and rtE-A3Cd.rv (5’-TCCGGC
TTATTCCTTTGC-3’ for eqA3Z2c-Z2d; and the primers E-APO-23 (5’-CAGAC
CCACAATGAATCCAC-3’; forward) and E-APO-26 (5’-CTGCTGATTCTGCC
TGAACCAG-3’; reverse) for eqA3Z3. The housekeeping gene for human
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) served as an internal control
for RT-PCR using forward primer human GAPDH A (5’-GTTGCCATCAATGA
CCCCTTCATTG-3’) and reverse primer human GAPDH B (5’-GCTTCACCAC
CTTCTTGATGTCATC-3’). To detect ELR1, RT-PCR and primer ELR1.fw (5’-
CCAAGGCTGATGCCCTGAGC-3’) and primer ELR1.rv (5’-GGCCTGGCAG
CTCTCGGCAG-3’) were used to verify equine cDNA. PCRs were run for 30 cycles
of 94°C for 30 s, 1 min at 60°C, and 72°C for 2 min.
   Quantitative real-time PCR analyses of eqA3 mRNA. Total RNA was isolated
from equine PBMCs and macrophages using an RNeasy minikit (Qiagen,
Hilden, Germany), according to the manufacturer’s instructions. Isolated RNA
was reverse transcribed with QuantiTect Reverse Transcription (Qiagen, Hilden,
Germany). The eqA3 fragments were amplified from cDNA and quantified using
SYBR green PCR Master Mix (Applied Biosystems, Warrington, United King-
dom) with an Applied Biosystems 7500 Real-Time PCR system (Applied Bio-
systems, Foster City, CA) and A3-specific primers as follows (fw indicates forward
and rv indicates reverse): qPCR-A3Ccd.fw (5’-ACCATCATGGAAGGC
ACTTCATTCC-3’) and qPCR-A3Ccd.rv (5’-TGCAGCTTCTCCAATGGGTT
TTTGA-3’) for A3Z2c-Z2d; qPCReq3Ce.fw (5’-AGTGGAAGGAAGGTTGA
GCGGC-3’) and qPCReq3Ce.rv (5’-CGGAACCAATCGAGGAAGCAGA-3’)
for A3Z2e; and qPCReq3H-2.fw (5’-CCGGGAACGGAAACACACAGCATC-
3’) and qPCReq3H-2.rv (5’-ACGGAGCAGCTTCAGCTGGTAGCA-3’) for
A3Z3. After initial incubations at 50°C for 2 min and 95°C for 10 min, 40 cycles
of amplification were carried out for 15 s at 95°C, followed by 1 min at 60°C. The
amplification product was normalized to that of equine GAPDH.
  Sequencing of viral transcripts. CrFK cells (1 x 106) were infected with
DNase I (Roche, Mannheim, Germany)-treated EIAV-luc (VSV-G pseudo-
typed) (1,000 pg of reverse transcriptase) using pONY8.1luc, pONY3.1, and
pMD-G produced in 293T cells together with eqA3s or pcDNA3.1(). At 10 h
postinfection, cells were washed with phosphate-buffered saline (PBS), and DNA
was isolated using a DNeasy DNA isolation kit (Qiagen, Hilden, Germany). An
880-bp fragment of the luciferase gene was amplified using Taq DNA polymerase
(Fermentas, St. Leon-Rot, Germany) and the primers 5 luc3@812nt (5 -GATA
TGTGGATTTCGAGTCGTC-3 ) and Eluc.rv (5 -AGGCGGCCGCTTTACAC
GGCGATCTTT-3 ). Each of 30 cycles was run at 95°C for 30 s, 50°C for 1 min,
and 72°C for 2 min. For better selective amplification of hypermutated viral
genomes, the PCR denaturation temperature was lowered to 88°C (30 cycles of
1 min at 88°C, 1 min at 50°C, and 2 min at 72°C). The PCR products were cloned
into pJet1.2/blunt vector (Fermentas, St. Leon-Rot, Germany) and sequenced.
The nucleotide sequences of at least 10 independent clones were analyzed.
   Immunoblot analysis. Cells were cotransfected with plasmids for viral vectors
of EIAV and A3 expression plasmids, and lysates were prepared 2 days later.
Cell lysates were prepared by removing the medium from transfected cells,
washing them with PBS, and lysing them in radioimmunoprecipitation assay
buffer (25 mM Tris · HCl, pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium
deoxycholate, 0.1% sodium dodecyl sulfate). Virions were pelleted by centrifu-
gation of filtered (0.45-µm-pore size) culture supernatant through a 20% sucrose
cushion at 35,000 rpm in an SW40Ti rotor for 1.5 h and resuspended with
radioimmunoprecipitation assay buffer. Protein concentration in the lysates was
quantitated using Bradford reagent (Bio-Rad, Munich, Germany). Lysates con-
taining 20 µg of protein were separated by sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis and transferred to polyvinylidene difluoride filters.
Filters were probed with mouse anti-HA antibody (1:10,000 dilution; MMS-
101P; Covance, Mu¨nster, Germany), mouse anti-V5 antibody (1:5,000 dilution;
MCA1360; ABDserotec, Düsseldorf, Germany), or a mixture of both or with
mouse anti-a-tubulin antibody (1:4,000 dilution; clone B5-1-2; Sigma-Aldrich,
Taufkirchen, Germany) or mouse anti-VSV-G antibody (1:10,000 dilution; clone
P5D4, Sigma-Aldrich, Taufkirchen, Germany), followed by horseradish peroxi-
dase-conjugated rabbit anti-mouse antibody (a-mouse immunoglobulin G-horse-
radish peroxidase; GE Healthcare, Munich, Germany), and developed with ECL
chemiluminescence reagents (GE Healthcare, Munich, Germany).
  Immunofluorescence. HeLa cells grown on polystyrene coverslips (Thermo
Fisher Scientific, Langenselbold, Germany) were transfected with A3 expression
plasmids by applying FuGENE (Roche Applied Science, Mannheim, Germany)
transfection reagent (DNA-FuGENE ratio of 1:3). At 1 day posttransfection,
cells were fixed in 4% paraformaldehyde in PBS for 30 min, permeabilized in
0.1% Triton X-100 in PBS for 45 min, incubated in blocking solution (10%
donkey antiserum [Sigma-Aldrich, Taufkirchen, Germany] in PBS) for 1 h, and
treated with anti-HA antibody (MMS-101P; Covance, Mu¨nster, Germany) and
anti-nucleolin (ab22758; Abcam, Cambridge, United Kingdom) in a 1:1,000
dilution in blocking solution for 1 h. Donkey anti-mouse Alexa Fluor 488 (In-
vitrogen, Karlsruhe, Germany) and anti-rabbit Alexa Fluor 594 were used as
secondary antibodies in a 1:300 dilution in blocking solution for 1 h. Finally,
nuclei were stained using DAPI (4 ,6 -diamidino-2-phenylindole; 1:1000 in PBS)
(Millipore, Billerica) for 5 min. The images were captured by using a 40x
objective on a Zeiss LSM 510 Meta laser scanning confocal microscope. Optical
sections were acquired from 1-/m-thick layers.
  Phylogenetic analysis. All A3 sequences in the databases from mammalian
species within Laurasiatheria were retrieved for analysis, as follows: Sus scrofa,
A3Z2 (NM_001097446); Bos taurus, A3Z1 (EU864534), A3Z2 (NM_
001077845), and A3Z3 (DQ974646); Ovis aries, A3Z1 (EU864543), A3Z2
(EU864535), and A3Z3 (NM_001093784); Canis lupus, A3Z3 (XM_538369) and
A3Z1 (XM_847690); Felis catus, A3Z3 (NM_001112710), A3Z2a (ABW83272),
A3Z2b (ABW83273), and A3Z2c (ABW83271); Lynx lynx, A3Z3 (EU007553)
and A3Z2 isolate 1 (EU007546); Puma concolor, A3Z2 (EU007545); Panthera
pardus, A3Z3 (EU007551) and A3Z2 (ABA62303); Panthera leo, A3Z3
(U007549), A3Z2 isolate 7 (EU007543), and A3Z2 isolate 2 (EU007544); Pan-
thera tigris, A3Z3 (EU007550), A3Z2 (AAY99623), A3Z2 isolate 2 (EU016361),
and A3Z2 isolate 3 (EU016362). The sequences were aligned at the amino acid
level with MUSCLE (http://www.drive5.com/muscle/) (15, 16), visualized for
manual correction with Se-Al (freely distributed by Andrew Rambaut at http:
//tree.bio.ed.ac.uk/software/seal/), and back-translated to the nucleotide level
using PAL2NAL (http://www.bork.embl.de/pal2nal) (88). Maximum-likelihood
(ML) phylogenetic analysis was performed with the program RAxML HPC
(randomized accelerated maximum likelihood for high performance computing)
(84, 85) using the GTR 4 model of evolution and the CAT approximation of
rate heterogeneity (83), introducing three partitions that corresponded to each of
the codon positions. Four independent runs of 1,000 bootstraps were performed,
and for each the final tree topology was optimized without resorting to the CAT
approximation. The best of the four final trees was chosen (ln  8697.653751;
respective optimized values for the alpha parameter of the gamma function for
each codon position were 1.312, 1.015, and 4.327), but there were no significant
differences among the corresponding likelihood values using an SH (for Shimo-
daira and Hasegawa) test (80). Bootstrap support values for the nodes were
obtained from the combined four sets of 1,000 trees. A pairwise distance matrix
was also generated under the ML framework. Bayesian phylogenetic analysis was
performed with BEAST, version 1.4.7 (http://beast.bio.ed.ac.uk) (14), with the
GTR+Γ4 model of evolution and for both strict clock and uncorrelated log
normal relaxed clock, introducing three partitions that corresponded to each of
the codon positions, and unlinking parameters across codon positions. Two
independent chains of 50 million steps were calculated, writing every 1,000 steps,
and analyzed with a burn-in of 10 million steps. Compatibility of both chains was
assessed by calculating the corresponding Bayes factor (86), and both chains
were combined into one. The combined chains from the relaxed and the strict
clock were also compared by calculating the Bayes factor on the corresponding
likelihoods. There was only marginally better support for the relaxed clock
calculations (log Bayes factor, 2.1). The Bayesian maximum clade credibility tree
was built based on the relaxed clock combined chain, and its likelihood was
calculated under ML framework and compared with the best RAxML tree. The
Bayesian tree was worse than the best ML tree, albeit not significantly worse in
an SH test (ln  8713.565178; score difference between the log ML values for
the trees, 15.911427; standard deviation of the score difference after nonpara-
metric bootstrap, 11.028095) (80). The Bayesian posterior probabilities were
therefore calculated by projecting the trees from the combined Bayesian chain
onto the best ML tree. The reference cladogram for the animal species included
in the taxon sample was pruned out from a mammalian tree constructed after
the supertree methodology (3), using TREEPRUNER (freely distributed by
Olaf Bininda-Emonds at http://www.uni-oldenburg.de/molekularesystematik
/33997.html).
  Nucleotide sequence accession numbers. The sequences reported here have
been deposited in the GenBank database (accession number): eqA3Z1b 
(FJ532287), eqA3Z2a-Z2b (FJ527822), eqA3Z2c-Z2d (FJ527823), eqA3Z2e
(FJ532288), eqA3Z3 (FJ532289), and eqA3Z3v1 (FJ532286).
RESULTS
   The evolution of eqA3 implies several gene duplications. In
the genome sequence from the horse whole-genome assembly,
released by the Broad Institute of MIT/Harvard (NCBI
GenBank accession no. NW_001799702), we identified six pre-
dicted A3 genes: A3Z1a, -Z1b, -Z2a-Z2b, -Z2c-Z2d, -Z2e, and
-Z3. The different A3 genes in the horse genome span ca. 0.25
Mb of the chromosome 28, and closely related genes are
clearly organized in tandem repeats (Fig. 1). The phylogenetic
relationships of the A3 genes within the placentalia superorder
of Laurasiatheria are depicted in Fig. S1 in the supplemental
material. Phylogenies reconstructed with ML and with Bayes-
ian methodologies were mainly congruent, with the exception
of some ill-defined nodes. Thus, three main clusters can be
observed, corresponding to the A3Z1, -Z2, and -Z3 proteins.
Each of these clusters reflects grossly the topology of the cor-
responding species and encompasses genes from different
mammalian orders within Laurasiatheria (see Fig. S1 in the
supplemental material). Finally, the phylogenetic relationships
among eqA3Z2s suggest that the five copies forming the
present three genes have appeared after three recent duplica-
tion events (Fig. 1).
  Identification of A3 RNAs in equine cells. To functionally
characterize eqA3s, total RNAs from activated equine PBMCs
and equine spleen cells were tested by a combination of RT-
PCR and techniques used in 5’/3’ rapid amplification of cDNA
ends (Fig. 2A). From these sources, we cloned six equine
cDNAs (eqA3Z1b, -Z2a-Z2b, -Z2c-Z2d, -Z2e, -Z3, and
-Z3v1). The two eqA3Z3 cDNAs differ in a lack of 3 nucleo-
tides (AGC) at the 3  end of the A3Z3 coding region. RNA of
the predicted gene for eqA3Z1a could not be identified in
hematopoietic cells (Fig. 2A). It has been shown that the in
vivo tropism of EIAV is restricted to cells of the monocyte-
macrophage lineage (76, 77). Therefore, equine macropha-
gederived RNA was examined by RT-PCR using eqA3-specific
primers. Using semiquantitative PCR on macrophage total
RNA, we could detect A3Z2a-Z2b, -Z2c-Z2d, and -Z2e tran-
scripts while we failed to amplify any A3Z1 and -Z3 transcripts
(Fig. 2A). Quantitative real-time PCR showed that macro-
phagesexpress ~19-fold lower levels of A3Z3 than PBMCs
(Fig. 2B).
  The nomenclature classification of the eqA3s is based on
their phylogenetic relationships (see Fig. S1 in the supplemen-
tal material) and zinc (Z)-coordinating domain assignments
(37): eqA3Z1b has a 45.4% amino acid identity to human
A3A(A3Z1a); eqA3Z2a-Z2b and eqA3Z2c-Z2d have 42.9%
and 44.3% amino acid identity to human A3F (A3Z2e-Z2f),
respectively; eqA3Z2e a has 45% amino acid identity to human
A3C (A3Z2b); and eqA3Z3 shares 40.4% identical amino ac-
ids with human A3H (A3Z3) (see Fig. S2 in the supplemental
material). We used the cloned eqA3Z1b, -Z2a-Z2b, -Z2c-Z2d,
-Z2e, -Z3, and -Z3v1 cDNAs to generate expression plasmids
for HA-tagged A3s. To characterize subcellular distribution of
A3s, cells expressing eqA3s were analyzed by using an anti-HA
antibody in confocal microscopy (Fig. 2C). Immunofluores-
cence studies of transiently expressed eqA3Z1b in HeLa cells
showed a strict nuclear localization, as previously reported also
for human A3A (57). The subcellular distribution of eqA3Z2a-
Z2b is limited to the cytoplasm, and eqA3Z2c-Z2d is localized
in the nucleus. In contrast to human A3C that displays a
cytoplasmic and nuclear distribution (57), the eqA3Z2e could
be detected only in the cytoplasm. The eqA3Z3 and eqA3Z3v1
and the human A3H are distributed in the cytoplasm and in 
nuclear bodies (Fig. 2C). Costaining with an antibody against
the nucleolar nucleolin protein revealed that eqA3Z3 and hu-
man A3H localize in the nucleolus to the nucleoli.
  eqA3 proteins restrict EIAV, SIVagm, and AAV-2. To exam-
ine the restriction activity of eqA3 proteins, VSV-G
pseudotyped EIAV-luc and SIVagm-luc reporter viruses were
generated in human 293T cells in the presence of cotransfected
eqA3 expression plasmids. Reverse transcriptase-normalized
EIAV vector particles were used to transduce feline CrFK cells
because they show no Trim5a-dependent postentry restriction
of EIAV (72, 97). Infectivity of SIV vectors was analyzed by
infection of human HOS cells. At 3 days postinfection the cells
   FIG. 1. Identification of A3 coding regions in the genome of Equus caballus. Representation of the eqA3 genomic region showing 
the exon/intron organization of the A3 genes. Transcripts with exons (rectangles) and spliced-out introns (dotted lines) are indicated. 
Please note that the two eqA3Z3 cDNAs differ in a lack of three nucleotides (AGC) at the 3’ end of the A3Z3v1 coding region. The 
recent study of Bogerd et al. used a different nomenclature for the eqA3 genes: A3A1 for A3Z1a, A3A2 for A3Z1b, A3F1 for A3Z2a-
Z2b, A3F2 for A3Z2c-Z2d, A3C for A3Z2e, and A3H for A3Z3 (6). Chr, chromosome.
(FJ532287), eqA3Z2a-Z2b (FJ527822), eqA3Z2c-Z2d (FJ527823), eqA3Z2e
(FJ532288), eqA3Z3 (FJ532289), and eqA3Z3v1 (FJ532286).
RESULTS
The evolution of eqA3 implies several gene duplications. In
the genome s uence from the orse whole-genome assembly,
released by th Broad Institut of MIT/Harvard (NCBI
GenBank acce sion no. NW_001799702), we identified six pre-
dicted A3 genes: A3Z1a, -Z1b, -Z2a-Z2b, -Z2c-Z2d, -Z2e, a d
-Z3. T e different A3 genes in the horse genome span ca. 0.25
Mb of th chromosome 28, and closel related genes are
clearly org ized i tandem repeats (Fig. 1). The phylogenetic
relatio ships of the A3 genes within the placentalia superorder
of Laurasiatheria are depicted in Fig. S1 in the supplemental
material. Phylogenies reconstructed with ML nd with Bayes-
ian methodologies were mainly congruent, with th exception
of som ill-defined nodes. Thus, three mai clusters can be
observ d, c rresponding to the A3Z1, -Z2, and -Z3 proteins.
Each of these clusters reflects grossly the topol gy of the cor-
responding species and encompasses genes from different
mammalian orders ithin Laurasiatheria (see Fig. S1 in the
supplemental material). Finally, the phylogenetic relationships
among eqA3Z2s suggest that the five copies forming the
present three genes have appeared after three recent duplica-
tion events (Fig. 1).
Identification of A3 RNAs in equine cells. To functionally
characterize eqA3s, total RNAs from activated equine PBMCs
and equine spleen cells were tested by a combination of RT-
PCR and techniques used in 5/3 rapid amplification of cDNA
ends (Fig. 2A). From these sources, we cloned six equine
cDNAs (eqA3Z1b, -Z2a-Z2b, -Z2c-Z2d, -Z2e, -Z3, and
-Z3v1). The two eqA3Z3 cDNAs differ in a lack of 3 nucleo-
tides (AGC) at the 3 end of the A3Z3 coding region. RNA of
the predicted gene for eqA3Z1a could not be identified in
hematopoietic cells (Fig. 2A). It has been shown that the in
vivo tropism of EIAV is restricted to cells of the monocyte-
macrophage lineage (76, 77). Therefore, equine macrophage-
derived RNA was examined by RT-PCR using eqA3-specific
primers. Using semiquantitative PCR on macrophage total
RNA, we could detect A3Z2a-Z2b, -Z2c-Z2d, and -Z2e tran-
scripts while we failed to amplify any A3Z1 and -Z3 transcripts
(Fig. 2A). Quantitative real-time PCR showed that macro-
phages express 19-fold lower levels of A3Z3 than PBMCs
(Fig. 2B).
The nomenclature classification of the eqA3s is based on
their phylogenetic relationships (see Fig. S1 in the supplemen-
tal material) and zinc (Z)-coordinating domain assignments
(37): eqA3Z1b has a 45.4% amino acid identity to human
A3A(A3Z1a); eqA3Z2a-Z2b and eqA3Z2c-Z2d have 42.9%
and 44.3% amino acid identity to human A3F (A3Z2e-Z2f),
respectively; eqA3Z2e a has 45% amino acid identity to human
A3C (A3Z2b); and eqA3Z3 shares 40.4% identical amino ac-
ids with human A3H (A3Z3) (see Fig. S2 in the supplemental
materia ). We used the cl ned eqA3Z1b, -Z2a-Z2b, -Z2c-Z2d,
-Z2e, -Z3, and -Z3v1 cDNAs to generate expression plasmids
for HA-tagg d A3s. To characterize subcellular distribution of
A3s, cells expressing eqA3s were analyzed by usi g an anti-HA
antibody in confocal microscopy (Fig. 2C). Immunofluores-
cence studies of transiently expressed eqA3Z1b in HeLa cells
showed a strict uclear localization, as previously reported also
for human A3A (57). The subcellular distribution of eqA3Z2a-
Z2b is limited to the cytoplasm, and eqA3Z2c-Z2d is localized
in the nucleus. In contrast to human A3C that displays a
cytoplasmic and nuclear distribution (57), the eqA3Z2e could
be detected only in the cytoplasm. The eqA3Z3 and eqA3Z3v1
and the human A3H are distributed in the cytoplasm and in
FIG. 1. Identification of A3 coding regions in the genome of Equus caballus. Representation of the eqA3 genomic region showing the
exon/intron organization of the A3 genes. Transcripts with exons (rectangles) and spliced-out introns (dotted lines) are indicated. Please note that
the two eqA3Z3 cDNAs differ in a lack of three nucleotides (AGC) at the 3 end of the A3Z3v1 coding region. The recent study of Bogerd et al.
used a different nomenclature for the eqA3 genes: A3A1 for A3Z1a, A3A2 f r A3Z1b, A3F1 for A3Z2a-Z2b, F2 for A3Z2c-Z2d, A3C for
A3Z2e, and A3H f r A3Z3 (6). Chr, chromosome.
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were lysed and used to quantify intracellular luciferase activity.
In addition, we tested the inhibitory capacity of the eqA3s on
the transduction of AAV-2-lacZ reporter vectors. We found
that the eqA3 expression plasmids produced functional active
antiviral proteins and that most showed a distinct specificity
against different viruses (Fig. 3A to C). All six eqA3 proteins
were detectable in purified EIAV particles by immunoblotting
(Fig. 3D), suggesting that no viral factor induced their exclu-
sion from EIAV virions. eqA3Z3 restricted any tested viruses:
EIAV infectivity was reduced by a factor 60, SIV was reduced
by factor 13, and AAV-2 was fivefold inhibited (Fig. 3A to C).
The eqA3Z1b and -Z2e showed only moderate activity on 
EIAV and reduced the infectivity by approximately threefold
each (Fig. 3A). Similarly, eqA3Z1b was weakly active against
SIV. In contrast, SIVagm infectivity was inhibited 70-fold by
eqA3Z2e, and eqA3Z1b reduced the infectivity of AAV-2 by
  FIG. 2. Differential expression of eqA3s. (A) Analysis of eqA3Z1a, eqA3Z1b, eqA3Z2a-Z2b, eqA3Z2c-Z2d, eqA3Z2e, and 
eqA3Z3 expression by RT-PCR of total RNA from equine activated PBMCs, spleen cells, and macrophages. Primer specificity 
in PCR was tested by using eqA3 plasmids as templates. PCRs were performed with specific primers to amplify ELR1 for species 
control, and GAPDH served as a loading control. (B) eqA3Z3 is expressed at a significantly lower level in macrophages. RNA 
was extracted from both equine PBMCs and macrophages. Levels of A3 expression were determined by quantitative real-time 
RT-PCR and expressed relative to the levels of the GAPDH RNA. (C) eqA3s show a different subcellular localization. HeLa 
cells were transfected with HA-tagged eqA3Z1b, eqA3Z2a-Z2b, eqA3Z2c-Z2d, eqA3Z2e, and eqA3Z3 and with human A3H 
and A3Z3. To detect A3 (green) immunofluorescence, staining was performed with an anti-HA antibody. Nuclei (blue) were 
visualized by DAPI staining. Nucleolar nucleolin protein (red) was detected with anti-nucleolin antibody. a, anti; hu, human.
nuclear bodies (Fig. 2C). Costaining with an antibody against
the nucleolar nucleolin protein revealed that eqA3Z3 and hu-
man A3H localize in the nucleolus to the nucleoli.
eqA3 proteins restrict EIAV, SIVagm, and AAV-2. To exam-
ine the restriction activity of eqA3 proteins, VSV-G
pseudotyped EIAV-luc and SIVagm-luc reporter viruses were
generated in human 293T cells in the presence of cotransfected
eqA3 expression plasmids. Reverse transcriptase-normalized
EIAV vector particles were used to transduce feline CrFK cells
because they show no Trim5-dependent postentry restriction
of EIAV (72, 97). Infectivity of SIV vectors was analyzed by
infection of human HOS cells. At 3 days postinfection the cells
were lysed and used to quantify intracellular luciferase activity.
In addition, we tested the inhibitory capacity of the eqA3s on
the transduction of AAV-2-lacZ reporter vectors. We found
that the eqA3 expression plasmids produced functional active
antiviral proteins and that most showed a distinct specificity
against different viruses (Fig. 3A to C). All six eqA3 proteins
were detectable in purified EIAV particles by immunoblotting
(Fig. 3D), suggesting that no viral factor induced their exclu-
sion from EIAV virions. eqA3Z3 restricted any tested viruses:
EIAV infectivity was reduced by a factor 60, SIV was reduced
by factor 13, and AAV-2 was fivefold inhibited (Fig. 3A to C).
The eqA3Z1b and -Z2e showed only moderate activity on
FIG. 2. Differential expression of eqA3s. (A) Analysis of eqA3Z1a, eqA3Z1b, eqA3Z2a-Z2b, eqA3Z2c-Z2d, eqA3Z2e, and eqA3Z3 expression
by RT-PCR of total RNA from equine activated PBMCs, spleen cells, and macrophages. Primer specificity in PCR was tested by using eqA3
plasmids as templates. PCRs were performed with specific primers to amplify ELR1 for species control, and GAPDH served as a loading control.
(B) eqA3Z3 is expressed at a sig ificantly lower level in macrophages. RNA was extracted from both equine PBMCs and macrophages. Levels of
A3 expressi n were determined by qu ntitative real-time RT-PCR and expr ssed relative to the levels of the GAPDH RNA. (C) eqA3s show a
different subcellular localization. HeLa cells were transfected with HA-tagged eqA3Z1b, eqA3Z2a-Z2b, eqA3Z2c-Z2d, eqA3Z2e, and eqA3Z3
and with human A3H and A3Z3. To detect A3 (green) immunofluorescence, staining was performed with an anti-HA antibody. Nuclei (blue) were
visualized by DAPI staining. Nucleolar nucleolin protein (red) was detected with anti-nucleolin antibody. , anti; hu, human.
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10-fold (Fig. 3B and C). eqA3Z2c-Z2d restricted both EIAV
and SIV by a factor of 12 and a factor of 120, respectively (Fig.
3A and B). Our results on the activity of A3Z2c-Z2d are in
contrast to the report of Bogerd et al. (6). Comparing the
sequence of A3Z2c-Z2d of Bogerd et al. (6), designated A3F2,
with our A3Z2c-Z2d expression plasmid revealed four differ-
ent amino acids (V40G, P48V, S339I, and K354N) (see Fig. S3
in the supplemental material). We introduced these amino
acid changes in our construct and tested A3F2 for its antiviral
activity (Fig. 4A). Both A3 proteins showed similar protein
expression levels (Fig. 4B) and identical subcellular distribu-
tions (Fig. 2C) (compare to reference 6), but A3F2 reduced the
infectivity of EIAV only twofold (Fig. 4A), confirming the
results of Bogerd et al. (6). We conclude that natural sequence
variants of some eqA3s can have a strong impact on their
activity against EIAV.
  To address the question whether eqA3 proteins show a cy-
tidine deaminase activity, EIAV vector cDNAs were analyzed
by PCR. We recovered an ~880-bp fragment of the luciferase
gene from infected cells, 10 h postinfection. The rate of the
detected G→A mutations in viral RT products was very low.
The G→A mutation rate was equal to or less than 0.07% of all
nucleotides for eqA3Z2a-Z2b, -Z2c-Z2d, and -Z3, and no
G→A mutations were detectable for eqA3Z1a and -Z2e (Fig.
5A, left panel). Based on the unsatisfactory results for deamination
activity of eqA3 proteins, we modulated the PCR con-
  FIG. 3. eqA3 proteins inhibit the infectivity of different viruses. (A) EIAV-luc (VSV-G pseudotyped) was produced in 
293T cells in the presence or absence of the indicated equine and human A3s. Infectivity of the viruses was determined 
by quantification of luciferase activity in CrFK cells with equal amounts of viruses at 3 days postinfection. (B) SIVagm 
vif viruses were produced in the presence or absence of the indicated A3 proteins. Infectivity of normalized amounts of viruses was 
determined by quantification of luciferase activity at 3 days postinfection. (C) AVV-2 viruses were generated by transfecting 293 
cells in the presence or absence of the indicated A3 proteins. Antiviral activity of A3 proteins was determined by quantification of 
ß-galactosidase expression at 3 days postinfection. (D) Equine and human A3 proteins are packaged in EIAV virions. Virions were 
generated by cotransfection of 293T cells with EIAV-luc and HA- or V5-tagged equine and human A3 expression plasmids or pcDNA3.1 
(vector). A3 expression in transfected cells was detected by immunoblotting using a mixture of anti-HA and anti-V5 antibodies. Cell 
lysates were also analyzed for equal amounts of total proteins by using anti-tubulin antibody. Packaged A3s in virions (normalized by 
RT activity) were detected by probing with anti-HA and anti-V5 antibody together on a parallel immunoblot. Immunoblots of virions 
were also probed with anti-VSV-G antibody as a control for the equal amounts of analyzed virions. cps, counts per second; a, anti.EIAV and reduced the infectivity by approximately threefold
each (Fig. 3A). Similarly, eqA3Z1b was weakly active against
SIV. In contrast, SIVagm infectivity was inhibited 70-fold by
eqA3Z2e, and eqA3Z1b reduced the infectivity of AAV-2 by
10-fold (Fig. 3 and ). eq 3 2c- 2d restricted both EIA
and SIV by a factor of 12 f t r f , r s ti el (Fig.
3A and B). Our results on t r i
contrast to the report f rd t l. the
sequence of A3Z2c-Z2d of r i at 3F2,
with our 3Z2c- 2d ex r ssi l s i r l f r iffer-
ent amino acids ( 40 , P48 , S339I, and 354 ) (see Fig. S3
in the supplemental material). e introduced these amino
acid changes in our construct and tested A3F2 for its antiviral
activity (Fig. 4A). Both A3 proteins showed similar protein
expression levels (Fig. 4B) and identical subcellular distribu-
tions (Fig. 2C) (compare to reference 6), but A3F2 reduced the
infectivity of EIAV only twofold (Fig. 4A), confirming the
results of Bogerd et al. (6). We conclude that natural sequence
variants of some eqA3s can have a strong impact on their
activity against EIAV.
To address the question wheth r eqA3 proteins show a cy-
tidine deaminase activity, EIAV vector cDNAs were analyzed
by PCR. We recovered a 880-bp fragment of the luciferase
ge e from fected cells 10 h postinfe tion. The ate of the
detected G3A mutations in viral RT products was very low.
The G3A mutation rate was equal to or less than 0.07% of all
nucleotides for eqA3Z2a-Z2b, -Z2c-Z2d, and -Z3, and no
G3A mutations were detectable for eqA3Z1a and -Z2e (Fig.
5A, left panel). Based on the unsatisfactory results for deami-
nation activity of eqA3 proteins, we modulated the PCR con-
FI . . eqA3 proteins inhibit the inf ctivity of different virus s. (A) EIAV-luc (VSV-G pseudotyped) was produced in 293T cells in the
presence or absence of the indicated equine and human A3s. Infectivity of the viruses was determined by quantification of luciferase activity in
CrFK cells with equal amounts of viruses at 3 days postinfection. (B) SIVagm vif viruses were produced in the presence or absence of the indicated
A3 proteins. Infectivity of normalized amounts of viruses was determined by quantification of luciferase activity at 3 days postinfection. (C) AVV-2
viruses were gene ated by transfecting 293 cells in the presenc or absence of the indicated A3 proteins. Antiviral activity of A3 protein as
determined by quantification of ß-galactosidase expression at 3 days postinfection. (D) Equine and human A3 proteins are packaged in EIAV
virions. Virions were generated by cotransfection of 293T cells with EIAV-luc and HA- or V5-tagged equine and human A3 expression plasmids
or pcDNA3.1 (vector). A3 expression in transfected cells was detected by immunoblotting using a mixture of anti-HA and anti-V5 antibodies. Cell
lys tes were lso analyzed for equal amounts of total proteins by using anti-t buli antibody. Packaged A3s in virions (normalized by RT activity)
were detected by probing with anti-HA and anti-V5 antibody together on a parallel immunoblot. I munoblots of virions were als probed with
anti-VSV-G antibody as a control for the equal amounts of analyzed virions. cps, counts per second; , anti.
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ditions to selectively amplify AT-rich DNA generated by G→A
hypermutations, as previously described for a three-dimensional
PCR method (87). Indeed, the rate of G→A mutations
detected by PCR using a denaturation temperature of 88°C
was ~7% of all nucleotides for eqA3Z3 and ~3% for A3Z2c-
Z2d (Fig. 5A, right panel; see also Table S1 in the supplemen-
tal material). In experiments with eqA3Z1b, -Z2a-Z2b, and
-Z2e, a low rate of 0.2 to 0.5% G→A mutations was now
detected, corresponding to their very weak antiviral activity
against EIAV. Under this PCR condition, no amplification
product was detectable in experiments omitting eqA3. The
editing context of the G→A exchanges in EIAV genomes
displays a dinucleotide preference of GG→AG and GA→AA
(Fig. 5B). In conclusion, eqA3s harbor the intrinsic activity to
deaminate cytidines and can deaminate EIAV genomes in at
least a subpopulation of the transducing particles under exper-
imental conditions.
   The dUTPase and S2 genes do not affect the susceptibility of
EIAV to eqA3s. EIAV encodes two genes, dUTPase (DU)
and S2, that are absent in the genome of HIV-1. To inves-
tigate the possibility that DU or S2 counteracts the antiviral
activity of eqA3s, EIAV DU and S2 mutation constructs
were generated. Since there were no antibodies against DU
and S2 available, no further biochemical studies on these
proteins were performed. Two EIAV-packaging constructs
were tested in which either the DU gene was inactivated by
an in-frame deletion of 270 bp (EIAVDDU) identical to the
method of Threadgill et al. (90) or the S2 gene was inacti-
vated by a deletion of 52 bp including the ATG start codon
of S2 (EIAVDS2), as described previously (55). We pro-
duced EIAV vectors of wt, DDU, or DS2 with and without
expression plasmids for eqA3s and measured the particle
infectivity on feline CrFK cells and on the equine macro-
phage-like cell line EML-3C. The results shown in Fig. 6
demonstrate that deletion of DU or S2 did not change the
antiviral activities of the eqA3Z2a-Z2b or -Z2e that are
inactive against wt EIAV. Moreover, wt, DDU, and DS2
vectors were equally inhibited by eqA3Z1b, -Z2c-Z2d, and
-Z3. Thus, we conclude that the resistance of EIAV to
eqA3Z2a-Z2b and -Z2e is not based on the function of the
dUTPase or the S2 protein and that DU and S2 are not
required for transduction of equine macrophage-like cells.
  EIAV restriction by human and nonprimate A3 proteins.
Previous studies investigated exclusively whether human
A3A and human A3G are antiviral active against EIAV (6,
48). To determine if other human and nonprimate A3 pro-
teins exert an inhibitory effect on the infectivity of EIAV, we
cotransfected 293T cells with the EIAV-luc reporter vector
together with expression plasmids encoding human A3A, -B,
-C, -DE, -F, -G, or -H; feline A3Z2a, -Z2b, -Z2c, -Z3, or
Z2b-Z3; canine A3Z1, or -Z3; porcine A3Z2-Z3; or
muA3Z2-Z3. In experiments using the human A3B expres-
sion plasmid, no RT activity after cotransfection with the
EIAV vector system was detectable in the cell supernatant.
Since the expression of the EIAV vectors is driven by the
cytomegalovirus promoter, this result would agree with a
previous study of Zhang et al., where the authors concluded
that human A3B is able to inhibit transcription of simian
virus 40 and cytomegalovirus promoters (99). Again, CrFK
cells were infected with vector stocks normalized for RT,
and 3 days postinfection the cells were used to quantify
intracellular luciferase activity. As shown in Fig. 3A and 7,
human A3F and -G, muA3Z2-Z3, and porcine A3Z2-Z3
proteins were found to exert a significant inhibitory effect on
the infectivity of EIAV. Specifically, human A3G and por-
cine A3Z2-Z3 reduced the infectivity of EIAV 90-fold and
145-fold, respectively. The other tested human and nonpri-
mate A3s showed no effect or a very weak inhibitory effect
against EIAV. Human A3s were packaged in EIAV inde-
pendent of their antiviral activity, with the notable exception
of human A3H (Fig. 3D).
  A single amino acid mutation in the active site of eqA3Z3
results in loss of antiviral activity. Because of the difficulties in
detecting eqA3-derived cytidine deamination in EIAV ge-
nomes, we studied the relevance of the zinc coordination do-
main for the antiviral activity. It has been reported that cyti-
dine deamination is largely dispensable for the inhibition
HIV-1 Dvif by human A3F and A3G (4, 30, 46, 61). But con-
troversially, several groups have reported a significant drop in
inhibition observed when active-site mutants of human A3G
were analyzed (8, 9, 22, 23, 56, 75). To address this question for
EIAV, we analyzed four previously described human A3F and
-G mutants called h3FAS1, h3FAS2, h3FAS1/2, and A3G-
E259Q (7, 23). Additionally, we generated four eqA3Z3 mu-
tants with related changes at the important amino acid posi-
tions of the Zn2+ coordinating site. Human A3F and -G
contain two Zn+ coordinating sites; only the CT Zn2+ coor-
dinating sites are enzymatically active while the amino-terminal
Zn2+ coordinating sites have been proposed to play a role
in the specific packaging of these two A3s into HIV-1 Dvif
particles (23, 60). In A3G-E259Q, a glutamic acid residue at
position 259 has been mutated to glutamine, which results in
loss of the cytidine deaminase activity of A3G (7). The catalytic
glutamic acid residues of the amino-terminal cytidine deami-
nase domain (CDD) in the A3F mutant h3FAS1 and of the CT
CDD in h3FAS2 are changed to alanines, and h3FAS1/2 car-
ries both point mutations (23). For eqA3Z3, in the single CDD
the mutations H84R, E86Q, C115S, and C118S were gener--
   FIG. 4. Double domain eqA3Z2c-Z2d protein variants differ in
their antiviral activity. (A) Single-cycle infectivity assays were 
performed for EIAV in presence or absence of A3Z2c-Z2d and 
the variant A3F2 differing in four amino acids. Infectivity of equal 
amount of viruses was determined by quantification of luciferase 
activity. (B) Immunoblot analysis of the indicated eqA3 proteins 
using an HA tag-specific antibody. a, anti; cps, counts per second.
ditions to selectively amplify AT-rich DNA generated by G3A
hypermutations, as previously described for a three-dimen-
sional PCR method (87). Inde d, th rate of G3A utations
detected by PCR using a enaturation temperature of 88°C
was 7% of all nucleotides for eqA3Z3 and 3% for A3Z2c-
Z2d (Fig. 5A, right panel; see also Table S1 in the supplemen-
tal material). In experiments with eqA3Z1b, -Z2a-Z2b, and
-Z2e, a low rate of 0.2 to 0.5% G3A mutations was now
detected, corresponding to their very weak antiviral activity
against EIAV. Under this PCR condition, no amplification
product was detectable in experiments omitting eqA3. The
editing context of the G3A exchanges in EIAV genomes
displays a dinucleotide preference of GG3AG and GA3AA
(Fig. 5B). In conclusion, eqA3s harbor the intrinsic activity to
deaminate cytidines and can deaminate EIAV genomes in at
least a subpopulation of the transducing particles under exper-
imental conditions.
The dUTPase and S2 genes do not affect the susceptibility of
EIAV to eqA3s. EIAV encodes two genes, dUTPase (DU)
and S2, that are absent in the genome of HIV-1. To inves-
tigate the possibility that DU or S2 count racts the antiviral
activity of eqA3s, EIAV DU and S2 mutation constructs
wer generated. Since there were no antibodies agains DU
and S2 available, no further biochemical studies these
proteins were performed. Two EIAV-packaging constructs
were tested in which either the DU gene was inactivated by
an in-frame deletion of 270 bp (EIAVDU) identical to the
method of Threadgill et al. (90) or the S2 gene was inacti-
vated by a deletion of 52 bp including the ATG start codon
of S2 (EIAVS2), as described previously (55). We pro-
duced EIAV vectors of wt, DU, or S2 with and without
expression plasmids for eqA3s and measured the particle
infectivity on feline CrFK cells and on the equine macro-
phage-like cell line EML-3C. The results shown in Fig. 6
demonstrate that deletion of DU or S2 did not change the
antiviral activities of the eqA3Z2a-Z2b or -Z2e that are
inactive against wt EIAV. Moreover, wt, DU, and S2
vectors were equally inhibited by eqA3Z1b, -Z2c-Z2d, and
-Z3. Thus, we conclude that the resistance of EIAV to
eqA3Z2a-Z2b and -Z2e is not based on the function of the
dUTPase or the S2 protein and that and S2 are not
required for transduction of equine macrophage-like cells.
EIAV restriction by human and non ri .
Previous studies i stigated xclusively
A3A and ti i active against EI ( ,
48). To determine if other u n ri t r -
teins exert an inhibitory effect on the infectivity of EIA , e
cotransfected 293T cells with the EIAV-luc reporter vector
together with expression plasmids encoding human A3A, -B,
-C, -DE, -F, -G, or -H; feline A3Z2a, -Z2b, -Z2c, -Z3, or
Z2b-Z3; canine A3Z1, or -Z3; porcine A3Z2-Z3; or
muA3Z2-Z3. In experiments using the human A3B expres-
sion plasmid, no RT activity after cotransfection with the
EIAV vector system was detectable in the cell supernatant.
Since the expression of the EIAV vectors is driven by the
cytomegalovirus promoter, this result would agree with a
previous study of Zhang et al., where the authors concluded
that human A3B is able to inhibit transcription of simian
virus 40 and cytomegalovirus promoters (99). Again, CrFK
cells were infected with vector stocks normalized for RT,
and 3 days postinfection the cells were used to quantify
intracellular luciferase activity. As shown in Fig. 3A and 7,
human A3F and -G, muA3Z2-Z3, and porc ne 3Z2-Z3
proteins were found to exert a signific t inhibitory effect on
the i fectivity of EIAV. Specifically, human A3G and por-
cine A3Z2-Z3 reduced the infectivity of EIAV 90-fold and
145-fold, respectively. The other tested human and nonpri-
mate A3s showed no effect or a very weak inhibitory effect
against EIAV. Human A3s were packaged in EIAV inde-
pendent of their antiviral activity, with the notable exception
of human A3H (Fig. 3D).
A single amino acid mutation in the active site of eqA3Z3
results in loss of antiviral activity. Because of the difficulties in
detecting eqA3-derived cytidine deamination in EIAV ge-
nomes, we studied the relevance of the zinc coordination do-
main for the antiviral activity. It has been reported that cyti-
dine deamination is largely dispensable for the inhibition
HIV-1 vif by human A3F and A3G (4, 30, 46, 61). But con-
troversially, several groups have reported a significant drop in
inhibition observed when active-site mutants of human A3G
were analyzed (8, 9, 22, 23, 56, 75). To addre s this question for
EIAV, we analyz four previously described human A3F and
-G mutants called h3FAS1, h3FAS2, h3FAS1/2, and A3G-
E259Q (7, 23). Additionally, we generated four eqA3Z3 mu-
tants with related changes at the important amino acid posi-
tions of the Zn2 coordinating site. Human A3F and -G
contain two Zn2 coordinating sites; only the CT Zn2 coor-
dinating sites are enzymatically active while the amino-termi-
nal Zn2 coordinating sites have been proposed to play a role
in the specific packaging of these two A3s into HIV-1 vif
particles (23, 60). In A3G-E259Q, a glutamic acid residue at
position 259 has been mutated to glutamine, which results in
loss of the cytidine deaminase activity of A3G (7). The catalytic
glutamic acid residues of the amino-terminal cytidine deami-
nase domain (CDD) in the A3F mutant h3FAS1 and of the CT
CDD in h3FAS2 are changed to alanines, and h3FAS1/2 car-
ries both point mutations (23). For eqA3Z3, in the single CDD
the mutations H84R, E86Q, C115S, and C118S were gener-
FIG. 4. Double domain eqA3Z2c-Z2d protein variants differ in
their antiviral activity. (A) Single-cycle infectivity assays were per-
formed for EIAV in presence or absence of A3Z2c-Z2d and the
variant A3F2 differing in four amino acids. Infectivity of equal amount
of iruses was determi ed by qu ntification of luciferase activity.
(B) Immunoblot analysis of the indicated eqA3 proteins using an HA
tag-specific antibody. , anti; cps, counts per second.
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ated, resulting in eqA3Z3-H84R, -H86Q, -C115S, and -C118S,
respectively. Analyses of the effect of the A3F and A3G mu-
tants on EIAV infectivity showed that the A3 CT mutants lost
all or most of the antiviral activity: h3FAS2 and hA3FAS1/2
reduced the infectivity only two- to threefold, and A3G-E259Q
showed no inhibitory effect; wt A3F and the mutant h3FAS1
inhibited EIAV 10- and 15-fold, respectively (Fig. 8A). The
mutant h3FAS1 was slightly more active than the wt human
A3F, an effect also observed by Hakata et al. in connection
with HIV-1Dvif (23). The protein A3G-E259Q showed a re-
duced packaging, while all other active-site mutants were
found in EIAV particles at amounts similar to wt proteins (Fig.
8B). The eqA3Z3 mutants showed weak antiviral activity and
inhibited EIAV only twofold (Fig. 8A). We conclude that the
  FIG. 5. eqA3 triggers G-to-A hypermutation in a subpopulation of the EIAV-luc genomes. (A) EIAV vector sequences (880 
nucleotides [nt] of the luciferase gene) amplified by PCR at 10 h postinfection from CrFK cells transduced by EIAV generated in the 
presence or absence of eqA3Z1b, eqA3Z2a-Z2b, eqA3Z2c-Z2d, eqA3Z2e, eqA3Z3, and eqA3Z3v1. The mutations of 10 individual 
clones of each group are shown. Each mutation is indicated and coded with respect to the nucleotide mutation. PCR was done at a 
denaturation temperature (Td) of either 95°C or of 88°C. (B) Comparison of the dinucleotide sequence context of G (underlined) 
→A mutations in the positive-strand DNA of EIAV-luc derived from eqA3-expressing 293T cells.
ated, resulting in eqA3Z3-H84R, -H86Q, -C115S, and -C118S,
respectively. Analyses of the effect of the A3F and A3G mu-
tants on EIAV infectivity showed that the A3 CT mutants lost
all or most of the antiviral activity: h3FAS2 and hA3FAS1/2
reduced the infectivity only two- to threefold, and A3G-E259Q
showed no inhibitory effect; wt A3F and the mutant h3FAS1
inhibited EIAV 10- and 15-fold, respectively (Fig. 8A). The
mutant h3FAS1 was slightly more active than the wt human
A3F, an effect also observed by Hakata et al. in connection
with HIV-1 vif (23). The protein A3G-E259Q showed a re-
duced packaging, while all other active-site mutants were
found in EIAV particles at amounts similar to wt proteins (Fig.
8B). The eqA3Z3 mutants showed weak antiviral activity and
inhibited EIAV only twofold (Fig. 8A). We conclude that the
FIG. 5. eqA3 triggers G-to-A hypermutation in a subpopulation of the EIAV-luc genomes. (A) EIAV vector sequences (880 nucleotides [nt]
of the luciferase gene) amplified by PCR at 10 h postinfection from CrFK cells transduced by EIAV generated in the presence or absence of
eqA3Z1b, eqA3Z2a-Z2b, eqA3Z2c-Z2d, eqA3Z2e, eqA3Z3, and eqA3Z3v1. The mutations of 10 individual clones of each group are shown. Each
mutation is indicated and coded with respect to the nucleotide mutation. PCR was done at a denaturation temperature (Td) of either 95°C or of
88°C. (B) Comparis n of the dinucleotide sequence context of G (underlined) 3A mutations in the positive-strand DNA of EIAV-luc derived
from eqA3-expressing 293T cells.
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CT CDDs of human A3F and -G also play an essential role in
the inhibition of EIAV and that the CDD of eqA3Z3 is important
even though CDD mutants of eqA3Z3 remain partially
active against EIAV.
DISCUSSION
  The evolution of A3 genes tells us a story of gene duplication
and specialization throughout mammalian history. Three main
clades can be distinguished within the A3 genes, namely A3Z1,
A3Z2, and A3Z3. The distribution supports the hypothesis of
an ancient origin of the A3 genes in the proto-mammalian
genome, followed by early duplication events before the ap-
pearance of the main clades within Mammalia (38, 58). In this
sense, the chromosomal arrangement of the A3 genes in the
horse genome is paradigmatic: two copies of the A3Z1 genes,
followed by five copies in tandem of the A3Z2 genes, and a
single copy of the A3Z3 gene. Regarding the two eqA3Z1
genes, a homologous canine A3Z1 gene exists as a single gene
(58). This suggests that the extant A3Z1a and A3Z1b genes in
the horse genome appeared via duplication after the last com-
mon ancestor of Carnivora and Perissodactyla, which could be
dated some 62.5 million years ago (2). With respect to origins
of the five eqA3Z2 genes, they all also share a common an-
cestor that is more recent than the last common ancestor of
Perissodactyla and Carnivora and should therefore be consid-
ered inparalogs compared with the rest of the tree terminal
taxa (81). In the Bayesian relaxed clock results, there are no
significant differences between the heights of the nodes that
define the last common ancestor of the eqA3Z1 genes (me-
dian, 0.0633; 95% confidence interval, 0.033 to 0.1034 substi-
tutions per site) and the eqA3Z2 genes (median, 0.0742; 95%
confidence interval, 0.0525 to 0.105 substitutions per site). This
concordance can be interpreted to mean that both expansions,
A3Z1 and A3Z2, have occurred close in time, maybe even in
two simultaneous duplication events. This event(s) would have
generated, on the one hand, the ancestors of the present day
eqA3Z1a and eqA3Z1b and, on the other hand, the ancestor of
present day eqA3Z2a-d and of eqA3Z2e (Fig. 1). After the
duplication of the ancestor A3Z2a-d gene, which generated the
ancestor A3Z2a,c and A3Z2b,d genes, these later genes fused
and formed after an additional duplication the present A3Z2a-
Z2b and A3Z2c-Z2d double-domain A3 genes. While the ancestor
A3Z2a-d was involved in several genetic rearrangements,
the A3Z2e gene was preserved. Further research will be
necessary to determine whether the additional duplications of
the A3Z1 genes and of the A3Z2 genes in horse are shared
also by other species within the genus Equus (such as zebra or
donkey) or by other genera within the order Perissodactyla
(such as Rhinocerotidae or Tapiridae). Recently, read-through
transcripts of A3Z2 and A3Z3 genes have been identified in
cats and pigs (38, 58). We could not find such a transcript in
our equine cDNA samples. But very interestingly, an equine
   FIG. 6. Inhibition of EIAV by eqA3s is independent from dUTPase and S2. wt, DDU, and DS2 EIAV viruses were produced in the 
presence or absence of the indicated HA-tagged A3 expression vectors. Relative infectivity of equal amounts of the reporter viruses 
was determined by quantification of luciferase activity in CrFK cells (A) or EML-3C macrophage-like cells (B) at 3 days postinfection. 
cps, counts per second.
   FIG. 7. Inhibition of EIAV by nonprimate A3 proteins. EIAV 
luciferase reporter viruses were produced in 293T cells in the 
presence or absence of the indicated A3s. Infectivity of the 
viruses was determined by quantification of luciferase activity 
in CrFK cells infected with equal amounts of virions at 3 days 
postinfection. cps, counts per second.
CT CDDs of human A3F and -G also play an essential role in
the inhibition of EIAV and that the CDD of eqA3Z3 is im-
portant even though CDDmutants of eqA3Z3 remain partially
active against EIAV.
DISCUSSION
The evolution of A3 genes tells us a story of gene duplication
and specialization throughout mammalian history. Three main
clades can be distinguished within the A3 genes, namely A3Z1,
A3Z2, and A3Z3. The distribution supports the hypothesis of
an ancient origin of the A3 genes in the proto-mammalian
genome, followed by early duplication events before the ap-
pearance of the main clades within Mammalia (38, 58). In this
sense, the chromosomal arrangement of the A3 genes in the
horse genome is paradigmatic: two copies of the A3Z1 genes,
followed by five copies in tandem of the A3Z2 genes, and a
single copy of the A3Z3 gene. Regarding the two eqA3Z1
genes, a homologous canine A3Z1 gene exists as a single gene
(58). This suggests that the extant A3Z1a and A3Z1b genes in
the horse genome appeared via duplication after the last com-
mon ancestor of Carnivor and Perissodactyla, which could be
dated some 62.5 million years ago (2). With respect to origins
of the five eqA3Z2 genes, they all also share a common an-
cestor that is more recent than the last common ancestor of
Perissodactyla and Carnivora and should therefore be consid-
ered inparalogs compared with the rest of the tree terminal
taxa (81). In the Bayesian relaxed clock results, there are no
significant differences between the heights of the nodes that
define the last common ancestor of the eqA3Z1 genes (me-
dian, 0.0633; 95% confidence interval, 0.033 to 0.1034 substi-
tutions per site) and the eqA3Z2 genes (median, 0.0742; 95%
confidence interval, 0.0525 to 0.105 substitutions per site). This
concordance can be interpreted to mean that both expansions,
A3Z1 and A3Z2, have occurred close in time, maybe even in
two simultaneous duplication events. This event(s) would have
generated, on the one hand, the ancestors of the present day
eqA3Z1a and eqA3Z1b and, on the other hand, the ancestor of
present day eqA3Z2a-d and of eqA3Z2e (Fig. 1). After the
duplication of the ancestor A3Z2a-d gene, which generated the
ancestor A3Z2a,c and A3Z2b,d genes, these later genes fused
and formed after an additional duplication the present A3Z2a-
Z2b and A3Z2c-Z2d double-domain A3 genes. While the an-
cestor A3Z2a-d was involved in several genetic rearrange-
ments, the A3Z2e gene was preserved. Further research will be
necessary to determine whether the additional duplications of
the A3Z1 genes and of the A3Z2 genes in horse are shared
also by other species within the genus Equus (such as zebra or
donkey) or by other genera within the order Perissodactyla
(such as Rhinocerotidae or Tapiridae). Recently, read-through
transcripts of A3Z2 and A3Z3 genes have been identified in
cats and pigs (38, 58). We could not find such a transcript in
our equine cDNA samples. But very interestingly, an equine
read-through transcript is deposited in the GenBank database
(RNA molecule accession number XM_001501833). This at
least implies that some individual horses do express an addi-
tional A3.
Within the placentalia superorder of Laurasiatheria, A3Z2
I . I ition of EIAV by eqA3s is indep ndent from dUTPase nd S2. wt, DU, and S2 EIAV viruses wer produced in th presence
or absence of the indicated HA-tagged A3 expression vectors. Relative infectivity of equal amounts of the reporter viruses was determined by
quantification of luciferase activity in CrFK cells (A) or EML-3C macrophage-like cells (B) at 3 days postinfection. cps, counts per second.
FIG. 7. hibition of EIAV by nonprimate A3 proteins. EIAV lu-
ciferase reporter viruses were produced in 293T cells in the presence or
absence of the indicated A3s. Infectivity of the viruses was determined
by quantification of luciferase activity in CrFK cells infected with equal
amounts of virions at 3 days postinfection. cps, counts per second.
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CT CDDs of human A3F and -G also play an essential role in
the inhibition of EIAV and that the CDD of eqA3Z3 is im-
portant even though CDDmutants of eqA3Z3 remain partially
active against EIAV.
DISCUSSION
The evolution of A3 genes tells us a story of gene duplication
and specialization throughout mammalian history. Three main
clades can be distinguished within the A3 genes, namely A3Z1,
A3Z2, and A3Z3. The distribution supports the hypothesis of
an ancient rigin of the A3 genes in the proto-mammalian
genom , followed by e rly duplication events before the ap-
pearanc of the main clades within Mammalia (38, 58). In this
sense, the chromosomal arrangement of the A3 genes in the
horse genome is paradigmatic: two copies of the A3Z1 genes,
follow d by fiv copies in tandem of the A3Z2 g nes, and
single copy of the A3Z3 gene. Regarding the two eqA3Z1
genes, a homologous canine A3Z1 gene exists as a single gene
(58). This suggests that the extant A3Z1a and A3Z1b genes in
the horse genome appeared via duplication after the last com-
mon ancestor of Carnivora and Perissodactyla, which could be
dated some 62.5 million years ago (2). With respect to origins
of the five eqA3Z2 genes, they all also share a commo an-
cestor that is more recen than the last common ancestor of
Perissodactyla and Carnivora and should herefor be con id-
ered inparalogs compared with the est of the tree terminal
taxa (81). In the Bayesian relax d clock results, ther are no
significan differences betwee the heights of the nodes that
define the last common ancestor of the eqA3Z1 genes (me-
dian, 0.0633; 95% confidence interval, 0.033 to 0.1034 substi-
tutions per site) and the eqA3Z2 genes (median, 0.0742; 95%
confidence interval, 0.0525 to 0.105 substitutions per site). This
concordance can be interpreted to mean that both expansions,
A3Z1 and A3Z2, have occurred close in time, maybe even in
two simultaneous duplication events. This event(s) would have
generated, on the one hand, the ancestors of the present day
eqA3Z1a and eqA3Z1b and, on the other hand, the ancestor of
present day eqA3Z2a-d and f eqA3Z2e (Fig. 1). After the
duplication of the ancestor A3Z2a-d gene, which generated the
ancestor A3Z2a,c and A3Z2b,d genes, these later genes fused
and for ed ft r an additional duplication the present A3Z2a-
Z2b and A3Z2c-Z2d double- omain A3 genes. W ile the an-
cestor A3Z2a-d was involved in several genetic rearrange-
ments, the A3Z2e gene was preserved. Further research will be
necessary to determine whether the additional duplications of
the A3Z1 genes and of the A3Z2 genes in horse are shared
also by other speci s within the genus Equus (such as zebra or
donkey) or by other genera within the order P rissodactyl
(such as Rhinocerotidae or Tapiridae). Recently, read-through
transcripts of A3Z2 and A3Z genes have been identified in
cats and pigs (38, 58). We could not find such a transcript in
our equine cDNA samples. But very interestingly, an equine
read-through transcript is deposited in the Ge Bank database
(RNA m lecule a c sion number XM_001501833). This at
least implies that some individual horses do express an addi-
tional A3.
Within the placentalia superorder of Laurasiatheria, A3Z2
FIG. 6. Inhibition of EIAV by eqA3s is independent from dUTPase and S2. wt, DU, and S2 EIAV viruses were produced i the presence
or absence of the indicated HA-tagged A3 expression vectors. Relative infectivity of equal amounts of the reporter viruses was determined by
quantification of luciferase activity in CrFK cells (A) or EML-3C macrophage-like cells (B) at 3 days postinfection. cps, counts per second.
FIG. 7. Inhibition of EIAV by nonprimate A3 proteins. EIAV lu-
ciferase reporter viruses were produced in 293T cells in the presence or
absence of the indicated A3s. Infectivity of the viruses was determined
by quantification of luciferase activity in CrFK cells infected with equal
amounts of virions at 3 days postinfection. cps, counts per second.
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read-through transcript is deposited in the GenBank database
(RNA molecule accession number XM_001501833). This at
least implies that some individual horses do express an addi-
tional A3.
  Within the placentalia superorder of Laurasiatheria, A3Z2 
genes have also undergone several duplication rounds in cats
(58). Remarkably, the A3Z3 gene was never amplified and has
been preserved as a single gene in Felidae and in Equidae. A
similar situation is found within the superorder of Euarchon-
toglires in humans/primates, where after the amplification of
A3Z2 and A3Z1, the duplicated genes fused and formed dou-
ble-domain A3 genes (human A3B, -DE, -F, and -G) (37, 58).
Amplified A3Z3 genes have not been found, and in contrast to
amplification of A3Z1 and A3Z2 genes, it seems to be an
evolutionary disadvantage. Consistent with this hypothesis, it
was recently shown that nonfunctional human A3Z3 alleles are
highly prevalent and have been actively selected for (24, 62).
The discovery of the cellular antiviral cytidine deaminase
A3G in search for the Vif cofactor explained many in vitro
observations regarding the replication of HIV-1 and HIV-1
Dvif in specific human cells (5, 49, 78, 91, 100). It also contrib-
uted to explain the narrow host range of HIV-1 that shows
spreading replication only in humans and chimpanzees (49,
59). Such defined interactions of Vif proteins with cognate A3
proteins had been shown so far only for HIV, SIV, and Feline
immunodeficiency virus (49, 58, 74). But the discovery of the
Vif-A3 interaction also highlighted the conundrum of “simple”
mammalian retroviruses like Mo-MLV and Mouse mammary
tumor virus and their survival without accessory genes like the
vif gene (45,64–66). If simple retroviruses do get along without
encoding proteins that actively counteract the impact of anti-
viral A3s, it is unclear why lentiviruses have evolved or retained
the vif gene. A Vif-deficient lentivirus like EIAV might there-
fore be a possible evolutionary link to understand the biolog-
ical relevance of Vif and to further investigate the question
whether a virus is targeted by its species-own A3s (70). Equine
PBMCs express at least five different types of A3 genes. EIAV
was mostly sensitive to eqA3Z3 and eqA3Z2c-Z2d and was
only weakly inhibited by eqA3Z1b, eqA3Z2a-Z2b, and -Z2e.
However in macrophages, the natural target cells of EIAV,
anti-EIAV A3s (A3Z2c-Z2d and A3Z3) are expressed at low
levels or barely expressed. Some reports have suggested a
requirement for the S2 gene for high virus loads in vivo and
disease induction (19, 42). Our finding that EIAV S2 does not
affect susceptibility to eqA3s is consistent with studies by Li et
al. (43), who have recently shown that S2 is not required for
viral replication in vitro in several equine cell lines and mac-
rophages. In contrast, the dUTPase of EIAV is necessary for
viral replication in macrophages (17). Our data clearly show
that EIAV dUTPase does not protect against eqA3s. How does
EIAV survive and replicate without any A3-counteracting viral
function? We propose that EIAV may use multiple strategies
to interact with its species-own A3s: it tolerates packaging of
eqA3s that are not active against EIAV (A3Z1b, A3Z2a-Z2b,
and A3Z2e) and avoids the active antiviral eqA3Z3 by an
evolutionary adaption of its cellular tropism to macrophages
that showed very low expression levels of A3Z3. The A3Z2c-
Z2d was also active against EIAV and found to be expressed at
low levels in macrophages. Interestingly, the sequence of the
eqA3Z2c-Z2d of our horse samples compared with the se-
quences of Bogerd et al. (6) differed in four amino acids. This
genetic variation in A3Z2c-Z2ds influenced its anti-EIAV ac-
tivity significantly (Fig. 4A). Future experimental investiga-
tions and field studies are required to support our hypothesis
that the presence of these or other A3 single nucleotide poly-
morphisms and the expression of A3Z2-Z3 read-through trans-
cripts modulate the susceptibility of horses to EIAV infection
and disease induction.
    FIG. 8. Analysis of human A3F and A3G and eqA3Z3 active-site mutants for antiviral activity. (A) Different active-site mutants of 
human A3F and A3G and eqA3Z3 (A3Z3) were tested for antiviral activity against EIAV-luc produced in 293T cells by cotransfection 
with wt or mutant A3 expression plasmids. Transfection with pcDNA3.1 (vector) instead of the A3 expression plasmid was included 
as a control. CrFK target cells were infected with virus-containing supernatants normalized for RT, and luciferase was measured at 
3 days postinfection. (B) Virions were generated by cotransfection of 293T cells with EIAV-luc and mutant HA-tagged eqA3 and 
human A3 expression plasmids or pcDNA3.1 (vector). A3 expression in transfected cells was detected by immunoblotting using 
anti-HA antibodies. Cell lysates were also analyzed for equal amounts of total proteins by using anti-tubulin antibody. Packaged A3s 
in virions normalized by RT activity were detected by probing with anti-HA antibody. Immunoblots of virions were also probed 
with anti-VSV-G antibody as a control for equal particle loading. a, anti.
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the vif gene. A Vif-deficient lentivirus like EIAV might there-
fore be a possible evolutionary link to understand the biolog-
ical relevance of Vif and to further investigate the question
whether a virus is targeted by its species-own A3s (70). Equine
PBMCs express at least five different types of A3 genes. EIAV
was mostly sensitive to eqA3Z3 and eqA3Z2c-Z2d and was
only weakly inhibited by eqA3Z1b, eqA3Z2a-Z2b, and -Z2e.
However in macrophages, the natural target cells of EIAV,
anti-EIAV A3s (A3Z2c-Z2d and A3Z3) are expressed at low
levels or barely expressed. Some reports have suggested a
requirement for the S2 gene for high virus loads in vivo and
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eqA3Z2c-Z2d of our horse samples compared with the se-
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genetic variation in A3Z2c-Z2ds influenced its anti-EIAV ac-
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that the presence of these or other A3 single nucleotide poly-
morphisms and the expression of A3Z2-Z3 read-through tran-
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The evolutionary history of the A3 genes shows a clear ten-
dency toward the growth of the antiviral protein armory. This
increase proceeds through gene duplication and possibly also
gene fusion and alternative read-throughmechanisms. Since gene
fusion is more common than gene fission (36), it is tempting to
speculate that the read-through mechanism could act as a pread-
aptation, facilitating—even mechanistically—the gene fusion
event. The diversification of genes opens the door to neo-
functionalization (29) and/or subfunctionalization (47). Under
FIG. 8. Analysis of human A3F and A3G and eqA3Z3 active-site mutants for antiviral activity. (A) Different active-site mutants of human A3F
and A3G and eqA3Z3 (A3Z3) were tested for antiviral activity against EIAV-luc produced in 293T cells by cotransfection with wt or mutant A3
expression plasmids. Transfection with pcDNA3.1 (vector) instead of the A3 expression plasmid was included as a control. CrFK target cells were
infected with virus-containing supernatants normalized for RT, and luciferase was measured at 3 days postinfection. (B) Virions were generated
by cotra sfection of 293T cells with EIAV-luc and mutant HA-tagged eqA3 and human A3 expression pl smids or pcDNA3.1 (vector). A3
expression in transfected cells was detected by immunoblotting using anti-HA antibodies. Cell lysates were also analyzed for equal amounts of total
proteins by using anti-tubulin antibody. Packaged A3s in virions normalized by RT activity were detected by probing with anti-HA antibody.
Immunoblots of virions were also probed with anti-VSV-G antibody as a control for equal particle loading. , anti.
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  The evolutionary history of the A3 genes shows a clear ten-
dency toward the growth of the antiviral protein armory. This
increase proceeds through gene duplication and possibly also
gene fusion and alternative read-through mechanisms. Since gene
fusion is more common than gene fission (36), it is tempting to
speculate that the read-through mechanism could act as a pread-
aptation, facilitating—even mechanistically—the gene fusion
event. The diversification of genes opens the door to neo-
functionalization (29) and/or subfunctionalization (47). Under
 the “duplication-degeneration-complementation” model, mecha-
nisms that tend to preserve the duplicated genes act by partition-
ing the original functions in the ancestral gene between the sister
genes rather than generating new functions (21). We have shown
here that present-day eqA3 proteins appeared after recent gene
duplication events, have different cellular localizations, and dis-
play different activities against distinct viruses, and this is also true
for other species (58). In this sense, the different eqA3Z1 and
eqA3Z2 proteins, the different human A3Z2-Z2 and -Z2-Z1 pro-
teins, the different feline A3Z2 proteins, and even A3Z2-Z3 read-
through transcription products (38, 58) might be regarded as
specialized antiviral proteins that have evolved, taking over and
refining ancestral functions in the original gene. Alternatively, if
the evolutionary forces that have independently favored the con-
servation of the duplicated A3 genes in Equidae, in Felidae, and
in primates parallel the pressure that retroviruses pose on their
hosts, the maintenance of the duplicated genes in the host ge-
nome might reflect an increase in the retroviral diversity affecting
specific taxa at specific time points.
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CHAPTER 5
To get more insight into the role of APOBEC3 (A3) cytidine 
deaminases in the species-specific restriction of feline 
immunodeficiency virus (FIV) of the domestic cat, we 
tested the A3 proteins present in big cats (puma, lion, tiger, 
and lynx). These A3 proteins were analyzed for expression 
and sensitivity to the Vif protein of FIV.While A3Z3s and 
A3Z2-Z3s inhibited Dvif FIV, felid A3Z2s did not show 
any antiviral activity against Dvif FIV or wild-type (wt) 
FIV. All felid A3Z3s and A3Z2-Z3s were sensitive to Vif of 
the domestic cat FIV. Vif also induced depletion of felid 
A3Z2s. Tiger A3s showed a moderate degree of resistance 
against the Vif-mediated counter defense. These findings 
may imply that the A3 restriction system does not play a 
major role to prevent domestic cat FIV transmission to 
other Felidae. In contrast to the sensitive felid A3s, many 
nonfelid A3s actively restricted wt FIV replication. To test 
whether VifFIV can protect also the distantly related human 
immunodeficiency virus type 1 (HIV-1), a chimeric HIV-1.
VifFIV was constructed. This HIV-1.VifFIV was replication 
competent in nonpermissive feline cells expressing human 
CD4/CCR5 that did not support the replication of wt 
HIV-1. We conclude that the replication of HIV-1 in some 
feline cells is inhibited only by feline A3 restriction factors 
and the absence of the appropriate receptor or coreceptor.
  In the family of Retroviridae, the vif gene is present in most
members of the genus Lentivirus. Its absence in Equine infec-
tious anemia virus and in endogenous lentiviruses of the order
Lagomorpha might indicate that vif appeared later in lentivirus
evolution and strongly emphasizes that lentivirus replication is
not strictly dependent on Vif (20, 58). Nevertheless, in the
well-studied primate and feline lentiviruses, viruses with a vif
deletion barely replicate in vivo and are not pathogenic (10,
46). Functional studies revealed that the Vif protein of the
human immunodeficiency virus type 1 (HIV-1) binds in
the virus-producing cells the cellular cytidine deaminases
APOBEC3F (A3F) and APOBEC3G (A3G) and induces
their polyubiquitination and subsequent degradation by the
proteasome (27, 45, 54, 55). In addition, it is reported that
Vif of HIV-1 inhibits APOBEC3 (A3) proteins by other,
nondegrading mechanisms (for a review, see reference 6).
   During viral infections when either no Vif protein is made or
when HIV-1 faces A3 proteins normally absent in T cells or
macrophages, A3s can be incorporated in the viral particles
and often inhibit the next round of infection. Other than the
cytidine deaminase activity on single-stranded viral DNA dur-
ing reverse transcription, human A3F and A3G inhibit Dvif
HIV-1 by other means (2, 15, 16, 18, 28, 34). The finding that
HIV-1 does not infect species besides Homo sapiens and Pan
troglodytes is based on the species-specific adaptation of Vif to
human A3s and other host-virus restriction mechanisms. In
support of this model, HIV-1 is inhibited by A3s of rhesus
macaques, African green monkeys (AGM), pigs, mouse, cats,
and horses (4, 19, 25, 33). In the case of A3G from AGM, a
single amino acid at position 128 determines whether Vif of
HIV-1 or simian immunodeficiency virus (SIV) of AGM can or
cannot counteract its antiviral activity (3, 24, 43, 53).
  Similar to the situation of SIVs in primates, specific types of
the feline immunodeficiency virus (FIV) can be isolated from
many Felidae (49). Little is known about whether the diverse
FIV isolates have a restricted host range as do HIV-1 and the
SIVs (32). The phylogenetic data indicate that most of these
FIV types isolated from different felids are monophyletic
(summarized in references 39 and 48). However, recent FIV
cross-species transmissions have been observed in pumas in-
fected by the FIVs of domestic cats and bobcats, in leopards
and tigers infected with the FIVs of lions, and in free-ranging
leopard cats infected with FIV strains of domestic cats, indi-
cating that repeated and/or multiple historic FIV cross-species
felid-to-felid transmission events can occur in the wild or in
captivity (5, 13, 35, 39, 48, 51). With the exception of repeated
FIV transmissions from bobcats to pumas, these reports mostly
describe singular events supporting that FIV is not frequently
cross-species transmitted.
  Recently, we characterized the feline Felis catus A3 (FcaA3)
locus showing that it is less complex than that of primates but
significantly more evolved than that of rodents (31). Based on
an evolution-based nomenclature that reflects the identity of
the zinc (Z) coordinating domain(s) (21), cats encode a trip-
licate Z2 and a single Z3 A3 gene. In addition, a complex
process of readthrough transcription and alternative splicing
results in two-domain feline A3Z2-Z3 molecules (31; see also
below). These different feline A3 restriction factors display a 
specific pattern of restriction toward wild-type (wt) feline ret-
roviruses (FIV, Feline leukemia virus [FeLV], and Feline foamy
virus [FFV]) and variants devoid of their counterdefense pro-
teins: while wt FIV and FFV are almost resistant against any of
the feline A3s, FeLV is moderately inhibited by FcaA3Z2-Z3s.
In contrast, Vif-deficient FIV is restricted by the two-domain
FcaA3Z2-Z3 and slightly by the Z3 form, while Bet-deficient
FFV is restricted to variable degrees by the three FcaA3Z2
proteins (22, 31).
In the present study, we sought to determine whether the Vif
protein of the domestic cat FIV is counteractive against A3s of
four lineages within Felidae. Using single-round replicating
FIV-reporter viruses, we detected a very broad activity of
VifFIV inhibiting almost all tested A3s of Felidae similar to
their own species A3s. We further found that vifFIV cloned into
HIV to replace the expression of authentic vif enables such
chimeric HIV-1 to overcome the A3 restriction in feline cells,
allowing productive replication in cat cells engineered to ex-
press the human receptors for HIV-1.
MATERIALS AND METHODS
  Cells and transfections. The human cell lines 293T, HeLa, HOS (ATCC
CRL-1543), HOS.CD4.CCR5 (NIBSC ARP078), and the modified feline cell
line CrFK.CD4.CCR5 (33) were maintained in Dulbecco high-glucose modified
Eagle medium (Biochrom, Berlin, Germany) supplemented with 10% fetal bo-
vine serum (FBS), 2 mM L-glutamine, penicillin (100 U/ml), and streptomycin
(100 µg/ml). Ficoll-enriched human peripheral blood mononuclear cells
(PBMC) were stimulated with 5 µg of phytohemagglutinin (Murex Diagnostics,
Ltd., Dartfield, United Kingdom)/ml and incubated with 30 IU of human IL-2
(Proleukin; Chiron, Emeryville, CA)/ml in RPMI 1640 containing 10% FBS and
2 mM Glutamax I (Invitrogen, Karlsruhe, Germany) for 48 h before infection.
Plasmid transfections into 293T cells were performed with Lipofectamine LTX
(Invitrogen) according to the manufacturer’s instructions. Transfections were
done in 12-well plates seeded with 2.5 x 105 cells/well the day before transfection
and 2.2 µg of plasmid DNA. The standard transfection experiment contained 0.5
µg of FIV packaging construct, 0.5 µg of FIV-luciferase vector, 0.5 µg of A3
expression plasmid, 0.5 µg of Vif expression plasmid, and 0.2 µg of VSV-G
expression plasmid; in some experiments pcDNA3.1(+) (Invitrogen) was used
instead of Vif and/or A3 plasmids. For HIV-luciferase transfections, 1 µg of
HIV-Luc plasmid was used instead of both FIV plasmids. At 48 h posttransfec-
tion, cells and supernatants were collected.
   A3 and Vif plasmids. All A3s are expressed as carboxy-terminal hemaggluti-
nin (HA)-tagged proteins, except human (Homo sapiens) APOBEC3DE
(HsaA3DE), a gift from Y.-H. Zheng, that carries a carboxy-terminal V5-tag (9)
and human A3H splice variants (SV), gifts from Viviana Simon, that carry
amino-terminal Flag tags (14). The human A3G expression construct was pro-
vided by N. R. Landau (25). FcaA3Z2s and -Z3, big cat (Panthera tigris corbetti
[Pti], Lynx lynx [Lly], Panthera leo bleyenberghi [Ple], Puma concolor [Pco], Panthera
pardus japonensis [Ppa])-A3Z2s and -Z3s, and Equus caballus (Eca)-, Mus
musculus (Mmus)-, and Sus scrofa (Ssc)-A3 expression plasmids and human
A3B, -C, and -F were previously described (22, 30, 31, 58). FcaA3Z2b-Z3 (SV-
B), FcaA3Z2c-Z3 and big cat A3Z2-Z3 cDNAs were identified by reverse trans-
criptase PCR (RT-PCR) with the forward (fw) primer fAPO-30 (5-TGCATC
GGTACCACCAAGGCTGGAGAGAGGAATGG-3) and the reverse (rv)
primer fAPO-28 (5-AGCTCGAGTCAAGCGTAATCTGGAACATCGTATG
GATATTCAAGTTTCAAATTTCTGAAG-3) using cDNA of total RNA from
feline PBMC and Pfu polymerase (Fermentas, St. Leon-Rot, Germany) as desc
ribed previously (31). Each 30 cycles were run at 94°C for 30 s, 58°C for 1 min,
and 72°C for 2 min, and PCR products were cloned into the KpnI and XhoI sites
of pcDNA3.1(+) and sequence verified. A3Z2c-Z3 variants including
polymorphic sequences of exon 4 of four different Felis catus breeding lines were
generated by exchanging the following amino acids through overlapping ext
ension PCR: for Birman (BIR), G179A, F182S, and K186E; for Japanese Bobtail
(BOB), K186E; for British Shorthair (SHO), R172Q, G179D, F182L, and
K186E; for Turkish Van (VAN), K157E, H158Y, D165Y, H166N, and K186E
(see Fig. 1B, top panel). The resulting full-length constructs were cloned into
pcDNA3.1(+) using the KpnI and XhoI restriction sites. Human and feline
A3Z2-Z3 chimera were made by exchanging the N-terminal or C-terminal or
both zinc (Z)-coordinating domains of the FcaA3Z2c-Z3 template through overl
apping extension PCR. The resulting cloned PCR products were sequence
verified. The 5’ and 3’ fragments were amplified separately by using primer pairs
fApo3F-18 x fe3C/hu3H.rv (5’-GTTAACAGAGCCATTGTGGGTCTGGGCA
A-3’) and fe3C/hu3H.fw (5’-TTGCCCAGACCCACAATGGCTCTGTTAAC-
3’) x huA3H-HA.rv (5’-TTCAGCTCGAGTCAAGCGTAATCTGGAACATC
GTATGGATAGGACTGCTTTATCCTGTCAAG-3’) for FcaA3Z2c-HsaA3Z3
(FcaA3Z2c-HsaA3H); CEM15-CEM13 (5’-TAAGCGGAATTCTATCTAAGAG
GCTGAACATG-3’) x hu3C/fe3H.rv (5’-CTTTGTTGGCCGGGATGGAG
ACTCTCCCGT-3’) and hu3C/fe3H.fw (5’-ACGGGAGAGTCTCCATCCCGG
CCAACAAAG-3’) x fAPO-28 for HsaA3Z2b-FcaA3Z3 (HsaA3C-FcaA3Z3)
and the plasmids human A3C or A3H (HapII RDD-SV-183 [FJ376614] [14]) and
FcaA3Z2c-Z3 as a template. To test the relevance of the interdomain linker
of FcaA3Z2c-Z3, both feline domains were replaced by human sequences:
HsaA3Z2b-HsaA3Z3 (HsaA3C-HsaA3H) was constructed by overlapping PCR
using the primer pairs CEM15-CEM13 x fe3C/hu3H.rv and fe3C/hu3H.fw x
huA3H-HA.rv and the plasmids human A3H (HapII RDD-SV-183) and
HsaA3Z2b-FcaA3Z3 as a template. The 5 and 3 fragments were then mixed
and amplified with the two external primers. The resulting full-length mutants
were cloned into pcDNA3.1(+) using KpnI and XhoI restriction sites. V5-tagged
pVifHIV-1 of HIV-1NL4-3 was generated by amplifying the vif gene from pNL-
LucR-E- (7) using fw primer HIV1_5_HH (5’-TGCAGGTACCATGGAAA
ACAGATGGCAGGTGATGAT-3’) and rv primer HIV1_3’_HH (5’-AATGG
CGGCCGCTCACGTAGAATCCAGTCCCAAGAGCGGGTTTGGGATAG
GCTTGCCGTGTCCATTCATTGTATGGCTC-3’). The amplicon was cloned
into pcDNA3.1(+) carrying a Woodchuck hepatitis virus posttranscriptional reg-
ulatory element (WPRE) (11) via KpnI and NotI restriction sites. pVifSIVagm was
provided by N. R. Landau and the V5 tag containing Vif of FIV (pVifFIV) was
described previously (31). pVIFFIV expresses the codon-optimized vif of FIV-
34TF10, and it was generated by cloning the codon-optimized vif gene containing
a V5 tag sequence at the 3 end, into pcDNA3.1(+) using the KpnI and NotI
restriction sites; a 3’-WPRE element was included in the NotI and ApaI sites. Vif
of FIV-34TF10 and Vif of FIV-PPR (expressed in the packaging construct
pCPRDEnv) share 90.4% identical amino acids. All sequences of plasmid DNA
were obtained by dye terminator sequencing on an ABI 3730xl (Applied Biosys-
tems, Darmstadt, Germany).
  Viruses and infections. FIV single-cycle luciferase vectors (FIV-Luc) were
produced by cotransfecting 293T cells with the following: the replication-defi-
cient packaging construct pFP93 (derived from clone FIV-34TF10 [GenBank
accession number M25381], a gift from Eric M. Poeschla [23]), which expresses
gag, pol, and rev but does not express env or vif (referred as FIVvif in Results);
the replication-deficient packaging construct pCPREnv (derived from clone
FIV-PPR [GenBank accession number M36968], a gift from Garry P. Nolan [8]),
which expresses all FIV genes, including Vif, but not env (referred as wt FIV in
Results); the FIV luciferase vector pLiNSin (31); a VSV-G expression plasmid
pMD.G; an A3 expression plasmid; or empty vector pcDNA3.1(+). Vector
pLiNSin was derived from pGiNSin, a self-inactivating (Sin) vector variant of
pGiNWF (23), which is a minimal bicistronic FIV transfer vector plasmid coding
for enhanced green fluorescent protein (EGFP) and neomycin phosphotransfer-
ase containing the posttranscriptional regulatory element WPRE and the FIV
central DNA flap. In addition, the luciferase reporter vectors FIVvif plus Vif
were produced by cotransfecting 293T cells with pFP93, pLiNSin, a Vif expres-
sion plasmid (pMD.G), and an A3 expression plasmid or empty vector
pcDNA3.1(+). Gag-Pol of strains FIV-34TF10 and FIV-PPR show ~96% iden-
tical amino acids. HIV-Luc vif was produced by cotransfecting 293T cells with
pNL-LucR E vif (25) and pMD.G, together with defined A3 expression plas-
midsor pcDNA3.1(+) and a Vif expression plasmid or empty vector
pcDNA3.1(+). The RT activity of viruses was quantified by using the Cavidi HS
Lenti RT kit (Cavidi Tech, Uppsala, Sweden). For reporter virus infections, HOS
cells were seeded at 2.0 x 103 cells/well 1 day before transduction in 96-well
plates and then infected with reporter virus stocks normalized for RT activity.
Firefly luciferase activity was measured 3 days posttransduction with the Stea-
dylite HTS reporter gene assay system (Perkin-Elmer, Cologne, Germany) ac-
cording to the manufacturer’s instructions on a MicroLumat Plus luminometer
(Berthold Detection Systems, Pforzheim, Germany). Transductions were per-
formed in triplicates; the means and standard deviations of each triplicate are
shown. Replication-competent NL-BaL (NL4.3 with the env BaL) (26) virus
stocks were prepared by harvesting the supernatant of transfected 293T cells.
The cloning used to generate pNL-BaL.vifFIV and pNL-LucR-E-vifFIV results
in an in-frame insertion of FIV vif in the HIV-1 vif coding region. The constructs
were designed to express VifFIV by internal initiation. Three fragments were
amplified separately using pVIFFIV and pNL-LucR-E- as template DNA and
the primer pairs Vpu_mut_5’out_HH (5’-GAACCGGTACATGGAGTGTATT 
AT-3’) and HIV1_vif_FIV1.rv (5’-CTCTTCGCTCATGGCCTATGTATGCAG
ACC-3’); HIV1_vif_FIV2.fw (5’-GGTCTGCATACATAGGCCATGAGCGAA
GAG-3’) and HIV1_vif_FIV2a.rv (5’-CTCCATTCTATGGTCAGGTGCTGTC
C-3’); and HIV1_vif_FIV3.fw (5’-GGACAGCACCTGACCATAGAATGGA
G-3’) and HIV1_vif_FIV3.rv (5’-TGCAGAATTCTTATTATGGCTTCCA-3’).
The forward primer HIV1_vif_FIV2.fw was used to insert a stop codon upstream
of the FIV Vif-V5 start codon. The fragments were fused through overlapping
extension PCR, and the final fragment was amplified by using the forward
Vpu_mut_5’out_HH and reverse HIV1_vif_FIV3.rv primers. The amplicon was
cloned into restriction sites AgeI and EcoRI of the HIV-1 plasmids. The se-
quence identity of the final HIV-derived plasmids was confirmed: vifFIV was
inserted without disturbing the reading frames of the overlapping pol and vpr
genes. The final vif region encodes for the first 76 amino acids of VifHIV, followed
by the vif-V5 of FIV (see Fig. 5A for details). 3 of the stop codon of FIV vif-V5,
the natural reading frame of the terminal 107 amino acids of vifHIV were main-
tained but are assumed to be nonfunctional. The kinetics of viral spreading
replication was determined with feline CrFK.CD4.CCR5 cells, human
HOS.CD4.CCR5 cells, and human PBMC by infection with 50-pg equivalents of
RT from NL-BaL and NL-BaL.vifFIV. Spreading virus replication was quantified
over 15 days using the Zeptometrix Retro-Tek HIV-1 p24 antigen enzyme-linked
immunosorbent assay (ELISA) (Zeptometrix, New York, NY) according to the
instructions of the manufacturer. For all transfections, transductions and infec-
tions, representative data are shown, and all experiments were repeated inde-
pendently at least three times.
   Immunoblot analysis. Transfected cells were lysed in radioimmunoprecipita-
tion assay (RIPA) buffer (25 mM Tris-HCl [pH 7.6], 150 mM NaCl, 1% NP-40,
1% sodium deoxycholate, 0.1% sodium dodecyl sulfate [SDS], protease inhibitor
cocktail set III [Calbiochem, Darmstadt, Germany]). Virions (filtered, 0.45-µm
pore size) culture supernatant) were pelleted by centrifugation through a 20%
sucrose cushion at 35,000 rpm in a SW40 Ti rotor for 1.5 h and resuspended in
RIPA buffer. The protein concentration of the lysates was quantified by using
Bradford reagent (Applichem, Darmstadt, Germany). Then, 20 µg of each sam-
ple was separated by SDS-PAGE and transferred to polyvinylidene difluoride
filters. Filters were probed with mouse anti-hemagglutinin (anti-HA) antibody
(1:10,000 dilution, MMS-101P; Covance, Münster, Germany), mouse anti-Flag
M2 antibody (1:1,000, clone M2; Sigma-Aldrich, Taufkirchen, Germany), mouse
anti-V5 antibody (1:5,000 dilution, MCA1360; ABDserotec, Düsseldorf, Ger-
many), mouse anti-a-tubulin antibody (1:4,000 dilution, clone B5-1-2; Sigma-
Aldrich), mouse anti-capsid p24 hybridoma supernatant (1:50 dilution, a-p24
183-H12-5C; provided by Egbert Flory), or mouse anti-VSV-G antibody (1:
10,000 dilution; clone P5D4; Sigma-Aldrich), followed by horseradish peroxidase-
conjugated rabbit anti-mouse antibody (a-mouse-IgG-HRP; GE Healthcare,
Munich, Germany), and developed with ECL chemiluminescence reagents
(GE Healthcare).
   Statistical analysis. The data were analyzed by using a Dunnett t test using
GraphPad InStat 3 software (GraphPad Software, San Diego, CA). This is a
multiple-comparison method that uses a pooled standard deviation and allows a
comparison of multiple values to a single control. P values of <0.05 were
considered significant.
  Data deposition. The novel sequences reported here have been deposited
in the GenBank database (accession number): FcaA3Z2b-Z3 SV-B
(HM100128), FcaA3Z2c-Z3 (GU097660), PtiA3Z2-Z3 (GU097663),
PleA3Z2-Z3 (GU097662), LlyA3Z2-Z3 GU097661), and PcoA3Z2-Z3
(GU097659). 
RESULTS
  Complex splicing and readthrough transcription of feline
A3s. Recently, we described five different Felis catus A3
cDNAs (FcaA3Z2a, -Z2b, -Z2c, -Z3, and the readthrough
splice variant [SV]-Z2b-Z3 [now designated FcaA3Z2b-Z3
SV-A]) representing the genes of the sequenced Abyssinian cat
genome (22, 31, 33). During the present study, we identified
the alternative splice variant B (SV-B) of A3Z2b-Z3 with ex-
ons 1 to 4 of A3Z2b, whereas the previously described
A3Z2b-Z3 splice variant A (SV-A) differs in exon 4 that is
derived from the A3Z2c gene (Fig. 1A). Via RT-PCR we
identified another two-domain A3 readthrough transcript in
feline PBMC, A3Z2c-Z3. The A3Z2c-Z3 cDNA is composed
of the fused open reading frames of A3Z2c and A3Z3 (Fig.
1A). All readthrough A3s differ moderately from each other in
three or six amino acids. In these two-domain feline A3 pro-
teins, the Z2 and Z3 domains are naturally separated by a
linker region that is derived from the 156-nucleotide (nt) long
unique 5’ region of the A3Z3 Exon 2 (Fig. 1). In addition, we
cloned expression plasmids of A3Z2c-Z3s containing the poly-
morphic sequences detected in exon 4 of A3Z2c of the four
domestic cat breeds Japanese Bobtail (BOB), Birman (BIR),
British Shorthair (SHO), and Turkish Van (VAN) (31). The
exon 4-derived variability of the cat breeds with respect to the
reference Abyssinian sequence affected up to five amino acids
(Fig. 1B, top panel; for details, see Materials and Methods).
  FIV Vif broadly counteracts Felidae A3s. To test these A3s
against FIV, we analyzed the infectivity of wt, Dvif FIV, and Dvif
FIV plus VifFIV produced in the presence of the described feline
A3s and human A3G using single-round luciferase reporter vec-
tors. In the wt FIV vector system (based on FIV-PPR), the Vif
protein is expressed in its natural genomic context, whereas the
Dvif FIV vector system (based on FIV-34TF10) lacks the vif gene.
To complement Vif in trans, plasmid pVifFIV expressing a codon-
optimized Vif protein of FIV-34TF10 with a C-terminal V5 tag
was used. The Vifs of FIV-34TF10 and of FIV-PPR share 90.4%
identical amino acids and Gag-Pol proteins of both FIV strains
are ~96% identical.
  293T cells were cotransfected either with wt FIV or Dvif FIV
or Dvif FIV plus the VifFIV expression plasmid and one of the
A3 expression plasmids. At 2 days posttransfection, virus-con-
taining cell supernatants were collected, normalized for RT
activity, and used to transduce HOS cells. The intracellular
luciferase activity in transduced HOS cells was analyzed 3 days
postinfection (dpi), a time when provirus formation had fin-
ished. Similar to recent findings (31), expression of the three
A3Z2 isoforms did not inhibit wt or Dvif FIV (compare the first
bar with the second and third bars in sets II to IV, Fig. 2A;
variations are not statistically significant). A3Z3 reduced the
infectivity of Vif-deficient FIV ~5-fold (statistically significant,
P < 0.01), but not if Vif was expressed (compare the first bar
with the second and third bars in set V, Fig. 2A). Both the Vif
of the wt FIV packaging construct and of the VifFIV expression
plasmid induced a depletion of A3Z2s and of A3Z3 proteins in
the producer cells, indicating that the V5 tag in Vif did not
compromise the Vif function (compare the first lane with the
second and third lanes in sets II to IV of cell lysate, Fig. 2B).
Interestingly, not only A3Z3 also A3Z2 proteins were easily
detectable in particles of Dvif FIV (see first lane of set II to V,
virion lysates, Fig. 2B). In analyzing the double-domain A3s,
we found that both A3Z2-Z3s were active against Dvif FIV (6-
to 12-fold inhibition; P < 0.01) but were completely or mostly
inactive when Vif was coexpressed (compare the first bar with
the second and third bars in sets VI and VII, Fig. 2A).
A3Z2b-Z3 splice variants A and B showed indistinguishable
expression levels and activities (data not shown); therefore, all
figures show only experiments performed with the A3Z2b-Z3
(SV-A).
  The high genetic variability in exon 4 of A3Z2c in some cat
breeds (31) made us wonder whether these amino acids are the
result of a positive selection in response to FIV. We found that
the A3Z2c-Z3 constructs called BIR, BOB, SHO, and VAN
(see above) were at least as active as the parental A3Z2c-Z3
(Abyssinian cat) under the experimental conditions. The A3 
constructs containing the exon 4 sequences from BIR, SHO,
and VAN significantly inhibited up to 15-fold, and the most
active variant with sequences of BOB reduced the infectivity of
Dvif FIV by 38-fold (first bar in sets IX, XI, and XII, Fig. 2A).
Coexpression of VifFIV fully counteracted the A3Z2c-Z3s from
the Abyssinian cat and constructs with sequences of BIR and
SHO (second and third bars in sets IX and XI, Fig. 2A) and
mostly rescued FIV also from A3Z2-Z3s with the exon 4 vari-
ability of BOB, with a difference of no statistical significance
for vif FIV plus VifFIV and significance for wt FIV (P < 0.05)
(second and third bars, set X, Fig. 2A). Vif could not completely
restore the infectivity of Dvif FIV+VifFIV or wt FIV
made in the presence of VAN (statistically significant, P < 0.05
or P < 0.01, respectively), and it remained reduced by ~5-fold
(second and third bars, set XII, Fig. 2A). Immunoblots of the
virus producer cells demonstrated equal expression of the A3
proteins and a Vif-dependent depletion (compare the first lane
   FIG. 1. Representation of APOBEC3 (A3) coding regions in the genome of Felis catus. (A) Transcripts with translated exons (Z2, 
gray rectangles; Z3, black rectangles) and spliced-out introns (dashed lines) are indicated. Three readthrough transcripts were found: 
the already described two-domain FcaA3Z2c-Z3 (31) and the two splice variants (SV) A3Z2b-Z3 (SV-A) and A3Z2b-Z3 (SV-B) that 
include the exon 4-derived sequence of either A3Z2b or -Z2c in an additionally spliced version (for details, see reference 31). (B) 
Schematic representation of the exon structure of the A3Z2-Z3 readthrough transcripts. The locations of amino acid replacements 
in FcaA3Z2c-Z3 are indicated with respect to exon 4 variability of major cat breeds (upper figure) and A3Z2-Z3 genes of big cats 
(lower figure). A plus sign indicates the insertion of an amino acid. Numbers in shaded boxes indicate exons from Z2c, and those in 
open boxes indicate exons from Z3. The region of Z2-Z3 proteins designated “linker region” protein is encoded by exon 2 of A3Z3, 
a sequence that is untranslated in single-domain A3Z3. BIR, Birman; BOB, Japanese Bobtail; SHO, British Shorthair; VAN, Turkish 
Van; Pti, Panthera tigris corbetti; Ppa, Panthera pardus japonensis; Ple, Panthera leo bleyenberghi; Lly, Lynx lynx; Pco, Puma concolor.constructs cont ining the exon 4 sequenc s from BIR, SHO,
and VAN significantly inhibited up to 15-fold, and the most
active variant with sequences of BOB reduced the infectivity of
vif FIV by 38-fold (first bar in sets IX, XI, and XII, Fig. 2A).
Coexpression f VifFIV fully counteracted the A3Z2c-Z3s from
the Abyssinian cat and constructs with sequences of BIR and
SHO (second and third bars in sets IX and XI, Fig. 2A) and
mostly rescued FIV also from A3Z2-Z3s with the exon 4 vari-
FIG. 1. Representation of APOBEC3 (A3) coding regions in the genome of Felis catus. (A) Transcripts with translated exons (Z2, gray rectangles;
Z3, black rectangles) and spliced-out introns (dashed lines) are indicated. Three readthrough transcripts were found: the already described two-domain
FcaA3Z2c-Z3 (31) and the two splice variants (SV) A3Z2b-Z3 (SV-A) and A3Z2b-Z3 (SV-B) that include the exon 4-derived sequence of either A3Z2b
or -Z2c in an additionally spliced version (for details, see refere ce 31). (B) Schematic epresentation of the exon structure of the A3Z2-Z3 readthroug
transcripts. The locations of amino acid replacements in FcaA3Z2c-Z3 are indicated with respect to exon 4 variability of major cat breeds (upper figure)
and A3Z2-Z3 genes of big cats (lower figure). A plus sign indicates the insertion of an amino acid. Numbers in shaded boxes indicate exons from Z2c,
and those in open boxes indicate exons from Z3. The region of Z2-Z3 proteins designated “linker region” protein is encoded by exon 2 of A3Z3, a
sequence that is unt anslated in single-domain A3Z3. BIR, Birman; BOB, Japanese Bob ail; SHO, British Shorthair; VAN, Turkish Van; Pti, Panther
tigris corbetti; Ppa, Panthera pardus japonensis; Ple, Panthera leo bleyenberghi; Lly, Lynx lynx; Pco, Puma concolor.
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with the second and third lanes in sets II to VII and IX to XII,
Fig. 2B). As expected, the antiviral activity of HsaA3G was not
counteracted by VifFIV. Taken together, these findings suggest
that the genetic variability in exon 4 of A3Z2c-Z3 has a minor
effect on the infectivity of domestic cat FIV. However, amino
acids derived from exon 4 of Turkish Van do have some impact
on the counteraction of VifFIV. Because our studies, described
below, implicate that VifFIV interacts with both Z domains of
A3Z2c-Z3, the mechanism of the moderate Vif resistance of
VAN cannot be explained and requires further investigation.
  Our finding that Vif of FIV potently inhibited mostly all
tested A3s of the domestic cat prompted us to evaluate the
ability of VifFIV to counteract A3 proteins of felid species
different from the domestic cat lineage. For this purpose,
A3Z2, A3Z3, and A3Z2-Z3 expression plasmids of Panthera
tigris corbetti, Lynx lynx, Panthera leo bleyenberghi, Puma con-
color, and A3Z2 of Panthera pardus japonensis, representing
three lineages within Felidae, were analyzed for their anti-FIV
activity. Because only the F. catus chromosomal A3 locus is
characterized (31), the felid A3 cDNAs of big cats cannot be
related to a specific Z2 gene or to a specific Z2-Z3 readthrough
transcript. Comparing the protein sequence of FcaA3Z2c-Z3
to those of big cats, many amino acids changes become obvi-
ous, especially in exons 2 and 4 of A3Z2 and exon 4 of A3Z3
(Fig. 1B, bottom panel). Testing the big cat A3s in the FIV
luciferase vector system, we surprisingly detected no strong
inhibitory activity against the wt domestic cat FIV (see the
second and third bars in sets II to XVI, Fig. 2C). The felids
A3Z2s did not much affect the infectivity of wt or vif FIV
(sets II to VIII, Fig. 2C) similar to the inert antiviral activities
of the domestic cat counterparts (sets II to IV, Fig. 2A). How-
ever, we found for some felid A3Z2s a mild, sometimes signif-
icant, inhibition of ~1.5- to 2-fold of FIV (see sets II to VIII,
Fig. 2C). Vif-deficient FIV was significantly (P < 0.01) inhib-
ited by A3Z3s and A3Z2-Z3s, but in all cases the antiviral
activity was efficiently suppressed by Vif (compare the first bar
to the second and third bars, set IX to XVI, Fig. 2C). Com-
pared to the infectivity data (Fig. 2C), Vif induced a robust
depletion of all big cat A3s in the corresponding producer cells
(compare the first lane to the second and third lanes in sets II
to XVI, Fig. 2D). The tiger A3s were slightly, but significantly,
more active than those of the other big cat A3s (see sets II, X,
and XIII, Fig. 2C), such as PtiA3Z2-Z3, inhibited in this ex-
periment the infectivity of vif FIV by 85-fold and inhibited
FIV ca. 3- to 5-fold despite the coexpression of Vif (P < 0.01,
compare the first bar to the second and third bars, set XIII,
Fig. 2C).
  To demonstrate that the moderate inhibition of FIV by tiger
A3Z2-Z3 is relevant, a titration of cat Vif and tiger A3 plas-
mids in the context of vif FIV was performed (Fig. 2E and F).
In contrast to the standard assays, where each 500 ng of
pVifFIV and A3 expression plasmids were transfected, 4, 20,
100, or 500 ng each of FcaA3Z2c-Z3, PtiA3Z2-Z3, and VifFIV
was used. Human A3G was included as a control for a VifFIV-
   FIG. 2. FIV Vif of domestic cats overcomes the antiviral activity of Felidae A3s. VSV-G pseudotyped wt FIV (expressing Vif), 
Dvif, and Dvif plus VifFIV luciferase reporter vectors were produced in 293T cells cotransfected with HA-tagged A3 expression 
plasmids of the domestic cat and chimeric A3s with major amino acid exchanges of exon 4 of A3Z2c of four cat breeding lines 
(A and B) and big cats (C and D). Roman numbers indicate a set of transfections with the same A3 plasmid. Plasmid pVifFIV 
expresses a V5-tagged Vif protein. pcDNA3.1(+) (pcDNA) was included as a control. Reporter vector infectivity was determined by 
quantification of luciferase activity in HOS cells transduced with vector particles normalized for RT. Asterisks represent statistically 
significant differences (∗, P < 0.05; ∗∗, P < 0.01 [Dunnett t test]) relative to the pcDNA control. A3 and Vif (Vif-V5) expression in the 
transfected 293T producer cells were detected by immunoblotting with anti-HA antibody for A3 or anti-V5 for Vif (B and D). Cell 
lysates were also analyzed for equal amounts of total proteins by using anti-tubulin antibody. For panel B, Felis catus A3s proteins 
were also analyzed for encapsidation into released FIV particles. Encapsidated A3 proteins were detected on immunoblots probed 
with anti-HA antibody. Vector particle lysates were analyzed for equal amounts of viral proteins by using anti-VSV-G antibody. (E) 
Increasing amounts of A3 (0, 4, 20, 100, and 500 ng of plasmid) were tested against Dvif FIV and Dvif FIV plus Vif (500 ng of pVifFIV 
plasmid) and alternatively Dvif FIV in the presence of 500 ng of A3 plasmid with increasing amounts of VifFIV (0, 4, 20, 100, and 
500 ng of plasmid) was analyzed (F). Corresponding immunoblots of lysates of the vector producer cells are shown. A3 and Vif 
(Vif-V5) expression in transfected 293T producer cells were detected by immunoblotting with anti-HA antibody for A3 or anti-V5 
for Vif. Cell lysates were also analyzed for equal amounts of total proteins by using anti-tubulin antibody. a, anti; cps, counts per 
second; BIR, Birman; BOB, Japanese Bobtail; SHO, British Shorthair; VAN, Turkish Van; Fca, Felis catus; Pti, Panthera tigris corbetti; 
Ppa, Panthera pardus japonensis; Ple, Panthera leo bleyenberghi; Lly, Lynx lynx; Pco, Puma concolor; Hsa, Homo sapiens; (var1), A3Z2 
variant transcript detected in the indicated species.
ability of BO , with a difference of no statistical significance
for vif FIV plus VifFIV and significance for wt FIV (P 0.05)
(second and third bars, set X, Fig. 2A). Vif could not com-
pletely restore the infectivity of vif FIVVifFIV or wt FIV
made in the presence of VAN (statistically significant, P 0.05
or P  0.01, respectively), and it remained reduced by 5-fold
(second and third bars, set XII, Fig. 2A). Immunoblots of the
virus producer cells demonstrated equal expression of the A3
proteins and a Vif-dependent depletion (compare the first lane
with the second and third lanes in sets II to VII and IX to XII,
Fig. 2B). As expected, the antiviral activity of HsaA3G was not
counteracted by VifFIV. Taken together, these findings suggest
that the genetic variability in exon 4 of A3Z2c-Z3 has a minor
effect on the infectivity of domestic cat FIV. However, amino
acids derived from exon 4 of Turkish Van do have some impact
on the counteraction of VifFIV. Because our studies, described
below, implicate that VifFIV interacts with both Z domains of
A3Z2c-Z3, the mechanism of the moderate Vif resistance of
VAN cannot be explain d and requires further investig tion.
Our finding that Vif of FIV potently inhibited mostly all
tested A3s f the domestic at prompted us to evaluate th
ability of VifFIV to counteract A3 protein of felid speci s
different from the domestic cat lineag . For t is purpose,
A3Z2, A3Z3, and A3Z2-Z3 ex ression lasmids of Panthera
tigris corb tti, Lynx lynx, Panthera leo bleyenberghi, Puma con-
color, and A3Z2 of Panthera p rdus japonensis, representing
three lineages within Felidae, were analyzed for their anti-FIV
activity. Because only the F. catus chromosomal A3 locus is
characterized (31), the felid A3 cDNAs of big cats cannot be
related to a specific Z2 gene or to a specific Z2-Z3 readthrough
transcript. Comparing the protein sequence of FcaA3Z2c-Z3
to those of big cats, many amino acids changes become obvi-
ous, especially in exons 2 and 4 of A3Z2 and exon 4 of A3Z3
(Fig. 1B, bottom panel). Testing the big cat A3s in the FIV
luciferase vector system, we surprisingly detected no strong
inhibitory activity against the wt domestic cat FIV (see the
second and third bars in sets II to XVI, Fig. 2C). The felids
A3Z2s did not much affect the infectivity of wt or vif FIV
(sets II to VIII, Fig. 2C) similar to the inert antiviral activities
of the domestic cat counterparts (sets II to IV, Fig. 2A). How-
ever, we found for some felid A3Z2s a mild, sometimes signif-
icant, inhibition of 1.5- to 2-fold of FIV (see sets II to VIII,
Fig. 2C). Vif-deficient FIV was significantly (P  0.01) inhib-
ited by A3Z3s and A3Z2-Z3s, but in all cases the antiviral
activity was efficiently suppressed by Vif (compare the first bar
to the second and third bars, set IX to XVI, Fig. 2C). Com-
pared to the infectivity data (Fig. 2C), Vif induced a robust
depletion of all big cat A3s in the corresponding producer cells
(compare the first lane to the second and third lanes in sets II
to XVI, Fig. 2D). The tiger A3s were slightly, but significantly,
more active than those of the other big cat A3s (see sets II, X,
and XIII, Fig. 2C), such as PtiA3Z2-Z3, inhibited in this ex-
periment the infectivity of vif FIV by 85-fold and inhibited
FIV ca. 3- to 5-fold despite the coexpression of Vif (P  0.01,
c mp re the firs bar t second and third bars, set XIII,
Fig. 2C).
To demonstrate ha the moderate inhibition of FIV by tiger
A3Z2-Z3 is relevant, a titration f cat Vif and tiger A3 plas-
mids in the context of vif FIV was performed (Fig. 2E and F).
In contrast to the standard assays, where each 500 ng of
pVifFIV and A3 expression plasmids were transfected, 4, 20,
100, or 500 ng each of FcaA3Z2c-Z3, PtiA3Z2-Z3, and VifFIV
was used. Human A3G was included as a control for a VifFIV-
insensitive A3. The titration curves of human A3G and tiger
A3 in the absence of Vif were very similar to each other and
showed that in the range from 100 to 500 ng of plasmid tiger
FIG. 2. FIV Vif of domestic cats overcomes the antiviral activity of Felidae A3s. VSV-G pseudotyped wt FIV (expressing Vif), vif, and vif
plus VifFIV luciferase reporter vectors were produced in 293T cells cotransfected with HA-tagged A3 expression plasmids of the domestic cat and
chimeric A3s with major amino acid exchanges of exon 4 of A3Z2c of four cat breeding lines (A and B) and big cats (C and D). Roman numbers
indicate a set of transfections with the same A3 plasmid. Plas id pVifFIV expresses a V5-tagged Vif protein. pcDNA3.1() (pcDNA) was included
as a control. Reporter vector infectivity was determined by quantification of luciferase activity in HOS cells transduce with vector particles
normalized for RT. Asterisks represent statistically significant differences (, P 0.05; , P 0.01 [Dunnett t test]) relative to the pcDNA control.
A3 and Vif (Vif-V5) expression in the transfected 293T producer cells were detected by immunoblotting with anti-HA antibody for A3 or anti-V5
for Vif (B and D). Cell lysates were also analyzed for equal amounts of total proteins by using anti-tubulin antibody. For panel B, Felis catus A3s
proteins were also a alyzed for encapsidation into released FIV particl s. Encapsidated A3 proteins were detected on immunoblots probed with
anti-HA antibody. Vector particle lysates were analyzed for equal amounts of viral proteins by using anti-VSV-G antibody. (E) Increasing amounts
of A3 (0, 4, 20, 100, and 500 ng of plasmid) were tested against vif FIV and vif FIV plus Vif (500 ng of pVifFIV plasmid) and alternatively vif
FIV in the presence of 500 ng of A3 plasmid with increasing amounts of VifFIV (0, 4, 20, 100, and 500 ng of plasmid) was analyzed (F).
Corresponding immunoblots of lysates of the vector producer cells are shown. A3 and Vif (Vif-V5) expression in transfected 293T producer cells
were detected by immunoblotting with anti-HA antibody for A3 or anti-V5 for Vif. Cell lysates were also analyzed for equal amounts of total
proteins by using anti-tubulin antibody. , anti; cps, counts per second; BIR, Birman; BOB, Japanese Bobtail; SHO, British Shorthair; VAN,
Turkish Van; Fca, Felis catus; Pti, Panthera tigris corbetti; Ppa, Panthera pardus japonensis; Ple, Panthera leo bleyenberghi; Lly, Lynx lynx; Pco, Puma
concolor; Hsa, Homo sapiens; (var1), A3Z2 variant transcript detected in the indicated species.
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insensitive A3. The titration curves of human A3G and tiger
A3 in the absence of Vif were very similar to each other and
showed that in the range from 100 to 500 ng of plasmid tiger 
A3Z2-Z3 and A3G were ca. 2- to 3-fold more inhibitory than
FcaA3Z2c-Z3 (Fig. 2E, left panel). We redid these experiment
in the presence of 500 ng of Vif expression plasmid (Fig. 2E,
right panel) and saw that only the highest amount of the tiger
A3Z2-Z3 plasmid (500 ng) inhibited FIV by ~5-fold.
  To further study whether a reduced Vif expression would
render FIV replication more vulnerable to A3 restriction, a
fixed amount of 500 ng of A3 expression plasmid and varied
concentrations of the Vif plasmid were used (Fig. 2F). We
found that FcaA3Z2c-Z3 was very sensitive to Vif and that 20
ng of pVifFIV could fully restore FIV infectivity. In stark con-
trast, the heterologous tiger A3Z2-Z3 inhibited FIV ~10-fold
in the presence of low amounts of Vif (20 and 100 ng of Vif
plasmid). Only with the highest amount of pVifFIV (500 ng)
was the antiviral activity of tiger A3Z2-Z3 reduced to an ~4-
fold inhibition (Fig. 2F). The corresponding immunoblots of
the vector producer cells (Fig. 2F) showed that the degree of
Vif-induced depletion of the tiger and cat A3Z2-Z3s corre-
lated with the differences of these A3 to inhibit FIV. Whereas
20 ng of pVifFIV was sufficient to deplete all detectable levels
of FcaA3Z2c-Z3, small amounts of tiger A3Z2-Z3 were de-
tectable even in the presence of 25-fold more Vif plasmid (Fig.
2F). Together, these results indicate that, depending on the
expression levels of A3 and of Vif, even a moderate Vif-
insensitive A3 (such as the tiger A3Z2-Z3) weakly inhibits FIV
replication. However, considering the results of the experi-
ments with the wt FIV vector system that expresses in cis
natural amounts of Vif (set XIII in Fig. 2C), it is likely that FIV
under in vivo conditions could counteract most of the inhibi-
tory effect of tiger A3Z2-Z3. Thus, we conclude that, in con-
trast to the reported species-specific interaction of VifHIV-1 to
human but not to nonhuman primate A3Gs (25, 52), VifFIV
showed barely any species specificity for felid A3s (Fig. 2C).
More studies are required to determine whether Vif expression
levels vary during natural infections, e.g., due to the presence or
absence of cellular host factors for splicing or posttranslational
protein modifications, and whether these variations are relevant
to preventing cross-species transmissions among felids.
   Nonfelid A3s are resistant to Vif of FIV. To further charac-
terize the specificity of VifFIV, we tested A3s from human and
other nonfelid species. These experiments were also done to
identify the nonfelid A3s that likely restrict cross-species trans-
mission of FIV in vivo. We generated FIV particles as de-
scribed above together with one of the human, equine, porcine,
or murine A3 expression plasmids. Again, HOS cells were
transduced with the FIV vector normalized for RT, and at 3
dpi the intracellular luciferase activities were quantified. As
shown in Fig. 3, human A3F, A3G, and haplotype (hap) and
splice variants (SV) of A3H, equine A3Z3, porcine A3Z2-Z3,
and murine A3Z2-Z3 proteins were found to exert a significant
inhibitory effect on the infectivities of wt and vif-deficient FIV.
In contrast to the activity of Vif against the antiviral effect of
A3s from Felidae (Fig. 2A and C), all nonfelid A3s showed
resistance to VifFIV (Fig. 3). Although human A3A, A3B, A3C,
and A3DE did not restrict FIV, we found that human A3H
alleles encoding a single nucleotide polymorphism cluster
(G105R, K121D, E178D, hapII-RDD) restricted FIV more
efficiently than “wild-type” A3H (hapI-GKE), which is very
similar to the described restriction pattern against HIV-1 (14).
The activity of A3H against FIV was independent of the tested
splice isoforms (SV-182, SV-183, and SV-200 [14]). Under
these experimental conditions, the human A3G reduced the
infectivity of FIV by 130-fold, human A3F and A3H (hapI-
GKE)by ~10-fold, and pig and mouse A3Z2-Z3 by 25-fold,
and the hapII-RDD variant of the human A3H reduced FIV
infectivity by 60-fold. The equine A3Z1b, A3Z2-Z2, and
A3Z2e proteins moderately inhibited FIV only 2- to 3-fold.
Together, the results demonstrate that humans, horses, mice,
and pigs have at least one A3 gene that likely forms part of the
barrier against a cross-species transmission of FIV.
   The double-domain FcaA3Z2c-Z3 protein contains two Vif
interaction sites. In order to induce proteasomal degradation,
VifHIV-1 binds either the C-terminal Z2f domain of human
A3F (HsaA3Z2e-Z2f) or the N-terminal Z2g domain of hu-
man A3G (HsaA3Z2g-Z1c) (17, 42, 56, 57). Protection of FIV
replication by VifFIV is always associated with depletion of the
antiviral feline A3 proteins, and VifFIV can even induce deple-
tion of the feline A3 proteins that do not restrict FIV (Fig. 2B,
compare A3 detection in cell lysates in the first, second, and
third lanes in sets II, III, and IV). These findings suggest that
VifFIV can interact with feline Z3 and Z2 domains.
  To test this hypothesis, Vif interaction with FcaA3Z2c-Z3
(Abyssinian breed) was assayed using feline and human A3Z2-
Z3 chimeras (Fig. 4A). For chimera FcaA3Z2c-HsaA3H
(FcaA3Z2c-HsaA3Z3), the feline A3Z3 was substituted by
HsaA3H (HsaA3Z3, hapII-RDD SV-183). Conversely, in
HsaA3C-FcaA3Z3 (HsaA3Z2b-FcaA3Z3), the N-terminal feline
A3Z2 was exchanged by human A3C (HsaA3Z2b). To test the
relevance of the interdomain linker of the parental feline protein,
both feline domains were replaced by human sequences, termed
HsaA3C-HsaA3H (HsaA3Z2b-HsaA3Z3) (Fig. 4A). These A3s,
together with A3Gs of human and AGM origin, were tested by
using the single-cycle Dvif FIV- and Dvif HIV-1-luciferase re-
porter viruses to determine their antiviral activities and their sus-
ceptibilities to FIV, HIV-1, and SIVagm Vif proteins. Viral vector
stocks were produced in 293T cells, and the infectivities of nor-
malized particles were measured on HOS cells by quantification
of the intracellular luciferase activity.
  All A3 chimera inhibited both viruses in the absence of Vif
proteins (Fig. 4B and C, compare the first bars in sets I, II, III,
and IV). VifFIV counteracted FcaA3Z2c-HsaA3H and
HsaA3C-FcaA3Z3, but not HsaA3C-HsaA3H, in both viral
systems (see the second bars in sets II, III, and IV of Fig. 4B
and C). The Vif of HIV-1 failed to inhibit feline-human chi-
mera FcaA3Z2c-HsaA3H (compare the first and third bars in
set II of Fig. 4B and C), the wt feline A3Z2c-Z3, and the
agmA3G (see the third bars in sets V and VII, Fig. 4B and C).
These results were expected because human A3H, feline A3s,
and agmA3G are resistant to Vif of HIV-1 (14, 25, 33). The
human-feline (HsaA3C-FcaA3Z3) and the human-human
(HsaA3C-HsaA3H) chimeras were sensitive to VifHIV-1 in the
HIV vector system (see the third bars in sets III and IV, Fig.
4C). However, in the FIV vector system VifHIV-1 insufficiently
counteracted the human-feline A3 (HsaA3C-FcaA3Z3) and,
like VifSIVagm, only weakly inhibited the human-human
(HsaA3C-HsaA3H) A3 chimera (compare third bar in set III
and IV of Fig. 4B and 4C). These unexpected results implicate
that Vif of HIV-1 can interact with the A3C domain if it is part
of an engineered double-domain A3 and that this interaction
can be modulated by viral proteins of the packaging constructs. 
It is thus possible that conformational changes in the human-
feline A3 (HsaA3C-FcaA3Z3) required for VifHIV-1 interac-
tion are induced or stabilized by binding of this A3 protein to
HIV-1 Gag but not by binding to FIV Gag. The SIVagm Vif
acted as an active inhibitor of agmA3G, human-feline A3
(HsaA3C-FcaA3Z3), feline-human A3 (FcaA3Z2c-HsaA3H)
in both viral vector systems, but was less efficient against the
human-human (HsaA3C-HsaA3H) chimera (compare the
fourth bars in Fig. 3B and C). Although the results support that
VifFIV can use both Z domains to inhibit feline single- and
double-domain A3s, conformational problems of the human
and feline chimeras might have influenced the sensitivity to
Vifs of HIV-1 and SIVagm. Taken together, we conclude that
both Z domains of FcaA3Z2c-Z3, but not the linker region,
interact with VifFIV.
  FIV Vif protects HIV-1 in feline cells. To corroborate the
observation that VifFIV can protect Dvif HIV-1 against feline
A3s (see the second bar in set V, Fig. 4C), we sought to
determine whether VifFIV expressed in cis in the proviral con-
text would also rescue HIV-1 from feline A3s. Therefore, two
HIV-1-derived constructs, termed NL-LucR-E-vifFIV (HIV-
Luc vifFIV) and NL-BaL.vifFIV, were generated, in which the
HIV-1 vif gene was replaced by the codon-optimized FIV-
34TF10 vif gene expressed by internal initiation (for details of
the construction, see Materials and Methods and Fig. 5A).
 To quantify protection by VifFIV in cis, we compared the
infectivities of the HIV-1 luciferase reporter viruses NL-
LucR-E-Dvif and NL-LucR-E-.vifFIV. The data in Fig. 5B
show that in human cells the six feline A3 proteins inhibited
Dvif HIV-1-mediated gene transfer to different degrees, de-
pending on the type of A3 protein, similar to previous results
(33). FcaA3Z2a isoforms reduced the infectivity of Dvif HIV-
Luc by 3- to 4-fold; A3Z3 inhibited the infectivity by 6-fold,
and the double-domain A3Z2-Z3 proteins inhibited the infec-
tivity by 14- to 33-fold. Importantly, VifFIV expressed by the
chimeric HIV-Luc fully protected HIV-1 against the antiviral
activity of all feline A3s under these experimental conditions
(see the second bars in sets II to VII, Fig. 5B). In these cases,
the expression of VifFIV induced the depletion of feline A3s in
    FIG. 3. Inhibition of FIV by nonfeline A3s. VSV-G pseudotyped FIV luciferase reporter vectors (wt FIV, expressing Vif; Dvif; and Dvif 
plus VifFIV) were produced in 293T cells in the presence or absence (pcDNA) of human A3s (A) or nonprimate equine, murine, and 
porcine A3s (B). The infectivity of the vector particles was determined by quantification of luciferase activity in HOS cells transduced 
with equal amounts of particles. pcDNA, pcDNA3.1(+); SV, splice variant; hapI, haplotype I; hapII, haplotype II; cps, counts per second; 
Eca, Equus caballus; Mmus, Mus musculus; Ssc, Sus scrofa. Roman numerals indicate a set of transfections with the same A3 plasmid.
It is thus possible that conformational changes in the human-
feline A3 (HsaA3C-FcaA3Z3) required for VifHIV-1 interac-
tion are induced or stabilized by binding of this A3 protein to
HIV-1 Gag but not by binding to FIV Gag. The SIVagm Vif
acted as an active inhibitor of agmA3G, human-feline A3
(HsaA3C-FcaA3Z3), feline-human A3 (FcaA3Z2c-HsaA3H)
in both viral vector systems, but was less efficient against the
human-human (HsaA3C-HsaA3H) chimera (com are the
fourth bars in Fig. 3B and C). Although the results support that
VifFIV can use both Z domains to inhibit feline single- and
double-domain A3s, conformational problems of the human
and feline chimeras might have influenced the sensitivity to
Vifs of HIV-1 and SIVagm. Taken together, we conclude that
both Z domains of FcaA3Z2c-Z3, but not the linker region,
interact with VifFIV.
FIV Vif protects HIV-1 in feline cells. To corroborate the
observation that VifFIV can protect vif HIV-1 against feline
A3s (see the second bar in set V, Fig. 4C), we sought to
determine whether VifFIV expressed in cis in the proviral con-
text would also rescue HIV-1 from feline A3s. Therefore, two
HIV-1-derived constructs, termed NL-LucREvifFIV (HIV-
Luc vifFIV) and NL-BaL.vifFIV, were generated, in which the
HIV-1 vif gene was replaced by the codon-optimized FIV-
34TF10 vif gene expressed by internal initiation (for details of
th construction, see Material and Methods and Fig. 5A).
To quantify protection by VifFIV in cis, we compa d the
infectivities of the HIV-1 luciferase reporter viruses NL-
LucREvif and NL-LucRE.vifFIV. Th data in Fig. 5B
show that in hum n c lls the six feline A3 proteins inhibited
vif HIV-1-m diated g ne transfer to different degrees, de-
pending on the type of A3 protein, similar to previous results
(33). FcaA3Z2a isoforms reduced the infectivity of vif HIV-
Luc by 3- to 4-fold; A3Z3 inhibited the infectivity by 6-fold,
and the double-domain A3Z2 Z3 proteins inhibited the infec-
tivity by 14- to 33-fold. Importantly, VifFIV expressed by the
chimeric HIV-Luc fully protected HIV-1 against the antiviral
activity of all feline A3s under these experimental conditions
(see the second bars in sets II to VII, Fig. 5B). In these cases,
the expression of VifFIV induced the depletion of feline A3s in
the producer cells and likely thereby rescued vector infectivity
(compare A3 detection in cell lysates in the first and second
lanes of sets II to VII in Fig. 5C). A3-mediated restriction of
marker gene expression was found to correlate with the pres-
ence of A3Z3 and A3Z2-Z3 proteins in released particles (see
FIG. 3. Inhibition of FIV by nonfeline A3s. VSV-G pseudotyped FIV luciferase reporter vectors (wt FIV, expressing Vif; vif; and vif plus
VifFIV) were produced in 293T cells in the presence or absence (pcDNA) of human A3s (A) or nonprimate equine, murine, and porcine A3s (B).
The infectivity of the vector particles was determined by quantification of luciferase activity in HOS cells transduced with equal amounts of
particles. pcDNA, pcDNA3.1(); SV, splice variant; hapI, haplotype I; hapII, haplotype II; cps, counts per second; Eca, Equus caballus; Mmus,
Mus muscu us; Ssc, Sus scrofa. Roman numerals indicate a set of transfections with t e same A3 pl smid.
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the producer cells and likely thereby rescued vector infectivity
(compare A3 detection in cell lysates in the first and second
lanes of sets II to VII in Fig. 5C). A3-mediated restriction of
marker gene expression was found to correlate with the pres-
ence of A3Z3 and A3Z2-Z3 proteins in released particles (see 
A3 detection in virion lysates in the first lanes of sets V, VI,
and VII in Fig. 5C). The moderately active A3Z2s were only
weakly detectable in lysates of the virions (see A3 detection in
virion lysates, first lanes of sets II, III and IV, Fig. 5C). Human
A3G was encapsidated in both particles, Dvif HIV-Luc and
HIV-Luc vifFIV (see A3 detection in virion lysates in set VIII
in Fig. 5C). Also, both reporter viruses were equally inhibited
by A3G (see both bars in set VIII of Fig. 5B), thereby strongly
supporting that HIV-Luc vifFIV does not express any residual
VifHIV-1 activity.
  Next, we evaluated the ability of VifFIV to support spreading
replication of HIV-1 in feline cells. Wild-type HIV-1 (NL-
BaL) and NL-BaL.vifFIV were used to infect feline
CrFK.CD4.CCR5 and human HOS.CD4.CCR5 cells that are
both genetically modified to express human CD4/CCR5. In
addition, we infected PHA/IL-2-activated human PBMC with
both viruses. From previous experiments, we knew that in
contrast to human PBMC, HOS.CD4.CCR5 cells do support
replication of Dvif HIV-1 (data not shown). Feline CrFK or
CrFK.CD4.CCR5 cells support replication of neither vif FIV
nor wt HIV-1 (33, 38, 44). In the supernatants of infected cells,
the amount of released CA.p24 was measured over a period of 15
days. The results shown in Fig. 5D demonstrated that wt HIV-1
replicated efficiently in HOS.CD4.CCR5 cells and in human
PBMC but not in the CrFK.CD4.CCR5 cells (Fig. 5D). In con-
trast, the VifFIV-encoding virus (NL-BaL.vifFIV) was able to rep-
licate to similar levels in the permissive human HOS.CD4.CCR5
and the nonpermissive feline CrFK.CD4.CCR5 cells (Fig. 5D).
Human PBMC did not support efficient spreading of NL-BaL.
vifFIV (Fig. 5D). The PBMC cultures showed highest permissivity
toward wt HIV-1 but yielded in very low p24 levels in the super-
natant after inoculation with NL-BaL.vifFIV (Fig. 5D), which
may be derived from the initial first round of infection. These data
confirm (see above) that the VifFIV-chimeric viruses carry a HIV
vif gene that is genetically and functionally fully inactivated. Ex-
pression of VifFIV was confirmed in virion lysates of the infected
HOS.CD4.CCR5 and CrFK.CD4.CCR5 cultures in which NL-
BaL.vifFIV showed spreading replication (Fig. 5E). At 12 dpi, the
signal for the Vif-V5 was weaker than the V5 signal of samples of
day 5 in both cultures, which may be due to a partial loss of the
nonessential V5 tag of the VifFIV protein. We conclude that, at
least in some feline cell types, A3 proteins constitute the major
restriction mechanism acting inhibitory against HIV-1.
  FIG. 4. Analyses of human/feline A3 chimeras reveal Vif interactions with both Z-domains of FcaA3Z2c-Z3. (A) Schematic 
representation of human/feline A3Z2-Z3 chimera. Open bars denote feline sequences; filled bars denote human sequences. In 
FcaZ2-Z3, the Z2 and Z3 domains are naturally separated by a linker region (demarcated by dotted lines) that is encoded by exon 2 of 
Z3, which is untranslated in FcaA3Z3 (see Fig. 1A). FIVDvif (B) and HIVDvif (C) luciferase reporter particles were produced in 293T 
cells in the presence or absence (pcDNA) of feline and chimeric human/feline A3Z2-Z3s expression plasmids and expression plasmids 
for VifFIV, VifHIV-1, or VifSIVagm. To control the specificity of primate Vifs, human and AGM A3G expression plasmids were included. The 
infectivities of the vector particles were determined by quantification of luciferase in HOS cells transduced with equal amounts of vector 
particles. pcDNA, pcDNA3.1(+); cps, counts per second. Roman numerals indicate a set of transfections with the same A3 plasmid.
A3 detection in virion lysates in the first lanes of sets V, VI,
and VII in Fig. 5C). The moderately active A3Z2s were only
w akly det ctable in lysat s of th virions (see A3 detection in
virion lysates, first lanes of sets II, III and IV, Fig. 5C). Human
A3G was encapsidated in both particles, vif HIV-Luc and
HIV-Luc vifFIV (see A3 detection in virion lysates in set VIII
i Fig. 5C). Also, both reporter viru es w r equally inhibited
by A3G (see both bars in set VIII of Fig. 5B), thereby strongly
supporting that HIV-Luc vifFIV does not express any residual
VifHIV-1 activity.
Next, we evaluated the ability of VifFIV to support spreading
replication of HIV-1 in feline cells. Wild-type HIV-1 (NL-
BaL) and NL-BaL.vifFIV were used to infect feline
CrFK.CD4.CCR5 and human HOS.CD4.CCR5 cells that are
both genetically modified to express human CD4/CCR5. In
addition, we infected PHA/IL-2-activated human PBMC with
both viruses. From previous experiments, we knew that in
contrast to human PBMC, HOS.CD4.CCR5 cells do support
replication of vif HIV-1 (data not shown). Feline CrFK or
CrFK.CD4.CCR5 cells support replication of neither vif FIV
nor wt HIV-1 (33, 38, 44). In the supernatants of infected cells,
the amount of released CA.p24 was measured over a period of 15
days. The results sh wn in Fig. 5D demonstr ted that wt HIV-1
replicated fficiently in HOS.CD4.CCR5 cells d in human
PBMC but not in the CrFK.CD4.CCR5 cells (Fig. 5D). In con-
trast, the VifFIV-encoding virus (NL-BaL.vifFIV) was able to rep-
licate to similar levels in the permissive human HOS.CD4.CCR5
and the nonpermissive feline CrFK.CD4.CCR5 cells (Fig. 5D).
Human PBMC did not su port effici nt spreading of NL-BaL.
vifFIV (Fig. 5D). The PBMC cultures showed highest permissivity
toward wt HIV-1 but yielded in very low p24 levels in the s per-
natant after inoculation with NL-BaL.vifFIV (Fig. 5D), which
may be derived from the initial first round of infection. These data
confirm (see above) that the VifFIV-chimeric viruses carry a HIV
vif gene that is genetically and functionally fully inactivated. Ex-
pression of VifFIV was confirmed in virion lysates of the infected
HOS.CD4.CCR5 and CrFK.CD4.CCR5 cultures in which NL-
BaL.vifFIV showed spreading replication (Fig. 5E). At 12 dpi, the
signal for the Vif-V5 was weaker than the V5 signal of samples of
day 5 in both cultures, which may be due to a partial loss of the
nonessential V5 tag of the VifFIV protein. We conclude that, at
least in some feline cell types, A3 proteins constitute the major
restriction mechanism acting inhibitory against HIV-1.
DISCUSSION
Examples of FIV cross-species transmissions have been re-
ported and are cur ntly studied to gain increased understand-
FIG. 4. Analyses of human/feline A3 chimeras reveal Vif interactions with both Z-domains of FcaA3Z2c-Z3. (A) Schematic representation of
human/feline A3Z2-Z3 chimera. Open bars denote feline sequences; filled bars denote human sequences. In FcaZ2-Z3, the Z2 and Z3 domains
are naturally separated by a linker region (demarcated by dotted lines) that is encoded by exon 2 of Z3, which is untranslated in FcaA3Z3 (see
Fig. 1A). FIVvif (B) and HIVvif (C) luciferase reporter particles were produced in 293T cells in the presence or absence (pcDNA) of feline
and c imeric hum /feline A3Z2-Z3s expression plasmids and expression plasmids or VifFIV, VifHIV-1, VifSIVagm. To control the spec ficity of
primate Vifs, human and AGM A3G expression plasmids were included. The infectivities of the vector particles were determined by quantification
of luciferase in HOS cells transduced with equal amounts of vector particles. pcDNA, pcDNA3.1(); cps, counts per second. Roman numerals
indicate a set of transfections with the same A3 plasmid.
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   FIG. 5. HIV-1 is protected by VifFIV in feline cells. (A) Schematic representation of the insertion of the vifFIV (shaded) in the vif gene 
of the HIV-derived constructs (NL-LucR-E-vifFIV and NL-Bal.vifFIV) by fusion PCR. Overlapping pol (schematically depicted) and 
vpr genes are shown. Restriction enzyme recognition sites AgeI and EcoRI were used to clone the fusion PCR product. Position of 
PCR primers used are shown as arrows: primer 1, vpu_mut_5’out_HH; primer 2, HIV1_vif_FIV1.rv; primer 3, HIV1_vif_FIV2.fw; 
primer 4, HIV1_vif_FIV2a.rv; primer 5, HIV1_vif_FIV3.fw; and primer 6, HIV1_vif_FIV3.rv. “N” represents adenine (A), cytosine 
(C), guanine (G), or thymidine (T). (N)number represents the number of Ns. ∗, Stop codon. (B and C) The effect of VifFIV in cis for the 
infectivity of the chimeric HIV-1 constructs was tested by using single-cycle luciferase reporter viruses. VSV-G pseudotyped virus 
was produced by cotransfection of pNL-LucR-E-Dvif or pNLLucR-E-vifFIV in the presence or absence (pcDNA) of the indicated 
expression plasmids for feline A3 and human A3G. Infectivity of the viruses was determined by quantification of luciferase in HOS 
cells infected with normalized amounts of viruses (B). Asterisks represent statistically significant differences (∗, P < 0.05; ∗∗, P < 0.01 
[Dunnett t test]) relative to the pcDNA control. Corresponding immunoblots of cell lysates and virion lysates were probed with anti-
HA antibody for A3 expression (C). The expression of VifFIV was confirmed by probing the blot with an anti-V5 antibody. Cell lysates 
were also analyzed for equal amounts of total proteins by using an anti-tubulin antibody. Virus lysates were analyzed for equal amounts 
of viral proteins by using anti-p24CA (HIV-1 capsid) antibody. Roman numbers indicate a set of transfections with the same A3 
plasmid. (D and E) Replication of wild-type HIV-1(NL-Bal) and HIV-1(NL-Bal.vifFIV). Human HOS.CD4.CCR5 cells, feline CrFK.
CD4.CCR5 cells, and PHA/IL-2 activated human PBMC were infected with NL-BaL and NL-BaL.vifFIV at a multiplicity of infection 
of 0.05. (D) Culture supernatants were quantified every 2 or 3 days by p24CA ELISA. (E) Immunoblot analysis of virus lysates from 
infected CrFK.CD4.CCR5 and HOS.CD4.CCR5 cells on days 5 and 12 postinfection. Expression of VifFIV was confirmed by probing 
the filter with an anti-V5 antibody, the same blot was also stained with anti-p24CA (capsid) antibody to detect HIV-1. a, anti.
FIG. 5. HIV-1 is protected by VifFIV in feline cells. (A) Schematic representation of the insertion of the vifFIV (shaded) in the vif gene of the
HIV-derived constructs (NL-LucREvifFIV and NL-Bal.vifFIV) by fusion PCR. Overlapping pol (schematically depicted) and vpr genes are
shown. Restriction enzyme recognition sites AgeI and EcoRI were used to clone the fusion PCR product. Position of PCR primers used are shown
as arrows: primer 1, vpu_mut_5out_HH; primer 2, HIV1_vif_FIV1.rv; primer 3, HIV1_vif_FIV2.fw; primer 4, HIV1_vif_FIV2a.rv; primer 5,
HIV1_vif_FIV3.fw; and primer 6, HIV1_vif_FIV3.rv. “N” represents adenine (A), cytosine (C), guanine (G), or thymidine (T). (N)number
represents the number of Ns. , Stop codon. (B and C) The effect of VifFIV in cis for the infectivity of the chimeric HIV-1 constructs was tested
by using single-cycle luciferase reporter viruses. VSV-G pseudotyped virus was produced by cotransfection of pNL-LucREvif or pNL-
LucREvifFIV in the presence or absence (pcDNA) of the indicated exp ession plasmids for feline A3 and human A3G. Infectivity of the viruses
was determined by quantification of luciferase in HOS cells infected with normalized amounts of viruses (B). Asterisks represent statistically
significant differences (, P  0.05; , P  0.01 [Dunnett t test]) relative to the pcDNA control. Corresponding immunoblots of cell lysates and
virion lysates were probed with anti-HA antibody for A3 expression (C). The expression of VifFIV was confirmed by probing the blot with an
anti-V5 antibody. Cell lysates were also analyzed for equal amounts of total proteins by u ing an anti-tubulin antibody. Virus lysates were analyzed
for equal amounts of viral proteins by using anti-p24CA (HIV-1 capsid) antibody. Roman numbers indicate a set of transfections with the same
A3 plasmid. (D and E) Replication of wild-type HIV-1(NL-Bal) and HIV-1(NL-Bal.vifFIV). Human HOS.CD4.CCR5 cells, feline
CrFK.CD4.CCR5 cells, and PHA/IL-2 activated human PBMC were infected with NL-BaL and NL-BaL.vifFIV at a multiplicity of infection of
0.05. (D) Culture supernatants were quantified every 2 or 3 days by p24CA ELISA. (E) Immunoblot analysis of virus lysates from infected
CrFK.CD4.CCR5 and HOS.CD4.CCR5 cells on days 5 and 12 postinfection. Expression f VifFIV was confirmed by probing the filter with a
anti-V5 antibody, the same blot was also stained with anti-p24CA (capsid) antibody to detect HIV-1. , anti.
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DISCUSSION
  Examples of FIV cross-species transmissions have been re-
ported and are currently studied to gain increased understand-
ing regarding the permissiveness of selected and sometimes
endangered feline species to diverse, molecularly characterized
isolates of pathogenic FIV. These studies also serve as a valid
and experimentally easier-to-handle model for the evolution of
HIV from SIV. From these investigations of felids and their
immunodeficiency viruses, we know that lentiviruses of lion
(FIV-Ple) and puma (FIV-Pco) differentially replicate in acti-
vated PBMC of cats: FIV-Ple shows spreading replication, but
FIV-Pco did not replicate in cat PBMC (50). Subsequently, the
FIV-Pco isolate from experimentally infected cats contained
extensive G-to-A mutations reminiscent of A3 activity (41). It
was also described that pumas support the replication of FIV
from bobcats that are frequently transmitted between these
two species (12). In the cases where FIVs do replicate in
heterologous species or PBMC, one can assume that the Vif
protein can counteract the A3s of the novel, heterologous
hosts. Alternatively, but less likely, it is possible that certain
A3s are not active against some of the heterologous FIVs.
Based on our experiments, it appears that most of the di-
verse felid A3s of the domestic cat and big cats (lion, tiger,
puma, and lynx) are probably not major determinants to pre-
vent cross-species transmission of FIV of domestic cats to
these closely related animal species. The A3Z2c-Z3 protein of
tiger and the A3Z2-Z3 proteins containing amino acids of the
polymorphic exon 4 of some cat breeds were found to be
moderately resistance to the Vif of domestic cat FIV. For the
tiger A3 we showed that low levels of cat Vif insufficiently
counteracted its antiviral activity and regular Vif levels mostly
inhibited this A3. Further experiments analyzing spreading
FIV replications will be necessary to learn more about the
inhibitory impact of these moderately resistant A3s during a
longer observation period. We predict that FIV would quickly
adapt its Vif protein to a complete A3 counteraction after a
few rounds of replication in cells expressing, e.g., tiger
A3Z2-Z3 protein. These assumptions are in fact supported by
the ease with which FIV of the domestic cats infects other
Felidae. A contributing factor may be that restriction of FIV
replication and interspecies transmission by TRIM5 proteins is
lacking in Felidae due to an in-frame stop mutation in the
TRIM5 gene (29). However, other feline retroviruses and non-
retroviruses might be more sensitive to the tested felid A3s in
a species-specific manner, possibly explaining the positive se-
lection on the felid A3 genes and the high prevalence of non-
silent mutations in the A3Z2 genes in different cat breeding
lines (31). Polymorphic A3 genes are found also in humans,
horses, and mice and show differential antiviral activities (1, 14,
36, 37, 58). Experiments with wt and vif FIVs of other felids
will be required to ultimately demonstrate whether the FIV of
the domestic cat is unique or whether many FIVs have the
capacity to counteract heterologous felid A3s. The monophyly
of the FIV strains of the diverse Felidae is a strong argument
against frequent cross-species transmissions and, beside A3,
other cellular and noncellular factors such as contact rates
between different species likely determine or even limit inter-
species FIV spread (51).
  However, independent of whether feline A3s restrict FIV or
not, the VifFIV protein recognizes diverse feline A3 proteins
and induces their depletion (FcaA3Z3 versus FcaA3Z2 pro-
teins). Due to this broad reactivity, VifFIV has the capacity to
counteract also engineered two-domain A3Z2-Z3s that carried
only one domain of feline origin (Fig. 4B and C). It is currently
unclear whether feline A3Z2 and -Z3 proteins share a Vif
interaction domain, whether Vif interacts independently with
the Z2 and Z3 domains or whether the A3-Vif interaction in a
single molecule of FcaA3Z2-Z3 happens with both Z-domains
simultaneously or preferentially only with one domain. For the
virus, it is an obvious advantage that Vif interacts with both Z
domains. As a disadvantage for the feline host, the feline
A3Z2-Z3 proteins need to evolve at two regions at the same
time to escape the Vif-induced degradation. In contrast to
FIV, the HIV-1 Vif protein binds only a single Z domain in the
human A3F (HsaA3Z2e-Z2f) and A3G (HsaA3Z2g-Z1c): Z2f
or the Z2g, respectively (17, 42, 56, 57). It is hard to guess
whether the interaction of VifHIV-1 with only a single Z domain
is advantageous for either the virus or the host, and we do not
know why Vif of FIV appears to interact with both Z domains.
The interaction of VifFIV with A3Z2s may be a relict of an FIV
ancestor virus that was refractory also to these A3 types and
had to evolve a Vif protein that targets also Z2 proteins. In this
model, modern FIVs preserved the “ancient” function to in-
teract with A3Z2. Alternatively, the limited reagents used in
the present study might not properly reflect the FIV-cat inter-
action. Here, we tested reporter vectors based on the domestic
cat strains FIV-PPR (40) and FIV-34TF10 (47). We cannot
exclude that wt or Dvif variants of other FIV strains, e.g., from
other feline hosts, are more restricted by feline A3Z2 proteins
than these two FIV isolates. Moreover, cats might carry thus
far unidentified A3Z2 alleles that show a stronger inhibitory
activity than the described Z2 proteins.
  Because cats are resistant to HIV-1, we wanted to under-
stand how many genetic changes in HIV-1 or cats would be
required to circumvent this species block. We recently found
that the feline CD4 receptor does not support HIV-1 infection,
and we described the feline A3 proteins as restriction factors
for HIV-1 (33). In order to prevent HIV-1 restriction by feline
A3s, we replaced the vif gene of HIV-1 by vif of FIV. This
HIV-1vifFIV replicated in nonpermissive, feline A3-expressing
CrFK.CD4.CCR5 cells to levels of wt HIV-1 replication in the
permissive human HOS.CD4.CCR5 cells. Since the Felidae,
including the domestic cat, do not encode a functional copy of
the TRIM5 gene (29), cats likely will not exhibit a TRIM5-like
restriction against HIV-1. Other limitations and restrictions for
HIV-1 in cats might exist but, together, these results are en-
couraging to strengthen research on an animal model for
HIV-1 based on the domestic cat.
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SUMMARY
APOBEC3 (apolipoprotein B mRNA editing catalytic 
polypeptide 3 [A3]) proteins are an element of the intrinsic 
immunity of modern mammalia against retroviruses. The 
evolution of the A3 genes is characterized by an adaptive 
selection and a taxon-specific expansion and/or extinction. All 
A3 genes consist either of one zinc (Z)-coordinating domain 
(Z1, Z2 or Z3) or two Z-domains (Z2-Z1, Z2-Z2, Z2-Z3). While 
humans carry seven A3 genes, Equus caballus carries six and 
Felis catus four A3 genes. 
 The genome of Equus caballus carries two Z1, two Z2-Z2, 
one Z2 and one Z3 A3 gene. Some of the equine A3 are able 
to restrict the Equine infectious anaemia virus (EIAV). Equine 
macrophages, which are the natural target cells for EIAV, 
express only a limited repertoire of the A3 genes. In addition, 
the transcriptional level of the anti-EIAV A3 mRNAs was 
significantly lower in macrophages than in equine peripheral 
blood mononuclear cells. Equine A3 proteins hyper-mutated 
EIAV genomes supporting their predicted function. In contrast 
to all other extant lentiviruses, EIAV does not encode a vif 
gene. Other EIAV-specific genes as dUTPase and S2, whose 
relevance for the viral replication in previous studies was only 
insufficiently characterized, did not influence the inhibitory 
effect of the equine A3 proteins. Thus, EIAV does not have an 
antagonist against its species-own A3 proteins. These findings 
indicate that lentiviral replication can occur independent from 
a vif gene, which likely developed later in the evolution of the 
lentiviruses.
 Felis catus and of other Felidae encode A3 genes of the type 
Z2 and Z3. Beside one-domain molecules, also two-domain 
encoding read-through transcripts with two Vif interaction 
sites were detectable, that restricted different feline retroviruses. 
FIV (Feline immunodeficiency virus) encodes a Vif protein 
that counteracts the inhibitory effect of the feline A3 proteins. 
Despite a high genetic diversity in felid A3 genes, no strong 
resistance could be shown against the neutralizing activity of 
Vif of the domestic cat FIV. Non-feline A3 proteins restricted 
FIV independently of Vif, which proves that the interaction 
between A3 and Vif proteins is species-specific and thus limits 
interspecies virus transmission. 
 Species-specificity was also demonstrated for the interaction 
of feline A3 and the Vif protein of HIV-1. Feline cells that 
expressed human entry receptors were permissive for the 
transduction with a HIV-1 reporter virus but the virus was 
not able to spread in these cells. HIV replication in feline cells 
is strongly inhibited by the feline A3 proteins. In order to 
overcome this restriction, the vif gene of HIV-1 was replaced 
by vifFIV. This chimeric HIV-1 showed spreading replication 
in feline cells expressing human receptors. Altogether, these 
findings implicate the importance of a novel animal model for 
HIV-1 based on Felis catus.
ZUSAMMENFASSUNG
APOBEC3 (apolipoprotein B mRNA-editing catalytic polypeptide 
3 [A3]) Proteine sind ein Element der intrinsischen Immunität 
heutiger Mammalia gegenüber Retroviren. Die Evolution 
der A3 Gene zeichnet sich durch eine adaptive Selektion und 
eine taxonspezifische Expansion bzw. Extinktion aus. Alle A3 
Gene bestehen entweder aus einer Zink (Z)-koordinierenden 
Domäne (Z1, Z2 oder Z3) oder zwei Z-Domänen (Z2-Z1, Z2-
Z2, Z2-Z3). Während bei den Hominoidea sieben A3 Gene 
identifiziert werden konnten, waren es bei  Equus caballus sechs 
und bei Felis catus vier.
 Im Genom von Equus caballus konnten zwei Z1, drei Z2 und 
ein Z3 A3 Gen detektiert werden. Einige der equinen A3 Proteine 
sind in der Lage Equine Infectious Anemia Virus (EIAV) zu 
restringieren. Equine Makrophagen, die dem equinen Lentivirus 
EIAV als natürliche Zielzellen dienen, exprimieren nur ein 
limitiertes Repertoire an A3 Genen. Das Transkriptionslevel 
der antiviralen A3 mRNA war in den Makrophagen signifikant 
kleiner als in den analysierten Peripheral Blood Mononuclear 
Cells. In ihrer Funktion als Cytosin Deaminasen verursachen 
equine A3 Proteine hypermutierte EIAV-Genome. Im 
Unterschied zu allen anderen existierenden Lentiviren ist das 
Vif Protein nicht im EIAV-Genom kodiert. Andere EIAV-
spezifische Gene wie dUTPASE und S2, deren Bedeutung für die 
Virusreplikation in vorhergehenden Studien nur unzureichend 
nachgewiesen werden konnten, zeigten keinen Einfluss auf den 
inhibitorischen Effekt der equinen A3 Proteine. Somit fehlt EIAV 
ein Antagonist, der aktiv der A3 Restriktion entgegenwirkt. Dies 
deutet daraufhin, dass lentivirale Replikation unabhängig von 
einem vif Gen, das erst später in der Evolution der Lentiviren 
entstanden ist, erfolgen kann. 
 Im Felis catus Genom und anderen Vertretern der Felidae 
wurden ausschließlich A3 Gene der Nomenklatur Z2 und 
Z3 detektiert. Neben Ein-Domänen-Molekülen wurden 
auch durchlesetranskript-kodierte Proteine mit zwei Vif-
Interaktionsseiten nachgewiesen, die das Potential besitzen, 
unterschiedliche feline Retroviren zu inhibieren. FIV (Feline 
Immunodeficiency Virus) kodiert für ein Vif Protein, dass der 
antiviralen Wirkung der felinen A3 Proteine entgegenwirkt. 
Trotz der gewichtigen genetischen Diversität der A3 Gene 
innerhalb der Felidae konnte keine Resistenz gegen die 
neutralisierende Aktivität des Vif Proteins gezeigt werden. 
Nicht-felide A3 Proteine restringieren FIV unabhängig von Vif, 
was beweist, dass die Interaktion zwischen A3 und Vif Proteinen 
spezies-spezifisch ist und dadurch eine interspezifische 
Virustransmission limitiert wird.
 Die Spezies-Spezifität wurde ebenfalls für die Interaktion der 
felinen A3 Proteine mit dem Vif Protein von HIV-1 nachgewiesen. 
Feline Zellen, die humane Rezeptoren exprimieren, waren für 
die Transduktion mit einem HIV-1 Reportervirus permissiv, 
jedoch war das Virus nicht in der Lage, in diesen Zellen zu 
replizieren. Dieser zytoplasmatische Block lässt sich auf einen 
starken inhibitorischen Effekt der A3 Proteine zurückführen. 
Um diese Restriktion zu umgehen, wurde das vif Gen von HIV-
1 durch vifFIV ausgetauscht. Das chimäre HIV-1 zeigte eine 
sich ausbreitende Replikation in felinen Zellen, die humane 
Rezeptoren exprimieren. Diese Ergebnisse sind von besonderer 
Bedeutung für ein auf Felis catus basierendes Tiermodell für 
HIV.
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